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Abstract 
 
 
The G2019S mutation within the LRRK2 gene, is the most common genetic cause 
of Parkinson’s, being responsible for 20-40% of all familial PD cases, depending 
on the population under study. The actual function of the LRRK2 protein is not 
yet clear, although it has been implicated in several pathways including synaptic 
vesicle regulation, endocytosis and membrane trafficking. The gain of function 
G2019S mutation increases the kinase activity of the LRRK2 protein, 
contributing to the pathogenesis of PD. Several hypotheses exist on how G2019S 
contributes to PD, including regulation of dopamine metabolism and/or several 
Rab proteins, which have been identified as binding LRRK2, but the exact Rab is 
not consistent. Using the Drosophila visual system as an in vivo model, these 
hypotheses were addressed. HPLC analysis established that young flies 
expressing LRRK2-G2019S in their dopaminergic neurons (TH>G2019S flies) 
have lower levels of dopamine than control flies. In addition, inhibition of 
dopamine release by tetanus toxin showed an increase in visual sensitivity in 
control and old TH>G2019S flies, while young TH>G2019S flies showed a 
decrease in visual responses. Furthermore, new transgenic flies were generated, 
LexAop-LRRK2 and LexAop-G2019S, giving us the opportunity to use the Gal4 
and LexA binary expression systems simultaneously at the same animal. 
Additionally, the expression protein levels of LRRK2 and G2019S were 
examined, indicating that LRRK2 is consistently expressing at higher levels than 
G2019S. That indicates that the kinase activity of the LRRK2 protein plays a 
vital role on the protein levels expression. Finally, the genetic screening that was 
performed in order to identify LRRK2-substrates in vivo identified six Rab 
proteins. Among those were Rab3, Rab5, Rab9, Rab10, Rab18 and Rab40, while 
Rab1 and Rab19 were identified interacting with the dopaminergic neurons of 
the flies. Overall, this study confirms the early hyperactivity in young 
TH>G2019S flies that could trigger the beginning of neurodegeneration, which is 
the hallmark of Parkinson’s.  
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1. Introduction 
 
A major problem in Parkinson’s disease (PD) is to understand the mechanism(s), 
which lead to neuropathology and loss of brain function. This thesis focuses on 
the most common known cause of Parkinson’s, mutations in the LRRK2 (leucine 
rich repeat kinase) gene. Although this gene was identified nearly 15 years ago, 
its cellular location, function and binding partners are all still unknown. Here I 
explore how mutations in LRRK2 regulate dopamine, a neurotransmitter affected 
in PD, and Rab proteins, proposed as a possible target of the LRRK2 enzyme. To 
facilitate this, the fly model of LRRK2 was deployed, as this has been shown to 
recapitulate many of the features of PD.  
1.1 Parkinson’s disease (PD) 
 
1.1.1 Overview of PD: 
 
“Neurodegenerative disorder” is an umbrella term for a wide variety of 
conditions, in which the neurons in the human brain are lost. PD is the second 
most common neurodegenerative disease in the developed world after Alzheimer 
disease, with its prevalence estimated being 6.3 million people worldwide. In the 
UK alone, more than 120,000 people have been reported suffering from PD, and 
this prevalence is set to rise in the years to come because of our ageing 
population.  
 
PD was first described in 1817 by the physician James Parkinson as ‘the shaking 
palsy’ based on the motor symptoms of the disorder. Over time, a more well 
rounded picture of the clinical phenotype of the disease emerged, revealing that it 
actually is a multisystem disorder (Archibald et al., 2009).  
 
1.1.2 Clinical presentation of PD 
 
Clinically PD is heterogeneous and many subtypes may be recognised on the 
basis of age of onset, predominant clinical features and progression rate. There 
are two major clinical subtypes existing including a tremor-predominant form 
that is mostly observed in younger people, and a “postural imbalance and gait 
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disorder” (PIGD) that is usually observed in older people (>70 years old) (Obeso 
et al., 2010). It is widely accepted that people with PD suffer both from motor 
and non-motor symptoms, as described in further detail below. 
 
1.1.3 Motor symptoms 
 
The main clinical manifestations of the disease include tremor, rigidity, 
bradykinesia and postural instability. As the most apparent symptom, patients 
afflicted with PD present with tremor. This is typically evident at rest (resting 
tremor), when the limb is relaxed and usually disappears with voluntary 
movement and sleep. Bradykinesia, also known as slowness of movement, is 
another manifestation of the disease, which appears being the most disabling 
symptom in the early stages of the disease, as well as rigidity, which is resistance 
to limb movements. Postural instability, leading to impaired balance, festinating 
gait, which mostly includes abnormal walking pattern and stiffness in walk, and 
facial motion are less common characteristics of the disease (Andalib et al., 
2014).  
 
1.1.4 Non-motor symptoms 
 
Even though the motor symptoms of PD are well defined, the non-motor features 
are most of the time under-estimated and subsequently under-treated. Non-motor 
symptoms and their management have been recognized by the UK National 
Institute for Clinical Excellence as an important unmet need in PD (Parkinson’s 
Disease, 2006). It has been estimated that 62% of non-motor symptoms of PD 
might remain undeclared to health-care professionals because the patients might 
be embarrassed or even unaware that these symptoms can be linked to PD (Mitra 
et al., 2008). The lack of recognition and treatment of those symptoms have 
important therapeutic and societal implications, as when they are left untreated 
they have a huge effect on the quality of life. A large range of symptoms 
comprise the non-motor symptom complex of PD, as they are summarized on 
Table 1.1 (Chaudhuri et al., 2009).  
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Table 1.1: Non-motor symptoms of Parkinson’s disease 
Neuropsychiatric symptoms 
Depression, Apathy, Anxiety 
Cognitive dysfunction 
Dementia 
Attention deficit 
Hallucinations, Illusions 
Panic attacks 
Sleep disorders 
Insomnia 
Restless legs and periodic limb movements 
REM behavior disorder 
Vivid dreaming 
Autonomic symptoms 
Bladder disturbances 
Sweating 
Orthostatic hypotension 
Erectile impotence 
Gastrointestinal symptoms 
Dribbling of saliva 
Ageusia 
Nausea 
Constipation 
Sensory symptoms 
Pain 
Olfactory disturbance 
Visual dysfunction (contrast sensitivity, colour 
vision) 
 
 
The non-motor symptoms of PD occur not only in advanced stages of the disease 
but also in early stages, and include olfactory deficits, constipation, rapid-eye 
movement (REM) and depression. These might precede the expression of the 
motor symptoms even by a whole decade (Chaudhuri et al., 2006, Naidu and 
Chaudhuri 2008). 
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1.1.5 Pathophysiology of PD 
 
The hallmark of PD is the progressive loss of the melanised dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) with an intact striatum, the 
area to which the SNpc normally project. Other sets of neurons are also lost, but 
the loss of SNpc is extremely dramatic and is the major pathological event linked 
to the movement disorder seen in PD clinically. However, cell death alone is not 
sufficient for pathological diagnosis.  This pathology is usually accompanied by 
the presence of Lewy bodies and Lewy neurites, with the Lewy bodies being 
intracellular accumulations of the protein alpha-synuclein, in a fibrillar form. 
Lewy bodies themselves are not truly diagnostic for PD as they are found in 
other disorders as well. For example, Lewy bodies are also present in cognitive 
disorders such as Alzheimer’s disease. However, we have a two-part, additive 
logic for the neuropathology of PD; Lewy bodies and nigral cell loss are both 
required. Although, there are overlaps in the syndromes, the definitional 
approach cleanly delimits what PD is and what it isn’t.  The loss of dopaminergic 
neurons leads to the loss of dopamine release in the striatal projection areas of 
these neurons. That has as a result the typical motor dysfunction, which only 
becomes evident when approximately 80% of striatal dopamine and 50% of 
nigral neurons are lost (Cookson et al., 2008). In contrast, PD is very poorly 
understood from an etiological viewpoint.  
 
1.1.6 Medical treatment of PD 
 
Over the past half century, an enormous progress has been made in the treatment 
of PD, but levodopa (L-DOPA) remains the most potent drug for controlling PD 
symptoms (Jankovic 2008). Each patient’s therapy can be individualized, and 
diverse drugs other than levodopa are presently available. Among these drugs are 
dopamine agonists, catechol-o-methyl-transferase (COMT) inhibitors and 
nondopaminergic agents. Head-to-head comparisons of drugs within classes are 
rare, and the differences that have emerged are related to the effects on motor 
fluctuations, dyskinesias, on/off times and adverse effects of the specific agents 
within each class (Jankovic and Aguilar 2008).  
 
 17 
At the moment, L-DOPA, is mainly used in order to alleviate the symptoms of 
the disorder, but is frequently associated with motor complications, such as 
fluctuations and dyskinesias or other complications after 5 years of treatment 
(Jankovic 2005). For that reason, there is currently a debate on when in the 
course of PD is more appropriate to initiate levodopa therapy (Stern 2004; 
Weiner 2004). The addition of carbidopa, which is a peripheral dopa 
decarboxylase inhibitor, enhances the therapeutic benefits of levodopa. In 
patients who are sensitive to peripheral side effects, including vomiting and 
nausea, additional carbidopa can be added to the conventional 
carbidopa/levodopa preparation. The most common problem in patients taking 
levodopa is delayed onset of response after injecting a dose of levodopa. Another 
problem is different types of levodopa-induced dyskinesias including “peak-dose 
dyskinesias” and “wearing-off” dyskinesias (Fahn 2000; Jankovic 2002). That 
raises concern, as young-onset PD patients seem particularly likely to develop 
levodopa-induced dyskinesias.  
 
Due to these side-effects of levodopa experts recommend the delay of levodopa 
until the symptoms of parkinsonism are affecting the quality of every day life of 
the patients. Indeed, many clinicians recommend using dopamine (DA) agonists 
as the initial dopaminergic therapy (Jankovic 2000). DA agonists exert their 
pharmacologic effect by directly activating DA receptors, bypassing the 
presynaptic synthesis of DA (Jankovic and Aguilar 2008). 
 
In addition to the dopaminergic drugs, nondopaminergic drugs are being 
prescribed as well, such as anticholinergics and amantadine, as they can provide 
satisfactory symptoms relief at the early stages of the disease. The 
anticholinergic drugs are very useful in younger patients who are primary 
bothered by tremor. Even though they are quite effective, their usefulness is 
limited by the anticholinergic side effects including cognitive impairment, dry 
mouth and urinary problems.  
 
Finally, there are several surgical options in order to treat the movement 
symptoms. Besides thalamotomy and pallidotomy, another promising surgical 
approach for the treatment of tremors and other movement disorders is high-
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frequency deep brain stimulation (DBS) via electrodes implanted in the ventral 
intermediate (VIM) nucleus of the thalamus, globus pallidus (GPi), subthalamic 
nucleus (STN) or other subcortical nuclei. DBS surgery improves parkinsonian 
symptoms and prolongs the “on” time (Linazasaro 2003), along with other 
aspects of the quality of life (Diamond and Jankovic 2005).   
 
1.1.7 Epidemiology of PD 
 
PD was commonly considered to be “simply” an environmentally caused 
disorder in the 1970s and 1980s, although its pattern of familial inheritance has 
been recognized since the time of the French physician, Charcot. In recent years, 
several monogenic mutations were identified causing PD, but these mutations 
likely count only for a small proportion of PD cases. The large majority of cases 
are sporadic in nature with the most common risk factor being ageing. Insights 
into non-genetic causes are needed in order to advance our knowledge and 
understanding of the pathogenesis of the disease so more effective therapeutic 
interventions can been discovered. The global burden of PD is set to rise in the 
years to come because of our ageing population. In a recent study on the world’s 
10 and Western Europe’s 5 most populous nations, it was estimated that the 
number of people with PD will rise from 4.1 to 4.6 million in 2005 by two times 
to 8.7 to 9.3 million in the year 2030. Moreover, six of the most populous 
countries are in Asia (China, India, Indonesia, Pakistan, Bangladesh and Japan) 
and the number of PD patients is expected to rise from 2.57 million in 2005 to 
6.17 million in 2030 (Dorsey et al., 2007).  
 
Many epidemiological studies are undertaken nowadays in order to explore the 
association between PD and various demographic and environmental factors as is 
indicated in the following summary table (Table 1.2).  
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Table 1.2: Epidemiological factors associated with PD (Tan 2013) 
                                             Factors Risk of PD 
Demographic factors 
Age 
Gender 
↑ 
Male  ↑ 
Lifestyle factors 
Smoking 
Caffeine 
Alcohol 
Tea 
Physical activity 
Obesity 
↓ 
↓ 
↓ 
↓ 
↓ 
↑ 
Occupational factors 
Pesticide 
Heavy metal exposure 
Head injury 
↑ 
↑ 
↑ 
Dietary factors 
Diary products/milk 
Uric acid 
Carbohydrates 
Fat 
Cholesterol 
Iron 
↑ 
↓ 
↑ 
↑ 
↑ 
↑ 
Pharmacological 
factors 
Oestrogens 
Statins 
↓ 
↓ 
 
 
Tan et al. (2013) summarized the convincing evidence that alcohol, smoking and 
increased caffeine intake, are associated with a reduced risk of developing PD. 
Moreover, pesticide use and increased intake of dairy products are associated 
with increased risk of PD. However, it is important to bear in mind that the 
association of epidemiological factors with PD does not equate to causation or 
protection. These factors however provide important clues to direct further 
clinical and basic science studies so that the underlying pathogenic mechanisms 
behind PD can be unraveled. 
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1.2 Genetic background of PD 
 
Although studies based on these environmental factors are beginning to 
illuminate the mechanisms of idiopathic PD, more tremendous progress has been 
made with modeling the genetic forms of PD. This began with a linkage analysis 
study in 1996, with an Italian family with an autosomal dominant form of early 
onset PD (Polymeropoulos et al., 1996). In this, α-synuclein (SNCA) was 
identified as the causative gene of PD. This was supported by 
immunocytochemical studies, which identified α-synuclein as a component of the 
Lewy Bodies (Spillantini et al., 1998). Following this, and the recognition of 
early-onset, familial forms of the disease, and the identification of gene 
mutations that cause rare familial forms of PD (Table 1.3), more common highly 
penetrant mutations were identified in late onset PD. Most recently, Genome 
Wide Association Studies (GWAS) approaches identified moderate risk variants, 
and mapped multiple low risk conferring loci (Houlden & Singleton 2012). 
GWAS is considered as a breakthrough in human genetics as it marked the end 
of wholescale candidate gene association studies and linkage analysis studies, 
which were based on function. GWAS provide a very efficient method to 
identify common genetic loci in a genome-wide manner.    
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AD: Autosomal dominant, AR: Autosomal recessive, LOPD: Late onset PD, EOPD: Early onset PD
Table 1.3 Monogenic loci for Parkinson’s disease 
Locus Gene 
Chromosomal 
location 
Inheritance 
Type of 
parkinsonism 
Reference 
PARK1/PARK4 SNCA 4q21 AD LOPD/EOPD 
Polymeropoulos et al., 1996; 
Polymeropoulos et al., 1997 
Singleton et al., 2003 
PARK2 Parkin 6q25-q27 AR EOPD Kitada et al., 1998 
PARK5 UCHL1 4p14 AD LOPD Wintermeyer et al., 2000 
PARK6 PINKI 1p36 AR EOPD Valente et al., 2004 
PARK7 DJ1 1p36 AR EOPD Bonifati et al., 2003 
PARK8 LRRK2 12q12 AD LOPD 
Funayama et al., 2002; Paisan-Ruiz 
et al., 2004, Zimprich et al., 2004) 
PARK9 ATP13A2 1p36 AR EOPD Di Fonzo et al., 2007 
PARK13 HTRA2 2p12 AD LOPD Alnemri 2007 
PARK15 FBX07 22q12-q13 AR EOPD 
Shojaee et al., 2008; Paisan-Ruiz et 
al., 2010 
PARK17 
VPS35 
PANK2 
16q11.2 
AD 
AR 
LOPD 
EOPD 
Vilarino Guell et al., 2011 
Johnson et al., 2004 
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Various hereditary forms of PD that present similar clinical phenotypes to the 
sporadic ones have been recognized. In 2002, based on a genome-wide linkage 
analysis of a large Japanese family (the Sagamihara family) with autosomal 
dominant PD, a new locus linked to PD was identified, PARK8 (12p11.2-q13.1) 
(Funayama et al., 2002; Funayama et al., 2005).  
 
Although this confirmed the original hypothesis (that there is a genetic 
contribution to PD), the family demonstrated some unusual features. For 
instance, even though the disease had an autosomal dominant mode of 
inheritance, penetrance was incomplete. Despite the fact that some people had 
inherited the chromosomal region which tracked with disease, they did not 
always exhibit signs of PD. Furthermore, when autopsies were carried out on 
members of the family, no Lewy bodies were found, despite neurodegeneration 
in the substantia nigra, the main characteristic of PD (Hasegawa and Kowa, 
1997). It was concluded that this family represented an unusual, possibly even 
private disease that resembled PD.  
 
However, only 2 years later, several families were identified worldwide that were 
linked to the same chromosomal locus (Zimprich et al., 2004). In particular, 
several mutations at this locus were found to be within LRRK2 (leucine-rich 
repeat kinase 2) (Zimprich et al., 2004; Paisan-Ruiz et al., 2004). Further 
research on LRRK2 gene showed that mutations within this gene are relatively 
common, occurring with a prevalence ranging from 1-30% of all PD depending 
on the population under study (Cookson et al., 2005). This frequency is very high 
for a disease that until 1996 was considered to have no genetic background.  
 
Importantly, it was confirmed that the original Japanese family was also carrying 
a LRRK2 mutation, verifying the correct identification of the gene (Funayama et 
al., 2005). The penetrance of the mutations within the LRRK2 gene is age 
dependent, but incomplete (Hulihan et al., 2008; Latourelle et al., 2008), 
meaning that a proportion of mutation carriers survive until their late 80s without 
developing any of the PD symptoms (Kay et al., 2005), in contrast to the typical 
age of onset, which is around 50 years old. Confirmation of this gene as a cause 
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of PD was supported by further investigations of the Sagamihara kindred, when 
some family members did indeed have Lewy bodies (Hasegawa et al., 2008).    
 
1.3 Leucine-rich repeat kinase 2 (LRRK2) 
 
Leucine-rich repeat kinase 2 (LRRK2), once also known as dardarin, is a large 
multidomain protein that belongs to the ROCO superfamily. ROCO, a combined 
term of Roc (Ras of complex proteins) and COR (C-terminal of Roc), is 
characterized by the presence of conserved Ras-related GTPase or Roc domain 
followed by a COR domain. The human LRRK2 gene consists of 51 exons and 
encodes a large 2,527 amino acid protein. This multidomain protein contains an 
ankyrin-like (ANK) domain, several leucine-rich repeats (LRR), a Ras-like 
GTPase domain (ROC) along with its C-terminal domain (COR), a kinase 
domain and a WD40 motif (Figure 1.1). The presence of all these protein-protein 
interaction motifs within LRRK2 protein indicates that it may act as a scaffold 
for several other proteins, with an important role in cellular signalling. WD40 
domains in other proteins can also interact with lipids, raising the possibility that 
LRRK2 might be present at the intracellular membranes (McArdle and 
Hoffmann, 2008). In a few words, LRRK2 is a large protein with a central 
catalytic GTPase/kinase region, surrounded by protein-protein interaction motifs, 
forming homo- and possibly hetero-dimers (Greggio et al., 2009). 
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Figure 1.1: Schematic diagram of the human LRRK2 domains and 
the PD pathogenic mutations. The human LRRK2 is composed of 
several independent domains including armadillo repeats (ARM), ankyrin-
like repeats (ANK), leucine-rich repeats (LRR), Ras of complex proteins 
(ROC) GTPase, C-terminal of ROC (COR), Kinase and WD40. This gene 
includes the ROC and the kinase domains, which are enzymatic, whilst 
the rest are protein-protein binding domains. Several PD pathogenic 
mutations have been identified within LRRK2, with the most common 
being the G2019S mutation lying within the kinase domain.  
 
More than 75 LRRK2 nucleotide substitutions (some of them are summarised in 
Table 1.4) have been identified but not all of them contribute to the risk of 
Parkinsonism to the same degree. That is rather surprising given its large size. 
Genetic evidence for pathogenicity is only proven for p.R1441C, p.R1441G, 
p.Y1699C, p.G2019S, and p.I2020T substitutions (by linkage) and for p.R1628P 
and p.G2385R (by association). While some of these sequence variants may be 
pathogenic, some might only be benign or polymorphisms. This is a critical 
distinction in patient diagnosis and in interpreting LRRK2 function (Dachsel and 
Farrer, 2010).  
 
 
ARM ANK LRR  ROC 
1 705 860 984 1278 1335 1510 1511 1878 1879 2138 2142 2498 2527 
hLRRK2 
Domains 
Pathogenic PD 
mutations I1371V 
R1441C 
R1441G 
R1441H 
Y1699C 
Y1699G 
G2019S 
I2020T 
 COR  Kinase  WD40 
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Table 1.4: Neuropathology of LRRK2 forms of Parkinson’s disease (Bardien et al., 2011) 
Mutation Domain 
Substantia nigra 
neuronal loss 
Lewy bodies 
Ubiquitin 
staining 
Enzymatic impact 
References 
p.G2019S Kinase Yes Yes Yes 
Kinase ↑ 
GTPase ↓ 
Khan et al., 2005; 
Ross et al., 2006; 
Gaig et al., 2007; 
Giasson et al., 2008 
p.R1441C ROC Yes Yes Yes GTPase ↓ Zimprich et al., 2004 
p.R1441G ROC Yes No No GTPase ↓ Marti-Masso et al., 2009 
p.I2020T Kinase Yes Yes No None Funayama et al., 2002 
p.Y1699C COR Yes Yes Yes GTPase ↓ 
Khan et al., 2005; 
Zimprich et al., 2004 
p.I1371V ROC Yes Yes Limited GTPase ↓ Di Fonzo et al., 2006 
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Epidemiological studies indicate the non-synonymous G2019S mutation as the 
most common genetic cause of late onset PD (Richecko et al., 2014). This 
mutation is relatively common across several populations, being responsible for 
PD in ~2% of sporadic and ~5% of familial PD cases in Northern European and 
North American populations; certain groups are being enriched by the presence 
of this mutation with reported frequencies of ~10% in Portuguese PD patients, 
~20% in PD patients of Ashkenazi Jewish descent, and ~40% of North African 
Berber Arab PD patients (Houlden & Singleton 2012). It is very likely that the 
p.G2019S mutation has arisen on multiple occasions, but for the majority of the 
carriers, this mutation is believed to have been inherited from a common founder 
dating back 4,500-9,100 years, with the suggestion being that it arose in the Near 
East and then moved throughout the World with the Ashkenazi Diaspora 
(Bardien et al., 2011).  
 
This mutation lies within the activation loop of the kinase domain of the LRRK2 
protein leading to stabilization of the enzyme in the active form, causing 
enhanced phosphorylation activity (Mata et al., 2006). A 2-3-fold increase in the 
kinase activity of the G2019S-LRRK2 compared with the wild type protein has 
been consistently seen by many groups (West et al., 2005, Greggio et al., 2006, 
Smith et al., 2006, Guo et al., 2007).  
 
The reduced penetrance of LRRK2-G2019S mutation means that a lot of mutation 
carriers do not manifest the disease even in their eighties, and the variability in 
the age of onset indicate that LRRK2 induced PD is probably modified by a 
combination of environmental and genetic factors (Guo et al., 2006). Moreover, 
LRKK2 mutations seem to have a true dominant effect, as individuals 
heterozygous for the mutation have the same risk of disease compared to those 
who are homozygous (Cookson et al., 2010).  
 
The actual function and how mutations within LRKK2 gene contribute to the 
pathogenesis of PD is not clear yet. The isolated LRRK2 kinase domain has been 
shown to be catalytically inactive, indicating that the Roc and COR domains 
clearly are essential for control of the kinase activity (Greggio et al., 2008). Ras-
GTPases act as molecular switches, and depending on whether the GTPase is 
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active, will turn signal transduction cascades on or off. Typically, GTPases act to 
control the phosphorylation of a kinase, as appears to be the case for LRRK2. 
Moreover, autophosphorylation plays an important role in the regulation of 
kinase function, and autoregulatory interactions between the kinase and Roc-
GTPase domains are highly probable (Gloeckner et al., 2010). Given that the 
Roc-GTP domain is the region containing the majority of autoregulation sites, it 
is presumably regulated by the kinase domain, and may even be the major output 
of LRRK2 (Taymans and Cookson 2010). LRRK2 may exist as an oligomeric 
complex with minimal kinase activity, which upon GTP binding, dissociates to 
form an intermediate structure, which phosphorylates itself, forming a 
homodimer with activation of the kinase (Webber et al., 2009). Since the ROC 
domain is a molecular switch, if GTPase activity decreases as a result of 
mutations, turnover of GTP to GDP will diminish, with the consequence that the 
activating effect of GTP on the Roc domain will be of longer duration. As the 
Roc-COR domain has an excitatory effect on the kinase domain, a prolonged 
activation of the Roc domain will lead to an increase in kinase activity. 
Mutations that affect GTP binding or delete the GTPase domain will bring about 
loss of kinase activity (Bardien et al., 2011).  
 
This protein has been implicated in several cellular processes, including vesicle 
sorting and trafficking, autophagy, dopamine homeostasis, dopamine receptor 
activation, synaptogenesis, miRNA processing and cytoskeletal remodelling 
(Paisan-Ruiz et al., 2013; Migheli et al. 2013). Moreover, LRRK2 has been 
demonstrated being involved in the negative regulation of normal levels of 
dopamine. The over expression of selected mutants of LRRK2 cause a severe 
reduction in the dopamine levels of the brain (Liu et al., 2014). Liu et al. (2008) 
reported that L-DOPA causes improvement in movement, but not in the survival 
of dopaminergic neurons, indicating that changes in dopamine levels might be 
due to defects in metabolism or processing and handling of dopamine. 
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1.4 Dopamine and its involvement in PD 
 
Dopamine (DA) is a catecholamine neurotransmitter that is widely distributed in 
the central nervous system (CNS) and some peripheral areas including 
cardiovascular and renal system. The first time DA was found to occur in an 
organism was as a pigment-building metabolite in the plant Sarothamnus 
scoparius (Schmalfuss et al., 1931). Later on it was identified to be a substrate of 
aromatic amino acid decarboxylase (AADC) (Blaschko, 1942) and prevalent in 
invertebrates (Cottrell, 1967). At first DA was only considered being a precursor 
of the catecholamin neurotransmitters epinephrine (E) and norephinephrine (NE) 
or assumed to only be an intermediate in tyrosine degradation (Blaschko, 1942). 
Only later DA was recognized as an independent neurotransmitter 
(Hornykiewicz, 2002; Carlsson, 2003).  
   
Calabresi et al.  (2007) reported the importance of DA in the modulation of 
behavior and cognition; voluntary movement; motivation; punishment and 
reward; inhibition of prolactin production; sleep; dreaming; mood; attention; 
working memory; and learning. Impairment of DA transmission has been 
implicated in several diseases such as neuropsychiatric disorders, including 
attention deficit hyperactivity disorder (ADHD), Tourette syndrome (TS), 
schizophrenia, psychosis and depression. It has also been linked to 
neurodegenerative disorders including PD, Huntington disease (HD) and 
multiple sclerosis (MS) (Rangel-Barajas et al., 2014).  
 
The importance of the DAergic system in the brain was highlighted in PD, 
because of the degeneration of the DAergic neurons of the substantia nigra pars 
compacta. There are three main sources of DA in the CNS all involved in 
different neurophysiological features (shown in Figure 1.2): the nigrostriatal 
pathway, which is related with motor function, the mesocorticolimbic pathway, 
which is related with the cognitive function, motivation and emotion and finally 
the tuberoinfundibular pathway, which is involved to the secretion of prolactin 
(Ben-Jonathan, 1985; Jackson and Westlind-Danielsson, 1994).  
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Figure 1.2: Schematic presentation of the human central 
dopaminergic systems. Adapted from Felten and Shetty, 2010. 
 
The physiological effects of DA are mediated by dopaminergic receptors, which 
have widespread expression throughout the brain. The DA receptors belong to 
the G protein coupled receptors family (GPCRs), with five subtypes of 
mammalian DA receptors existing, which are divided in two families according 
to their structure and biological response. The D1-like family includes D1 and 
D5 receptors, while D2-like family consists of D2, D3 and D4 receptors. The 
D1-like family are positively coupled to adenylyl cyclase (AC) inducing the 
intracellular cyclic 3,5 adenine-monophosphate (cAMP) accumulation leading to 
the activation of the protein kinase dependent of cAMP (PKA) in contrast to the 
D2-like family that are negatively coupled to AC, which decreases the cAMP 
accumulation.  
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The DA receptors are the main target of several drugs including 
psychostimulants and antipsychotics. What is interesting is that DA receptors 
expression and intracellular signal transduction pathways change during 
degenerative process and neurotoxicity worsening the symptoms and the 
progression (Rangel-Barajas et al., 2015).  
 
Although DA is an important neurotransmitter in the brain, a substantial part of 
the overall DA in the body is produced outside the brain by mesenteric organs 
(Eisenhofer et al., 1997). The classical pathway for DA biosynthesis was already 
postulated by Blaschko in 1939 (Blaschko, 1939). The two-step biosynthesis of 
DA takes place in the cytosol of DAergic neurons and starts with the 
hydroxylation of L-tyrosine at the phenol ring by tyrosine hydroxylase (TH) to 
yield DOPA. This oxidation is strongly regulated and depends on 
tetrahydrobiopterin (BH4) as a co-factor, which is synthesized from guanosine 
triphosphate (GTP) by GTP cyclohydrolase (GTPCH). DOPA is then 
decarbozylated to DA by aromatic amino acid decarboxylase (DDC) as shown in 
Figure 1.3.  
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Figure 1.3: Dopamine biosynthesis pathway. Dopamine is synthesized 
by tyrosine via tyrosine hydroxylase (TH) catalysis to levodopa (L-DOPA), 
followed by decarboxylation by dopa decarboxylase (DDC) to dopamine. 
Responsible for dopamine metabolism are the intraneuronal monoamine 
oxidase A (MAOA) and glial and astrocyte MAOA and MAOB. Adapted by 
Youdim et al., 2006. 
 
 
At physiological concentrations DA does not exhibit toxicity, however 
malfunction of DA release and/or metabolism could lead to neurotoxicity. The 
underlying mechanisms are not clear yet but several evidences have shown that it 
can be caused by oxidative stress, neuroinflammation and apoptosis.  The 
enzymatic breakdown of DA to its inactive metabolites is carried out by 
catechol-O-methyl transferase (COMT) and monoamine oxidase (MAO). The 
biosynthesis of DA and other catecholamines can be limited by the action of the 
enzyme tyrosine hydroxylase (TH). After the biosynthesis of DA, it is 
incorporated into synaptic vesicles by the action of vesicular monoamine 
transporter 2 (VMAT2) where it is stored. DA is discharged by exocytosis into 
the cell membrane and dumped into the synapse (Juarez-Olguin et al., 2015).  
 
Dopamine metabolism is considered critical for the preferential susceptibility of 
ventrolateral SNc cells to damage in PD. It produces highly reactive species that 
oxidize lipids and other compounds, increasing oxidative stress and leading to 
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impaired mitochondrial function. At neutral pH, DA can auto-oxidize. Therefore, 
reduced sequestration of dopamine into synaptic vesicles, where the pH is lower 
and dopamine is more stable without being auto-oxidize, may represent a 
vulnerability factor for neurons. That means that dopamine neurons with low 
dopamine transporter activity in the cell membrane are less sensitive to oxidative 
stress induced by dopamine or neurotoxins and are also less affected in PD 
(Obeso et al., 2010).  
 
1.5 Retinal dopamine in PD 
 
Dopaminergic neurons are not only found in the substantia nigra, but also in the 
retina. Consequently, it may be no surprise that patients with PD frequently 
report problems with visual tasks, such as navigating around everyday 
environments and using maps (Bowen et al., 1972). In questionnaire studies, 
78% of patients with PD report at least one visual symptom, including 
difficulties in reading, double vision, and misjudging objects and distances 
(Archibald et al., 2011; Urwyler et al., 2014). Visual hallucinations are also very 
common, with a frequency of 74% after 20 years of disease (Fenelon et al., 2000; 
Hely et al., 2008).  
 
Neurochemical evidence for dopaminergic deficiency in the human retina was 
first advanced with reports of reduced tyrosine hydroxylase immunoreactivity of 
dopaminergic cells in five patients with PD (Nguyen-Legros, 1988). Tyrosine 
hydroxylase (TH) is uniquely required for the synthesis of dopamine and hence 
identifies DA-containing cells in the retina. Harnois and Di Paolo (1990) 
examined PD patients post-mortem and found that subjects not receiving L-
DOPA therapy at the time of the death had significantly lower retinal dopamine 
concentrations than controls. That also occurred for those whose death occurred 
less than 15h after their last dose. Tatton et al. (1990) treated monkeys with 
MPTP, a neurotoxin that destroys dopaminergic neurons, and showed that causes 
a dose-dependent, but reversible, reduction in TH immunoreactivity in amacrine 
cells. These studies confirmed the previously reported retinal dysfunction in 
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patients with PD and that it was dopaminergic deficiency itself that mediated 
these changes (Archibald et al., 2009).  
 
Deeper understanding of the underlying mechanisms leading to visual problems 
will shed new light on our understanding of the pathways leading to PD (Weil et 
al., 2016). The presence of dopaminergic neurons in the fly retina emphasizes the 
importance of using Drosophila as an animal model to test the connection 
between PD and the visual problems. 
 
1.6 Drosophila as an animal model 
 
Over 100 years of innovative experimentation with the “common fruit fly” or 
Drosophila melanogaster has placed this remarkable organism at the front line of 
contemporary biological research. The reasons why the small fruit fly is such a 
successful animal model are manifold. First of all, Drosophila is very easy and 
cheap to maintain in the lab; it can give rise to a large number of genetically 
identical progeny; it has a rather short life span ranging from 40 to 120 days 
depending on diet and stress (Piper et al., 2005; Pletcher et al., 2005); it shows 
complex behaviour, including learning and memory (McGuire et al., 2005; 
Margulies et al., 2005); driven by a sophisticated brain and nervous system 
(Nichols, 2006). Drosophila is encoded by approximately 13,600 genes as 
compared to 27,000 human genes, located on only 4 pairs of chromosomes as 
compared to 23 pairs in human (Adams et al., 2000). Indeed, many of these 
genes and processes are conserved between Drosophila and other organisms, 
notably humans. For example, it has been estimated that two-thirds of known 
human disease-causing genes are also present in the fly (Rubin et al., 2000; 
Reiter et al., 2001). Comparative analysis of whole genome sequencing revealed 
striking similarities in the structural composition of individual genes of Homo 
sapiens and Drosophila (Rubin et al., 2000). Moreover, the molecules and 
mechanisms underlying core modules of cell biology are also conserved: 
homologous genes mediate homologous pathways. Furthermore, fundamental 
cellular processes related to neurobiology are similar in Drosophila and humans, 
including synapse formation, neuronal communication, membrane trafficking 
 33 
and cell death; the neurobiological bases of behaviour are of the same origin in 
flies and humans, including sensory perception, integration and motor output 
(Hirth, 2010). 
 
Thanks to very well-characterized anatomy, development (Campos-Ortega, 
1997; Technau, 2008) and the availability of molecular genetic tools (Ashburner 
et al., 2004; Greenspan, 2004; Dahmann, 2008), Drosophila is one of the most 
extensively used genetic model organisms to study complex biological processes. 
While less complicated than the mammalian brain, Drosophila has a complex 
central nervous system, which is composed of neurons and glia, it is protected by 
the blood-brain barrier, and shares striking organization similarities with the 
vertebrate brain. In comparison to other model organisms like C.  elegans and the 
mouse, Drosophila provides a very powerful genetic model system for the 
analysis of brain and behavioural disorders related to human disease: its brain is 
complex enough in contrast to C. elegans and relevant to humans but it is still 
small enough compared to mouse for an in-depth structural and functional 
analysis (Heisenberg, 1997). Functional, developmental, and molecular 
similarities between these systems further testify that basic principles of neural 
circuitry are conserved from flies to humans (McGurk et al., 2015).  
 
Experimental manipulations and observations of cells and tissues are relatively 
easy in Drosophila, as the organs are of low complexity and size and can be 
often studied live or through straightforward fixation and staining protocols in 
the whole organism. More importantly, we can take advantage of the extensive 
fly genetic toolbox in order to create transgenic flies containing the sequence of 
interest, as is being described below.  
1.7 The Drosophila visual system 
 
Despite of its miniature body and tiny brain, Drosophila can survive in almost 
any corner of the world. It can find food, court mate, fight rival conspecific, 
avoid predators and amazingly fly without crashing into trees. Drosophila vision 
and its underlying neuronal machinery has been a key research model for at least 
half century for neurogeneticists.  
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The first mutant in Drosophila, which was identified by Morgan in 1910, was 
white, an ABC transporter, which when missing leads to white-eyed flies instead 
of the wild-type red-eyed flies (Morgan, 1910). This led to the conclusion that 
white is responsible for carrying precursors of the eye colour pigments into the 
developing eye (Morgan, 1910). Since then the fly eye continues to be the focus 
of research not only because adult eye phenotypes are very easy to detect but 
also because, unlike most organs in the fly, the eye is tolerant of genetic 
disruption of basic biological processes and is even dispensable for survival of 
the fly (Zhu, 2013).  Versatile technologies can be used to generate, identify, and 
characterize mutations in the retina and have elevated the eye to a system with 
unrivalled potential for deciphering gene function. The fly eye has been used to 
study cell cycle control, cell proliferation and differentiation, neuronal 
connectivity, apoptosis, programmed cell death and tissue patterning (Kang Sang 
and Jackson, 2005). 
 
The fruit fly has two compound eyes, each of which is composed of regularly 
arranged ommatidia, also known as facets (approximately 750) (Figure 1.4). 
Each facet has its own little lens that focuses light onto eight photoreceptors, 
which are arranged in such a way that six outer photoreceptors (R1-R6) surround 
two central ones (R7 stacked on top of R8). In contrast to vertebrate 
photoreceptors, insect photoreceptors depolarize in response to illumination 
(Borst, 2014). Spatial vision is conveyed by R1-R6. These photoreceptors are a 
homologous group of cells, each of which possesses the opsin Rhodopsin 1 
(Rh1), which shows broad spectral sensitivity. The different photoreceptors in 
one ommatidium have different optical axes, but corresponding photoreceptors 
within neighbouring ommatidia have parallel optical axes. Colour vision is 
enabled by R7 and R8 (Borst, 2014).  
 
Primary visual information is further processed in a part of the fly’s brain called 
the ‘optic lobe’. In each hemisphere, the optic lobe comprises more than 60% of 
all neurons. It consists of four layers of neuropil called the lamina, medulla, 
lobula and lobula plate, each of which is built from 750 repetitive, retinotopically 
arranged columns that reflect the spatial layout of the facet eye. Even though the 
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axons of photoreceptors R1-R6 connect to large monopolar cells of the lamina 
(L1-L5), the axons of photoreceptors R7 and R8 run through the lamina and 
terminate in specific layers of the medulla (Meinertzhagen and O’Neil, 1991). 
Photoreceptors release the neurotransmitter histamine (Hardie, 1989). Histamine-
gated chloride channels are expressed on the postsynaptic cells and mediate 
signal-inverting synaptic communication: a strong, transient hyperpolarisation 
upon illumination onset of the eye, which is followed by a sustained component. 
When the light is switched off, a rebound excitation occurs in the postsynaptic 
cells (Laughlin et al., 1987; Zheng et al., 2009).  
 
Each medulla column consists of more than 60 different cells, which can be 
grouped into medulla intrinsic (Mi) and trans-medulla neurons; with the latter 
connecting the medulla to the lobula complex (Strausfeld, 1976; Cajal and 
Sanchez, 1915; Fischbach and Dittrich, 1989). The terminals of all lamina 
neurons ramify in distinct, specific layers of the medulla (Takemura et al., 2008; 
Takemura et al., 2011). This layout suggests a splitting of photoreceptor signals 
into several parallel pathways that might subserve different functions.  
 
From the optic lobe, visual information takes three major routes: from columnar 
neurons of the lobula complex to various glomeruli in the central brain (Mu et 
al., 2012); from large-field tangential neurons of the lobula plate, to descending 
neurons that connect, via the cervical connective, to the motor centres in the 
thoracic ganglion (Strausfeld and Bassemir, 1985); and from tangential cells to 
neck motor neurons that directly control head movements (Strausfeld and Seyan, 
1985; Gronenberg et al., 1995).  
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Figure 1.4: Diagram of the structure of the Drosophila visual system.  
That includes the photoreceptors and the second-order amacrine (A) and 
lamina neurons (L1,L2). It also presents two types of medulla neurons (C 
and T) that project to the lamina. The visual lobes also include 
dopaminergic cells (DA), some intrinsic to the medulla, others projecting 
from the CNS to the lamina. Adapted from Afsari et al., 2014. 
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1.8 Similarities between the Drosophila and the human visual 
system 
 
As first described by the great neuroscientist Ramon Y. Cajal (1915), one of the 
greatest similarities between vertebrates and Drosophila are the neuronal circuits 
of vision. This was confirmed later by Sanes and Zipursky (2010). Cajal turned 
to the fly hoping to find a simple circuitry to allow easier tracing of neuronal 
connectivity. Instead, he found a complicated system rivaling that of vertebrates.  
 
Cajal argued that fly and vertebrate visual systems were essentially identical in 
key aspects (Cajal and Sanchez, 1915). What he actually said was “If from the 
visual organ of the insect we discount the crucial fact of the dislocation of the 
soma…then the analogy between the visual apparatus converts almost in 
identity”. In one of the most remarkable drawings from that early era, after he 
used silver staining, he made his point by translocating the fly somata to a 
vertebrate position without altering the neuropil, this is known as the 
“Flertebrate” arrangement (Figure 1.5).  
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Figure 1.5: The similarities between the fly and the vertebrate visual 
systems. Cajal fisrt described the similarities between the fly (A) and the 
vertebrate (C) visual systems. A) The fly visual system, where the somas 
appear in their natural position. B) In this drawing of the insect visual 
system Cajal “moved” the cell bodies to correspond to their positions in 
vertebrates, without making any changes of the positions of the synaptic 
contacts. That is referred as the “Flertebrate” arrangement. C) Schematic 
presentation of the main cell types in the vertebrate retina and their 
connections. Adapted from Sanes and Zimpursky, 2010.  
 
Later on modern cytochemical and ultrastructural techniques have been utilised 
in order to compare the fly and the vertebrate visual system providing strong 
evidence in support of Cajal’s view (Figure 1.6). Some of the similarities 
between the two systems include; there are a small number of main neuronal 
types (five in the vertebrate and six in the fly retina), divided into numerous 
subtypes; multiple contact synapses with a single presynaptic terminal abutting 
multiple postsynaptic elements; multiple cellular layers with regular arrangement 
of neurons in each layer; orderly mapping of neuronal arrays at each level onto 
those at the next level; segregation of synapses made by specific subtypes into 
parallel sublaminae within soma-free neuropil (Sanes and Zipursky, 2010).  
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Figure 1.6: Structures underlying the first stages of visual 
processing in the fly and mammalian visual systems. A) Mammalian 
visual system, showing retina, dorsal lateral geniculate nucleus (LGN), 
superior colliculus, and primary visual cortex. B) The Drosophila visual 
system, showing retina, lamina, medulla, and the lobula complex, which 
comprises the lobula and the lobula plate. C) and D) represent similar 
steps in transfer of information through early stages of vertebrate and 
Drosophila visual systems. (Adapted from Sanes and Zimpursky, 2010).  
 
Moreover, similarly to humans, Drosophila contains dopaminergic neurons, 
which actually branch in their visual system (Hindle et al., 2013). The principal 
DA cell in the human retina is an amacrine subtype called A18 although a 
second, less well defined DA cell has also been identified in primate and rodent 
retinas (Mariani, 1990; Mariani, 1991; Kolb et al., 1992; Witkovsky et al., 2005).  
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1.9 Drosophila as an animal model for neurodegenerative diseases 
 
Neurodegenerative diseases represent a subset of human diseases with certain 
features in common. These disorders are usually characterized by the progressive 
loss of specific neuronal populations depending on the disease type. Most of the 
times they are of adult onset and generally are asymptomatic during the 
development and maturation of the nervous system. Even though 
neurodegenerative diseases were once considered being one of the most obscure 
and intractable of all human illnesses, this situation is changing, due to 
breakthroughs in human genetics that help pinpoint genes associated with 
familial forms of diseases including Alzheimer’s disease and PD (Bonini et al., 
2003; Muqit and Feany, 2002; Driscoll et al., 2003). The identification of these 
genes has helped investigators to characterize the mechanisms of 
neurodegeneration at the molecular level. New light will be shed in our 
understanding of the underlying pathogenic mechanisms thanks to the 
identification of these disease-associated mutations.  
 
Despite the contribution of human genetics in disease understanding, studies on 
human subjects are of very limited use for elucidating the signalling pathways 
and cellular processes underlying the neurodegenerative process. This is because 
of both ethical and technical limitations. Moreover, most human 
neuropathological studies are based on post-mortem tissues that almost never 
reflect the earliest pathologic events at the presymptomatic stage. To overcome 
this problem the most powerful approach for studying disease has always been 
the use of animal models. Invertebrate animals, especially Drosophila, have 
proven to be an excellent model for human neurodegenerative diseases (Lu et al., 
2009; Cauchi and Van den Heuvel 2006).  
 
Apart from all the other advantages of Drosophila as an animal model that have 
been described above, it has been proven that most of the genes implicated in 
familial forms of disease have a fly homolog (Reiter et al., 2001). The key 
approaches used in order to study the underlying mechanisms of human disease 
in Drosophila include the mis-expression of a human disease gene, in its wild 
type or mutant form, loss and gain of function of the Drosophila homolog of a 
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human disease gene and finally genetic screens to identify enhancers and 
suppressors that are able to modify a phenotype caused by the mis-expression of 
the human version of a disease related gene or the Drosophila homolog.  
 
For a model system to functionally approach a condition as complex as PD, 
changes to specific tissues that can result in recapitulation of phenotypes that 
resemble symptoms of the disease are key. The Drosophila adult brain has been 
characterised to contain clusters of dopaminergic neurons (Nassel and Elekes, 
1992). Feeding of flies with various toxins has led to degeneration of 
dopaminergic neurons indicating that there is a susceptibility of dopamine-
producing neurons to toxins that is conserved between mammals and flies 
(Coulom and Birman 2004). 
 
1.10 Genetic toolbox in Drosophila 
 
The genetic power and tractability of Drosophila is optimized by the extensive 
genetic toolbox available for their manipulation. Traditionally, prior to the 
sequencing of the Drosophila genome in 2000, genetic manipulation relied, 
predominantly, upon forward genetic approaches (St Johnston, 2002). By using 
this approach we can identify genes (or set of genes) responsible for a particular 
phenotype of an organism. 
DNA-damaging agents, such as chemical mutagents, have been widely used in 
order to induce mutations in forward genetic studies. The chemical mutagenesis 
offers the advantages of a relatively high mutation rate and broad target range. 
Ethyl methanesulphonate (EMS) was first introduced by Lewis and Bacher  
(1968) and since then has been the most commonly used chemical mutagen in 
Drosophila. EMS is an alkylating agent that induces single-base changes (point 
mutations), which disrupts gene function by causing missense and nonsense 
mutations (Adams and Sekelsky, 2002).  
 
An alternative means of creating novel mutants is the use of transposable 
element insertions, which is an extremely powerful mean of gene disruption.  
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The P-element of Drosophila has been engineered to suit various purposes. The 
fastest and easiest way to use a P-element in Drosophila is to order a stock that 
carries an insertion in the gene of interest. The mutated gene can be rapidly and 
easily identified using the P-element as a tag.  P-elements are very inefficient 
mutagens, however, the most common approach is to screen the large collection 
of P-element insertions existing, rather than generating new insertions by 
mobilizing the P-element oneself (Johnston, 2002). Forward genetics remain 
important due to their ability to generate allelic series of mutations, ranging from 
nulls (amorphs) to weak partial loss of function mutations (hypomorphs) (St 
Johnston, 2002). Whilst forward genetics has proven highly successful in the 
study of gene function, the sequencing of the Drosophila genome has led to an 
expansion of the Drosophila genetic toolbox through more favourable reverse 
genetic approaches (Adams and Sekelsky, 2002). In contrast to forward genetics, 
reverse genetics is based on the principle of mutating specific, known genes and 
observing the resultant phenotypes, thus allowing elucidation of gene function. 
Some reverse genetic approaches also rely upon forward genetic approaches, 
such as chemical or transposon mediated mutagenesis, that have been modified 
to allow targeting of specific genes. For example, P-elements inserted near to a 
known gene of interest can be mobilized, allowing excision of the P-element and 
the generation of a double stranded DNA break (Adams and Sekelsky, 2002). 
Inaccurate repair of such breaks will often occur, allowing deletion of the gene 
sequence flanking the P-element insertion site and generating a specific null 
mutant. In order to prevent loss of such mutations through homologous 
recombination Drosophilist’s utilise what are known as balancer chromosomes. 
The use of transposable elements has proven highly versatile in Drosophila 
genetics with them also being utilized to allow misexpression of genes, using 
P[EP]-elements, or to characterize the temporal and spatial expression of genes 
through enhancer trapping (O'Kane and Gehring, 1987). They also allow for the 
generation of transgenic fly lines via transposon-mediated transformation (Rubin 
and Spradling, 1982). This process involves the insertion of a gene of interest 
into a plasmid between two P-element ends followed by the microinjection of 
this construct, along with a transposase, into syncytial blastoderm embryos. 
Typically, the gene of interest will be inserted into a construct containing an 
Upstream Activator Sequence (UAS), allowing implementation of the 
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Drosophila tissue specific expression system known as the UAS/Gal4 system. 
This system can also be used to implement alternative reverse genetic 
approaches, as opposed to those that rely upon modifications to classical forward 
genetic methods, for example RNA interference (RNAi) (Hammond et al., 2001). 
Based upon known gene sequences it is now possible to design double stranded 
RNAs against specific genes, allowing for target silencing of homologous genes 
through RNAi mediated degradation of cognate messenger RNA (mRNA) 
(Dietzl et al., 2007).  
 
Another way that allow us to selectively mutagenize specific regions of the 
genome, allowing us to perform detailed mechanistic studies in a variety of 
organisms including Drosophila is the CRISPR/CAS9 system. Cas9 is an 
endonuclease that is targeted to sequences from the invading pathogen by a 
crRNA (CRISPR RNA), that provides specificity to the endonyclease by base 
repairing with a 20 nt complimentary sequence within the DNA (Brouns et al., 
2008; Gasiunas et al., 2012; Jinek et al., 2012). Endogenously, another 
component, that is known as tracrRNA (trans-acting crRNA) forms a complex 
with the crRNA and targets its incorporation into the Cas9 complex. Fusion of 
the crRNA and the tracrRNA forms a chimeric RNA (sgRNA or chiRNA), which 
is composed of a 100 nt synthetic single guide, making this system even more 
simple that only requires two components to be expressed (Dahlem et al., 2012; 
Jinek et al., 2012; Cong et al., 2013; Mali et al., 2013). The specificity of the 
system is then determined by a 20 nt sequence at the 5’ end of the sgRNA, which 
can be altered to match any desired sequence in the DNA. In Drosophila this 
system has been engineered by the co-injection of two plasmids into syncytial 
blastoderm stage Drosophila embryos (Gratz et al., 2013). The one plasmid is 
expressing the Cas9 gene under the Hsp70 promoter and the second produces the 
sgRNA driven by a pol III promoter from the U6 gene. Another technique 
involves the co-injection of in vitro transcribed Cas9 mRNA and sgRNA into 
early stage embryos, which achieves much higher mutagenesis rates compared to 
the other method (Bassett et al., 2013; Yu et al., 2013). 
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1.10.1 Balancer chromosomes 
 
Balancer chromosomes are essential for the maintenance of fly stocks as well as 
for mating scheme design. Balancer chromosomes carry multiple inversions 
through which the relative positions of genes have been significantly rearranged. 
They segregate normally during meiosis, but they supress recombination with a 
normal sequence chromosome and the products of any recombination that does 
occur are lethal due to duplications and deletions of chromosome fragments 
(aneuploidy). Moreover, most of the balancer chromosomes are lethal in 
homozygosis. Together these properties are essential for stock maintenance, 
since they eliminate all genotypes that differ from the parental combination. 
Another key feature of balancer chromosomes is the presence of dominant and 
recessive marker mutations. Through their dominant marker mutations, balancer 
chromosomes are easy to follow in mating schemes (Figure 1.7). For instance, by 
making sure that a recessive mutant allele of interest is always kept over 
dominantly marked chromosomes, the presence of this allele can be “negatively 
traced” over the various generations of a mating scheme; especially since 
recombination with the balancer chromosomes can be excluded. There are many 
balancer chromosomes existing, including some on the X chromosome (FM7a, 
FM7c), on the 2nd chromosome (CyO, SM6a) and on the 3rd chromosome (TM3, 
TM6B). There are no balancer chromosomes on the 4th chromosome, as there is 
no recombination happening (Roote and Prokop 2013).  
 
 45 
 
 
Figure 1.7: Balancer chromosomes allow following of mutations 
during chromosomal segregation. Balancer chromosomes allow 
researchers to select flies of the desired genotype during crossing 
schemes. In this example parent flies carrying the mutations of interest 
are crossed together (A) with the aim of obtaining offspring processing 
both of the mutations (C). Each one of the parents are carrying one of the 
mutations of interest on the 2nd chromosome with the balancer 
chromosome CyO on the alternative allele, which carries a dominant 
marker that gives a phenotype of curly wings. Following crossing of the 
parent flies produces progeny possessing either curly (B and D) or 
straight (C) wings. Those with the curly wings should possess the 
balancer chromosome while equally those with straight wings must have 
the genotype of interest carrying both of the mutations (one on each allele 
of chromosome 2). That allows researchers to follow alleles and obtain 
flies of the desired genotype during mating schemes.  
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1.10.2 The Gal4-UAS binary system 
 
The introduction of the Gal4/UAS binary system in Drosophila (Brand and 
Perrimon, 1993) revolutionised our ability to achieve gene expression in a tissue-
specific and time-dependent manner. One fly contains the Gal4 component, 
which generates the yeast protein Gal4 under the control of a Drosophila 
enhancer/promotor. The second fly contains the ‘Upstream Activating Sequence’ 
(UAS), which binds Gal4 and transcribes the gene of interest. As there is no 
Drosophila equivalent of the Gal4 transcription factor that binds to this UAS 
sequence, in the absence of Gal4 these fusion transgenes are mostly inactive. 
Once mated, such flies express the gene of interest in the pattern of the 
enhancer/promotor. Thus, this binary system gives the opportunity to express the 
desired gene where Gal4 determines the expression pattern in which the gene 
downstream of the UAS is going to be expressed (Figure 1.8). In practice, the 
Gal4 and UAS constructs are contained in a P-element, along with markers (e.g. 
w+), so that, once the transgene has been injected into an egg, successful 
transformants can be identified (in this case by orange eyes). 
 
Many choices of Gal4 lines are available, including ubiquitous (Actin-5c), pan-
neuronal (elav), in the dopaminergic neurons (tyrosine hydroxylase), early or late 
in eye development, and those inducible by heat-shock. Equally, many validated 
UAS stocks are available, including UAS-hLRRK2, UAS-G2019S, UAS-R1441C 
and RNAi lines. 
 
The utility of the Gal4-UAS system led to the generation of another independent 
binary system for Drosophila, the LexA-LexAop system (Lai and Lee, 2006). 
LexA binds to and activates the LexA operator (LexAop). The LexA-lexAop 
system uses the LexA DNA-binding domain from a bacterial transcription factor 
that can be linked to the Gal4 activation domain. Usually that system is 
combined with Gal4 for simultaneous gene manipulations and alone for high 
levels of gene over- or mis-expression.  
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Figure 1.8: Directed gene expression in Drosophila. 
In order to achieve this cell or tissue specific expression of a gene of 
interest a fly line that expresses Gal4 under the control of a tissue specific 
promoter is crossed to a second line that the gene of interest has been 
inserted downstream of the UAS, which is the binding site of Gal4. Once 
these two components are together in a mating scheme, progeny will be 
generated in which that gene of interest is only expressed in that cell or 
tissue specific pattern. Fly images generated using the Genotype Builder 
from Roote and Prokop (2013).  
 
1.11 Modelling PD 
 
As described above, a key goal in PD is to discover the underlying mechanism of 
the degeneration of the dopaminergic neurons. The discovery of genetic causes 
of PD (Section 1.2) allowed the creation of transgenic rats, mice, flies and worms 
as model organisms. Although rodent models of α-synuclein, Parkin, DJ-1 or 
Pink1 exhibit various pathological and behavioral phenotypes, the cardinal 
feature of PD, namely selective degeneration of dopaminergic neurons, has not 
been readily reproduced (Beal and Thomas, 2007). It is possible that the short 
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lifespan of mice may have precluded observation of the late-onset dopaminergic 
degeneration phenotype. Alternatively, various fundamental differences in 
dopaminergic neuron physiology between mice and humans could make mice 
less vulnerable to the dysfunction of the individual PD genes (Lu and Vogel, 
2009).  In contrast, many researchers that used Drosophila as an animal model 
for PD managed to recapitulate the PD symptoms (reduced movement, DA 
neuron loss).  
 
The synthesis pathway for DA (outlined above Figure 1.3) is conserved in 
Drosophila and humans with distinct clusters of DA neurons detectable in the 
developing and adult fly brain (Monastirioti, 1999).  
 
Comparable to the human condition, the Drosophila DA system is also involved 
in the locomotor control. Therefore, it is considerable to assume that loss of DA 
neurons can also affect locomotion in Drosophila comparable to the situation in 
PD. Indeed, loss of subsets of DA neurons in the brain as well as locomotion 
defects are the two principal parkinsonian-like phenotypes used to characterise 
fly models of PD. Both phenotypes have been induced by mis-expression of the 
wild type and/or mutant forms of human PD genes, including α-synuclein (Feany 
and Bender 2000; Seugnet et al., 2009), PINK1 (Todd and Staveley 2008; Wang 
et al., 2006; Yang et al., 2008), Parkin (Yang et al., 2003; Haywood and Staveley 
2004; Haywood and Staveley 2006; Wang et al., 2007; Sang et al., 2007) and 
LRRK2 (Lee et al., 2007; Liu et al., 2008; Imai et al., 2008; Ng et al., 2009; 
Venderova et al., 2009). A major contribution to our understanding of the way 
cellular pathways provide a link, leading to a common phenotype was provided 
by the discovery of the interaction of PINK1 and Parkin at the mitochondria 
(Pickrell and Youle, 2015).  
 
1.12 LRRK2 Drosophila models of PD 
 
Since LRRK2-G2019S is the most common cause of PD, and is a gain of function 
mutation, it is straightforward to create a fly model using the Gal4-UAS system 
to provide the ectopic expression of this mutation.  
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Lee at al. (2007) created a fly model for the fly homolog of LRRK2 (dLRRK) by 
generating and characterising LRRK transgenic alleles and loss of function 
mutants in Drosophila, and clearly demonstrated an endogenous role of LRRK2 
in preventing the degeneration of DA neurons. This study shows no loss of 
dopaminergic neurons or deficits in climbing ability. Transgenic expression of 
pathogenic mutants and wild type dLRRK did not exhibit any significant defects, 
while dLRRK loss-of-function mutants show severely impaired locomotive 
activity. Moreover, dopaminergic neurons in dLRRK mutants showed severe 
reduction in tyrosine hydroxylase immunostaining and shrunken morphology, 
implicating a degeneration in the mutants.   
 
Liu et al. (2008) created a gain-of-function LRRK2 Drosophila model by 
overexpressing the human wild-type LRRK2 and the mutant form LRRK2-
G2019S. Expression of both forms of LRRK2 led to retinal degeneration, 
selective loss of DA neurons in the brain, early mortality, and locomotor 
impairment. Moreover, LRRK2-G2019S caused a more severe parkinsonism-like 
phenotype than wild-type LRRK2. Treatment with L-DOPA improved the mutant 
LRRK2-induced locomotor impairment but did not prevent the loss of TH-
positive neurons, similar to LRRK2-linked human PD.  
 
Imai et al. (2008) used Drosophila in order to understand the normal 
physiological function of LRRK2 and how its dysfunction leads to DA 
neurodegeneration. They provided genetic and biochemical evidence that dLRRK 
modulates the maintenance of DA neuron by regulating protein synthesis. 
Moreover, they came to the conclusion that LRRK2 primes phosphorylation of 
4E-BP and that event has an important function in mediating the pathogenic 
effects of mutant dLRRK. Their final conclusion was that there is loss of 
dopamine and of dopaminergic neurons accompanied by behavioural deficits.  
 
Ng et al. (2009) reported that their transgenics, G2019S, Y1699C and G2385R 
variants, all exhibited late-onset loss of DA neurons in selected clusters that are 
accompanied by locomotion deficits compared with their hLRRK2-expressing 
flies. This finding is consistent with the report by Imai et al. (2008), as the 
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mutant LRRK2-mediated degeneration occurs only towards the terminal age of 
the fly and is restricted to selected clusters of DA neurons, whereas transgenic 
flies expressing wild-type LRRK2 are spared from this age-associated phenotype. 
This study completely matches the findings of other investigators (Lee et al., 
2007; Imai et al., 2008) which are in contrast to the report by Liu et al (2007) 
where degeneration in Drosophila expressing either the wild-type or LRRK2-
G2019S was observed to occur non-selectively across all the DA neuronal 
clusters. Moreover, no retinal degeneration was observed in this study, even at 
flies aged 20 or 60 day old, in contrast to Liu et al. (2007) that detected 
significant retinal degeneration at as early as 3 weeks of age post-eclosion.  
 
Venderova et al. (2009) developed and characterised independent lines of WT 
and mutant LRRK2-expressing Drosophila. These flies displayed no overt 
developmental defects, notably a lack of nervous system pathology. This was 
probably unexpected given the association of LRRK2 with axonal development 
and outgrowth. These results indicate that expression of any of the human or 
other LRRK2 mutants result in loss of dopaminergic neurons. That is consistent 
with the notion that LRRK2 expression results in selective dopaminergic loss in 
Drosophila without overt effects on other neuronal subpopulations.   
 
Hindle et al. (2013) investigated the effect of LRRK2 mutations using Drosophila 
electroretinograms (ERGs). They demonstrated progressive loss of photoreceptor 
function in flies expressing the LRRK2-G2019S mutation in their dopaminergic 
neurons. The photoreceptors showed increased autophagy, apoptosis and 
mitochondrial disorganisation and also loss of vision was determined after 28 
days. Moreover, fly head dissections revealed extensive neurodegeneration 
throughout the visual system, even in regions not directly innervated by 
dopaminergic neurons. The other PD-related mutations that were tested didn’t 
reveal any photoreceptor deficits and there was no loss of vision with kinase-
dead transgenics. Furthermore, they manipulated the levels of dLRRK, which 
suggested that the G2019S mutation is a gain of function rather than dominant 
negative.  
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1.13 LRRK2 and its interacting proteins 
 
As a kinase, one of the key questions is which proteins are phosphorylated by 
LRRK2? In order to identify binding partners of LRRK2, many different 
research groups tested for specific protein interactions. LRRK2 has been 
implicated in several cellular processes including mitochondrial function (Smith 
et al., 2005), regulation of transcription (Kanao et al., 2010), and translation 
(Imai et al., 2008; Gehrke et al., 2010), Golgi protein sorting (Sakaguchi-
Nakashima et al., 2007), apoptosis (Ho et al., 2009) and dynamics of actin (Jaleel 
et al., 2007; Parisiadou et al., 2009) and microtubules (Gandhi et al., 2008; 
Gillardon 2009; Lin et al., 2009). As far as the localisation of LRRK2 is 
concerned, there is evidence that it localises to mitochondria (West et al., 2005; 
Biskup et al., 2006; Gloeckner et al., 2006; Hatano et al., 2007), the endoplasmic 
reticulum (Gloeckner et al., 2006; Vitte et al., 2010), Golgi (Biskup et al., 2006; 
Gloeckner et al., 2006; Hatano et al., 2007), and microtubule structures (Gandhi 
et al., 2008; Gloeckner et al., 2006). Moreover, LRRK2 has been associated with 
intracellular membranes (Biskup et al., 2006; Gloeckner et al., 2006; Hatano et 
al., 2007; Alegre-Abarrategui et al., 2009; Berger et al., 2010) and with vesicles 
in the endolysosomal pathway (Biskup et al., 2006; Hatano et al., 2007; Alegre-
Abarrategui et al., 2009; Shin et al., 2008; Higashi et al., 2009) implicating 
LRRK2 in intracellular membrane transport and lysosomal function. Some of 
these conflicting results may be the result of unphysiological extraction buffers, 
or to damage of cells during extraction. The characterisation of LRRK2 still 
remains of paramount importance in understanding the underlying mechanisms 
of PD pathogenesis. Nonetheless, it has been proposed LRRK2 has several 
protein binding domains, indicating that it may act as a scaffold for multiple 
interaction partners. Identification of its interacting proteins may provide 
important clues about its functional role(s). 
 
Shin et al. (2008) identified Rab5a as a LRRK2-interacting protein by using a 
yeast two-hybrid screening. By performing GST pull down and co-
immunoprecipitation assays they confirmed that LRRK2 interacts with Rab5a. 
Moreover, subcellular fractionation and immunocytochemical analyses 
confirmed that a fraction of both proteins co-localise in synaptic vesicles. Rab5 is 
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a key regulator of endocytic vesicular transport from plasma membrane to early 
endosomes (Carney et al., 2006). That confirms the original hypothesis that 
LRRK2 probably modulates synaptic function by regulating clathrin-mediated 
endocytosis of synaptic vesicles.  
 
Dodson et al. (2012) indicated that the fly homolog of LRRK2, dLRRK, plays a 
crucial role in regulating Rab7-dependent lysosomal positioning. hLRRK2 has 
been previously found to localise to Rab5-positive early endosomes and to 
physically interact with Rab5 (Shin et al., 2008) but an interaction between 
LRRK2 and Rab7 had not been described before. They described a physical 
interaction between the Drosophila LRRK and Rab7, where dLRRK localises to 
Rab7-positive late endosomes and lysosomes.  
 
Xiong et al. (2012) determined that LRRK2 also interacts with ArfGAP1 in vivo, 
based on co-immunoprecipitation assays. ArfGAP1 is a GTPase activating 
protein (GAP) for LRRK2 that enhances GTP hydrolysis of LRRK2 and reduces 
its toxicity both in vitro and in vivo. GTPase activity is regulated by GAPs and 
guanine exchange factors (GEF). GAPs enhance hydrolysis of GTP by GTPases 
and GEFs promote the release of GDP allowing access of GTP to the GTPase 
(Barr and Lambright, 2010; Vigil et al., 2010; East and Kahn, 2011). GAPs and 
GEFs have some specificity for their target proteins. They proved that LRRK2 
prosphorylates ArfGAP1 resulting in inhibition of the GAP activity of ArfGAP1 
providing reciprocal regulation of LRRK2 and ArfGAP1.  
 
Beilina et al. (2013) proved that LRRK2 also interacts with Rab7L1 (Rab7, 
member RAS oncogene family-like 1) based on protein-protein arrays with 
biotinylated Glutathione-S transferase (GST)-LRRK2, where LRRK2 was 
FLAG-tagged. Rab7L1 is localised to the trans-Golgi network, possibly in its 
GTP-bound form, where it is likely to recruit LRRK2 and other components to 
cooperatively cause TGN to be engulfed by the autophagosomes. What is 
interesting is that Rab7L1 has also been proposed as a high-risk loci for sporadic 
PD (MacLeod et al., 2013).  
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Martin et al. (2014) performed a LRRK2 tandem affinity purification and in vitro 
kinase screening of LRRK2-interacting phosphoproteins in order to identify 
candidate LRRK2 substrates and understand the connection between LRRK2 
kinase activity and neurotoxicity. They demonstrated that ribosomal proteins 
were major LRRK2 interactors and LRRK2 kinase targets and that LRRK2 is 
remarkably enriched in the ribosomal subcellular fraction. The main finding was 
that s15 is a novel in vivo LRRK2 substrate that underlies PD-related phenotypes 
in Drosophila and directly links LRRK2 toxicity to altered mRNA translation. 
This study revealed a novel mechanism of PD pathogenesis linked to elevated 
LRRK2 kinase activity and aberrant protein synthesis in vivo.  
 
Steger et al. (2016) made use of the power of modern phosphoproteomics in 
combination to genetic, biochemical and pharmacological approaches in order to 
establish direct in vivo LRRK2 substrates. From this study, Rab10 came up as 
interacting with LRRK2. Rab GTPases consist of ~70 family members in 
humans and they are involved in intracellular vesicular trafficking events 
(Stenmark, 2009; Rivero-Rios et al., 2015). The characteristic domain of Rab 
proteins is the switch II, and there is evidence that LRRK2 directly 
phosphorylates Rab10 at each T73 residue, which is located in that switch II 
domain. That region changes conformation upon nucleotide binding and 
regulates the interaction with multiple regulatory proteins (Pfeffer, 2005). 
Because of the high conservation of that T73 residue among the Rab proteins, 
more investigation was performed in order to test if LRRK2 can possibly 
phosphorylate other Rabs at the same position as well. They measured the 
LRRK2-mediated phorsphorylation of Rab8a, Rab1a, and Rab1b, all of which 
contain a Thr at the site equivalent to T73-Rab10 and all proteins were 
phosphorylated on the predicted LRRK2 phosphorylation site in the switch II 
domain. 
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1.14 Aims 
 
The aim of this project was to shed new light on our understanding of the chain 
of events that cause nerve cells with the LRRK2-G2019S mutation to die. A 
better understanding of the biological functions of LRRK2 and its roles in signal 
transduction pathways may be important for future therapeutic development for 
PD, and this is because the kinase pathway is an easy target for drug 
development. There were two main hypotheses in this study; the first one is that 
it is the regulation of dopamine by LRRK2-G2019S causing neuronal cells to die, 
and the second is that LRRK2 genetically interacts with Rab proteins leading to 
that neuronal loss. The different approaches that were deployed in order to 
address those hypotheses are summarized below: 
 
1. Visual assays were performed in order to assess the visual function of 
Drosophila mutants and controls. The Steady State Visually Evoked 
Potential assay (SSVEP) method was utilised. In that series of 
experiments, DA release was manipulated by expressing Tetanus Toxin 
(TNT) in the dopaminergic neurons of Drosophila.   
 
2. Make use of two different binary systems, including the Gal4-UAS and 
the LexA-LexAop binary systems in order to manipulate different genes at 
the same time. 
 
3. High Performance Liquid Chromatography (HPLC) analysis in order to 
measure the dopamine levels in the fly brain in different genotypes, 
including the hLRRK2-G2019S mutation, the hLRRK2 wild type and 
other mutants and controls. 
 
4. Expression of different Rab transgenes in Drosophila both in isolation 
and in combination with the G2019S mutation in order to test for genetic 
interaction between the different Rabs tested and LRRK2 in vivo.  
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2. Materials and Methods 
 
2.1 Drosophila Husbandry and Genetics 
 
2.1.1 Drosophila stocks 
 
Drosophila stocks used during this research project were purchased from 
Bloomington Drosophila Stock Centre (Indiana University, Bloomington, USA), 
the Vienna Drosophila RNAi Centre (VDRC; Institute of Molecular 
Biotechnology, Vienna, Austria), or were kindly donated from members of the 
Drosophila community. A detailed summary of stocks can be found in Table 2.1. 
All stocks, without exception were quarantined for at least 2 generations and 
were inspected for the presence of mites. Post-quarantine, mite free stocks were 
transferred to the stock rooms. 
 
All stocks were raised at either 18 oC or 25 oC and were transferred to a fresh 
medium every 4 or 2 weeks, respectively. All the experimental crosses 
performed were raised at either 25 oC or 29 oC, giving a generation time of ~ 10-
12 days (egg to adult). 
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Table 2.1 Stocks Used During The Course of This Investigation 
Summary of all the stocks used during this work. Only primary stocks are listed on this table; double balanced stocks, stocks combining multiple 
genetic elements are listed below 
Stock Chromosome Description Source 
Wild types 
Canton S (CS) n/a Wild-type, red eyes Elliott/Sweeney Lab Stock 
w1118 (w-) n/a Wild-type, white eyes Elliott/Sweeney Lab Stock 
wαpricot (wα) n/a Wild-type, orange eyes Bloomington Stock Centre 148 
Balancer Stocks 
CyO/Sco Second Second Chromosome Balancer Elliott/Sweeney Lab Stock 
TM3/TM6b Third Third Chromosome Balancer Elliott/Sweeney Lab Stock 
CyO-GFP/If;TM6b/MKRS Second & Third Second and Third Chromosome Balancer Elliott/Sweeney Lab Stock 
CyO/If; TM6b/MKRS Second & Third Second and Third Chromosome Balancer Elliott/Sweeney Lab Stock 
            Source Source 
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Stock                                     Chromosome                                Description                                                             Source 
Gal4 stocks    
Actin5c-Gal4/CyO-GFP Second Actin promoter; global driver Elliott/Sweeney Lab Stock 
LongGMR-Gal4/CyO-GFP Second Glass multimer reporter; eye specific driver Elliott/Sweeney Lab Stock 
TH-Gal4/TM3 Third Tyrosine hydroxylase; DA neuron specific driver 
Kind gift of Serge Birman via 
Stephen Goodwin 
elav-Gal4 Third 
Embryonic lethal abnormal vision; pan-neuronal 
specific driver 
Elliott/Sweeney Lab Stock 
LexAop Stocks 
LexAop-hLRRK2/Sm6a Second Human hLRRK2 transgene Generated during this study; 
University of Cambridge/ Fly Facility 
LexAop-hLRRK2-G2019S/Sm6a Second Human hLRRK2-G2019S transgene Generated during this study; 
University of Cambridge/ Fly Facility 
LexAop-hLRRK2/TM6c Third Human hLRRK2 transgene Generated during this study; 
University of Cambridge/ Fly Facility 
LexAop-hLRRK2-
G2019S/TM6c 
Third Human hLRRK2-G2019S transgene 
Generated during this study; 
University of Cambridge/ Fly Facility 
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Stock Chromosome Description Source 
    
LexA Stocks 
TH-LexA/CyO Second Tyrosine hydroxylase; DA neuron specific driver 
Kind gift of Yoshi Aso, Janelia Farm 
(unpublished) 
UAS Stocks 
UAS-hLRRK2 Third Human LRRK2 transgene (Liu et al., 2008) 
UAS-hLRRK2-G2019S Third Human LRRK2-G2019S mutant transgene (Liu et al., 2008) 
UAS-hLRRK2 Third Human LRRK2 transgene (Lin et al., 2010) 
UAS-hLRRK2-G2019S Third Human LRRK2-G2019S mutant transgene (Lin et al., 2010) 
UAS-hLRRK2/CyO Second Human LRRK2 transgene H. Lundbeck A/S, Denmark 
UAS-hLRRK2-G2019S/CyO Second Human LRRK2-G2019S mutant transgene H. Lundbeck A/S, Denmark 
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Stock Chromosome Description Source 
UAS-hLRRK2-D1994A/CyO Second Kinase-dead human LRRK2 transgene H. Lundbeck A/S, Denmark 
UAS-hLRRK2-I2020T/TM6b Third Human LRRK2-I2020T mutant transgene 
Kind gift of Katerina Venderova 
(Venderova et al., 2009)  
UAS-hLRRK2-R1441C/TM6b Third Human LRRK2-R1441C mutant transgene (Lin et al., 2010) 
UAS-TNT/CyO Second Expresses the TNTxLC transgene Elliott/Sweeney Lab Stock 
Mutant Stocks 
dLRRKe03680 Third PBac{RB} P-element disruption of dLRRK, 
generating a dLRRK null mutant 
Kind gift of Zhuohua Zhang  (Wang 
et al., 2008) 
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Table 2.2 UAS-Rab Drosophila Stocks Used During The Course of This Investigation 
Stock Chromosome Description 
Bloomington Stock Centre 
Number 
 
UAS-Rab1 
 
Third 
Expresses a YFP-tagged, wild type Rab1 protein under UAS control 
 
24104 
 
UAS-Rab2/TM3 
 
Third 
Expresses a YFP-tagged, wild type Rab2 protein under UAS control 
 
23246 
 
UAS-Rab4 
 
Third 
Expresses a YFP-tagged, wild type Rab4 protein under UAS control 
 
9767 
 
UAS-Rab5 
 
First Expresses a YFP-tagged, wild type Rab5 protein under UAS control 50788 
 
UAS-Rab6/CyO 
 
Second 
Expresses a YFP-tagged, wild type Rab6 protein under UAS control 
 
23251 
UAS-Rab7 Third 
Expresses a YFP-tagged, wild type Rab7 protein under UAS control 23270 
 
UAS-Rab8 
 
Second Expresses a YFP-tagged, wild type Rab8 protein under UAS control 
 
9782 
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UAS-Rab9 
 
Third Expresses a YFP-tagged, wild type Rab9 protein under UAS control 
 
9784 
 
UAS-Rab10 
 
Second Expresses a YFP-tagged, wild type Rab10 protein under UAS control 
 
24097 
 
 
UAS-Rab11 
 
Second Expresses a YFP-tagged, wild-type Rab11 protein under UAS control 
 
50782 
 
 
UAS-Rab14 
 
Second 
 
Expresses a YFP-tagged, wild type Rab14 protein under UAS control 
 
 
9793 
 
 
UAS-Rab18 
 
Third Expresses a YFP-tagged, wild type Rab18 protein under UAS control 
 
9796 
 
 
UAS-Rab19 
 
Second Expresses a YFP-tagged, wild type Rab19 protein under UAS control 
 
24150 
 
 
UAS-Rab21 
 
Second Expresses a YFP-tagged, wild type Rab21 protein under UAS control 
 
23242 
 
 
UAS-Rab23 
 
Third Expresses a YFP-tagged, wild type Rab23 protein under UAS control 
 
9802 
 
 
UAS-Rab26/CyO 
 
Second Expresses a YFP-tagged, wild type Rab26 protein under UAS control 
 
23245 
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UAS-Rab27 
 
Second Expresses a YFP-tagged, wild type Rab27 protein under UAS control 
 
9810 
 
UAS-Rab32 
 
Second Expresses a YFP-tagged, wild type Rab32 protein under UAS control 
 
23282 
 
 
UAS-Rab35 
 
Second Expresses a YFP-tagged, wild type Rab35 protein under UAS control 
 
9821 
 
 
UAS-Rab39 
 
Second Expresses a YFP-tagged, wild type Rab39 protein under UAS control 
9825 
 
 
UAS-Rab40/TM3 
 
Third Expresses a YFP-tagged, wild type Rab40 protein under UAS control 
 
9830 
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2.1.2 Drosophila Media 
 
Stocks were maintained in 25x95 mm plastic vials (Dutcher Scientific, UK) 
plugged with cotton wool (Fisher Scientific, UK) containing ~7 ml standard 
yeast-sucrose-agar media: 25 g/l sucrose, 3.75 g/l agar, 0.125 g/l CaCl2, 0.125 g/l 
FeSO4, 0.125 g/l MnCl2, 0.125 g/l NaCl, 2 g/l KNaC4H4O6, 4H20; following 
autoclaving and cooling for 1h to ~ 45 oC, the antifungal agents Bavistin (1.5 
mg/l in 100 % ethanol; BASF, Auckland, New Zealand) and Nipagin (0.7 mg/l in 
100 % ethanol; Sigma, UK) were added. Experimental flies kept on this media 
were transferred to fresh vials every 3-4 days.  
 
For the Rab set of experiments a new recipe was followed, and as before stocks 
were maintained in 25x95 mm plastic vials. This enriched fly food contained 120 
g agar, 469.4 g cornmeal, 444.2 g yeast and 1125 g sucrose. After approximately 
75 min and when the temperature was down to 70 oC, 81 ml of propionic acid 
was added and mixed with the rest of the ingredients. When the food had cooled 
down, 7 ml of fly food was added to the plastic vials (Fisher Scientific, UK).  
 
When required in large numbers stocks were raised in 1/3 pint bottles on a maize 
based medium (119.0 g/l maize meal, 17.5 g/l yeast, 15.9 g/l agar, 103.2 g/l 
sucrose). Post-cooking of the primary ingredients media was cooled to 45 oC and 
the antifungal agents Nipagin (0.4 mg/l in 100% ethanol; Sigma, UK) and 
propionic acid (0.4% v/v; Arcos Organics, Geel, Belgium) were added. The 
medium was then dispensed into 1/3 pint glass bottles and the bottles bunged 
using Flugs® (Dutscher Scientific, UK). Bottles containing medium were 
autoclaved at 121oC for approximately 20min.  
 
To encourage egg-laying medium could be supplemented with dried yeast or 
yeast paste. Experimental flies were kept at the maize-based media until eclosion 
at which time female flies were transferred to vials containing the standard yeast-
sucrose-agar medium. Experimental flies were then aged at 29 oC in constant 
darkness or with continuous flashing blue LED lights, depending on the 
experimental protocol.  
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2.1.3 Drosophila Anaesthesia 
 
In order to allow the identification of the gender and the genotype, adult 
Drosophila flies were anaesthetised on a porous gas pad using continuous 
administration of carbon dioxide (CO2). The constant flow of CO2 provided 
immediate and maintained anaesthetisation. The anaesthetised Drosophila adults 
were then observed using a dissecting microscope (Zeiss Stemi-2000, Carl Zeiss 
AG, Germany). CO2 was the principal technique used to anaesthetise flies in this 
research. However, cold immobilisation on dry ice was used in order to collect 
them for being further processed for Western blotting.  
 
2.1.4 Drosophila crossing techniques 
 
Crosses were performed by adding males to their virgin female mates. At 25 oC 
females that have been eclosed within the last 8 hours should reject courtship and 
therefore should be virgins (reviewed in Dickson, 2008). Virgin females can be 
identified because when they are newly eclosed they have a pale pigmentation, 
display a meconium that is visible through the abdominal cuticle, and they have 
unexpanded wings.  On this basis virgin females were collected daily through 
completely emptying vials and isolating virgins that were then kept at 25 oC for a 
week time in order to confirm their virgin nature.  Adult males and female 
virgins were then crossed in a fresh vial of medium or bottle. The Fo generation 
of flies was then removed after 7 days and transferred in a new vial or bottle in 
order to prevent over-crowding and specific selection of F1 flies for further 
crosses or experiments.  
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2.2 Physiological analyses 
 
 
2.2.1 Flash Electroretinograms (ERGs) 
Unanaesthetised female flies were left to crawl up a trimmed 200 μl Gilson 
pipette tip and were forced to the end by blowing down the wider end. The fly 
was fixed with its head protruding from the tip using nail varnish. After placing 
the fly in the ERG apparatus, glass electrodes were pulled and filled with 
Drosophila solution (0.13 M NaCl, 4.7 mM KCl, 1.9 mM CaCl2; Heisenberg, 
1971). One of the electrodes was placed on the surface of the eyes, where the 
recordings were made from, and the other on the mouthparts as a reference by 
using micromanipulators (Figure 2.1a). Once in position all flies were dark 
adapted for 5 min. ERGs were recorded in response to three to five stimuli (10 
sec apart, 0.5 sec long) from the blue component of an LED light (Kingbright, 
KAF-5060PBESEEVGC, maximum emission wavelength 465 nm, Taipei, 
Taiwan) placed ~6 cm in from of the fly.  In another set up that was used, only a 
single LED channel was present centered at 467 nm (Gaussian spectral profile, 
FWHM 34 nm) (Prizmatix FC5-LED). The input/output linearity of the LED was 
verified using both a photodiode and a photospectrometer (Ocean Optics 
USB2000). DASYLab software was used in order to record the ERGs and 
DASYView (Version 2.1.6) was used for the analysis of the data (DASYLab 
customised software, C. J. H. Elliott, University of York). The ERG method was 
only used to check that the fly gave a response, indicating proper electrical 
connection.  
An example of the ERG output is presented in Figure 2.1b. The photoreceptor 
response (1 in Figure 2.1) was measured as the difference in potential between 
the start level and the bottom of the first decline in the trace. The off-transient 
response was inferred from the potential difference between the start and the 
minimum levels (2 in Figure 2.1). The initial rate of recovery was measured as 
time taken to reach half way between the start and the minimum levels (3 in 
Figure 2.1).  
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Figure 2.1: Recording the visual response of Drosophila using the 
flash ERG. a) Flies were left to climb in a shortened Gilson pipette tip 
and exposed to 500 ms pulse of light from the blue component of an LED 
light. A glass electrode filled with Drosophila saline was placed on the 
surface of the eye in order to record the response of the visual network, 
while a second reference electrode was placed in the mouthparts. b) The 
ERG consists of 4 main elements: the photoreceptor response (1), the 
on-transient, the off-transient and the recovery phase (3). The 
photoreceptor response was determined as the difference between the 
starting potential and the potential a third of the distance along the 
recording. The off-transient amplitude can be inferred from the maximum 
potential (2), which measures the potential difference from the starting 
level to the minimum level (the peak of the off-transient). The initial phase 
of the recovery response was calculated as time taken to reach half the 
distance between the off-transient peak and the start level (3) (Hindle et 
al., 2013).  
 
2.2.2 Steady-State Visually Evoked Potential (SSVEP) assay 
 
The SSVEP assay, as was first described in Afsari et al. (2014), combines 
features of the flash ERG with a computational approach that is based on human 
visual experiments, in which flickering stimulation is linked to the analysis of 
‘frequency-tagged’ responses. Female adult flies were prepared as described in 
section 2.2.1 and their visual responses were verified (Figure 2.2). The fly was 
a) b) 
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illuminated by a blue light LED channel centred at a wavelength of 467 nm. The 
intensity of the light was controlled by a sequence generator encoded in Matlab 
(Version 2013a; Mathworks, Natick, MA; Source code at 
http://github.com/wadelab/flyCode), with the data acquisition toolbox installed. 
In some parts of the sequence, a single square wave was flickering about the 
mean illumination at a frequency of 12 Hz, was delivered. In other parts of the 
sequence, two square wave modulations with different frequencies were added 
together and delivered.  One of the frequencies used was at 12 Hz and the other 
was at 15 Hz. The responses to 11 different contrast levels of the probe were also 
recorded. The contrast levels ranged from 0 to 69% contrast in equal steps.  
 
For the SSVEP recordings the temporal contrast of the probe stimuli (F1) was 
swept through a range of values (0-69%) and the responses were measured both 
in isolation and in the presence of a 30% contrast mask at a different temporal 
frequency. When a mask contrast is applied at a different frequency (F2) the 
response to the swept input probe changes. The grey curves are used as a 
baseline, as they show the response when the mask is absent. The red curves 
show the response with the presence of a constant contrast (30%) mask as the 
probe contrast increases from 0% to 69%. 
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Figure 2.2: Recording and analysing the visual responses of 
Drosophila using the SSVEP method A) Flies were left to climb in a 
shortened Gilson pipette tip and exposed to a blue LED that is driven by a 
continuously flickering wave. A glass electrode filled with Drosophila 
saline was placed on the surface of the eye in order to record the 
response of the visual network, while a second reference electrode was 
placed in the mouthparts. B) The blue line represents the stimulus, which 
is the sum of two square waves of 12Hz and 15Hz known as 1F1 and 
1F2, respectively. The red line represents a typical response (1 second of 
data from a single trial) to this stimulus from a white-eyed fly. C) A Fourier 
analysis is used to separate the response into parts depending on 
frequency, which is then plotted. Harmonics of the input frequencies (12 
Hz and 15 Hz) are shown in the Fourier transform of the signal as blue 
(first harmonic) and purple (second harmonic) bars. Low order 
intermodulation terms (1F2-1F1 and 1F1+1F2) are shown in orange 
(Afsari et al., 2014). D) The SSVEP method is very sensitive, as it shows how 
the different components of the visual system contribute to the final signal. 
Different harmonics of the selected frequencies represent visual 
responses from the different components of the visual system.  
 
2.3 Molecular Biology 
 
2.3.1 Extraction of genomic DNA 
 
Genomic DNA was extracted from single adult flies by homogenisation in 50 μl 
of extraction buffer (10mM Tris-Cl pH8.2, 1mM EDTA, 25mM NaCl, 
Proteinase K 200 μg/ml). The proteinase K should be added fresh on the day of 
the experiment. The homogenate was incubated at 25-37oC (or room 
temperature) for 20-30 min, followed by heating to 95oC for 1-2 min in order to 
inactivate the proteinase K. 1-2 μl of supernatant was used as a PCR template. 
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For higher concentrations of genomic DNA, 15 adult flies of the same genotype 
were used using the Gentra Puregene DNA purification kit (Qiagen, UK) as per 
the manufacturer’s instructions (Qiagen, 2010). 1-2 μl of the extracted DNA was 
used per PCR reaction.  
 
2.3.2 Polymerase Chain Reaction (PCR) 
 
PCR reactions were run using PCR mastermix (Promega, UK; 25 U/ml Taq 
DNA polymerase, Taq Reaction buffer, 200μM of each dNTP, 1.5mM MgCl2) 
with 1μl of each primer and 0.5-1 mg of genomic DNA or 1-2 ng of plasmid 
DNA.  
 
Reactions were run in a Techne TC512 PCR thermocycler (CamLab, UK), 
typically for 30 cycles. The annealing temperatures that were used were 5oC 
lower than the lowest primers melting temperature (Tm) with an extension time 
of 1 min per kb. Standard PCR cycling conditions were: initial denaturation at 95 
oC for 10 min; cycles of 95 oC for 30 sec, Tm for 60 sec, 72oC for 5 min. 
Reactions were then cooled at 4 oC to prevent DNA decomposition. The primers 
used were designed using Primer3 software and synthesised by Eurogentec 
(U.K). A list of primers that were used during this investigation are summarized 
in Table 2.4. 
 
 
 
Table 2.3 Summary of the PCR Reagents 
PCR Reagents Volume (μl) 
PCR master mix 10μl 
Primer (Forward) 1μl 
Primer (Reverse) 1μl 
DNA 1μl 
dH2O 
Final volume 
7μl 
20μl 
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Table 2.4. Primer sequences summary  
Primers Sequence 
5’ pUAST 
 
CTGCAACTACTGAAATCTGC 
3’ pUAST 
 
ATCTCTGTAGGTAGTTTGTCCA 
5’ LexAop GAGCGCCGGAGTATAAATAGAG 
 
3’ LexAop CCATTCATCAGTTCCATAGG 
 
5’ hLRRK2 (used for sequencing) ATCAGTTTACCGAGCAGCCT 
 
5’ hLRRK2 TCCAGATCAACCAAGGCTCA 
3’ hLRRK2 TCAAAGACCTGGGCAGAAGT 
5’ DVM-5 ATTGCTGCTGGTGCCATCACGTTC 
3’ DVM-6 AGCCAACACAGAAGCCCACATCAC 
3’ Pry4-N CGACACTCAGAATACTATTCC 
5’ Plac1-N CAACCTTTCCTCTCAACAAGC 
 
 
2.3.3 DNA Agarose Gel Electrophoresis 
 
Agarose gel electrophoresis was performed in order to analyse DNA products 
from PCR reactions or restriction enzyme digests. 0.7% and 1 % agarose gels (in 
TAE buffer; 40 mM Tris acetate, 1 mM EDTA, pH 8.3) were used for large and 
small (<1kb) DNA products, respectively. Addition of SYBR® safe (Invitrogen, 
UK; 10 μl/100 ml) to the gel allowed the visualisation of the DNA using a blue 
light transilluminator. Bromophenol blue loading dye (0.25% w/v bromophenol 
blue, 30 % glycerol v/v in dH2O) was added to the DNA to assist with the 
loading. A 1Kb or 100bp DNA ladder (0.5 μl/lane, NEB, UK) was run alongside 
the DNA products in order to be able to determine the size. All gels were run at 
~80 V for 30-45 min. 
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2.3.4 DNA purification; Gel Extraction 
 
The DNA fragments that were further needed for cloning or sequencing were 
excised from electrophoresis gels, using a sharp sterile scalpel and visualisation 
by a blue light transilluminator box. Gel slices were transferred to 1.5 ml 
eppendorf tubes and processed according to the QIAquick® Gel Extraction kit 
(Qiagen, UK) via the manufacturer’s instructions (Qiagen, 2015). The DNA 
concentration was determined using a NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific, DE, USA).  
 
 
2.3.5 DNA Sequencing 
 
DNA sequencing was used in order to confirm the generation of new transgenic 
flies (Lexop-hLRRK2 and LexAop-G2019S). Samples were submitted, in 
accordance with provided guidelines, for sequencing by GATC Biotech 
(Konstanz, Germany). 
 
2.3.6 Restriction Endonuclease Digestion 
 
Plasmids contain several restriction sites that are specifically recognised by 
restriction enzymes. These enzymes can be used in order to specifically cleave 
plasmids, allowing for excision and insertion of DNA fragments during sub-
cloning. This approach was used to excise hLRRK2 and hLRRK2-G2019S from 
their donor plasmids and cleave their recipient plasmid, in both cases LexAop, 
for their insertion. Restriction enzymes were also used to cleave plasmid DNA 
from transformed clones in order to check for the presence of the plasmid and the 
newly inserted gene by gel electrophoresis. In every case the required restriction 
enzymes were added to the plasmid along with the appropriate buffer with a total 
reaction volume of 20 μl. Reactions were incubated for 2 hrs at 37oC followed by 
a 20 min incubation at 80oC to inactivate the enzymes. All the restriction 
products were run on an electrophoresis gel to ensure the correct cleavage of the 
restriction enzymes.  
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2.3.7 DNA ligation 
 
The purified DNA fragments that were previously treated with restriction 
enzymes were ligated together and into cleaved vector plasmids using T4 DNA 
ligase. Ligation reactions were typically a 3:1 (insert: vector (ng)) ratio, 
determined using the following formula: Insert mass (ng)= [3 x (insert length bp/ 
vector length bp)] x vector mass (ng). DNA concentration was ascertained using 
a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, DE, USA). For the 
ligation reaction 0.2 μl of T4 ligase (Fermentas, UK) was used with 2 μl of T4 
buffer (Fermentas, UK) and the DNA in a total reaction volume of 20 μl. All the 
reactions were incubated at 16oC overnight followed by a 10 min inactivation of 
the ligase at 65oC.  
 
For this course of investigation the donor vector for hLRRK2 and hLRRK2-
G2019S transgenes that was used was the pcDNA-DEST53 (Invitrogen). The 
backbone size without the insert was 7767bp and the insert size was 7584 bp 
(Figure 2.3). Gateway cloning was used as has been described previously 
(Greggio et al., 2006).  
 
The LexAop vector that was used was the pJFRC19-13XLexAop2-IVS-
myr::GFP, size 9011 bp (Figure 2.4).  
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Figure 2.3 Full sequence map for pcDNA-DEST53-LRRK2-WT. This is 
the donor vector that was utilised containing the LRRK2 and LRRK2-
G2019S sequences. The backbone vector sized 7767 bp and the insert 
LRRK2 gene 7584 bp. Gateway cloning was performed to create this 
vector with the 5’ cloning site being the attR1 and the 3’ being the attR2 
(none of these sites was destroyed). The map was created using the 
SnapGene software.  
 
 
 
Unique Cutters Bold
Sequence:  Untitled.dna  (Circular / 13,749 bp)
Enzymes:  Unique 6+ Cutters  (29 of 653 total)
Features:  19 visible, 19 total
Printed from SnapGene®:  9 Jun 2017  14:06 Page 1
TspMI - XmaI(51)  
BspDI - ClaI(10,218)  
EcoNI(9352)  
BbvCI(9349)  
XbaI(8821)  
ApaI(7901)  
PspOMI(7897)  
SmaI  (53)
EagI  (146)
KasI  (239)
NarI  (240)
SfoI  (241)
PluTI  (243)
BssHII  (637)
SV40 poly(A) signal
lac operator
lac promoter
CAP binding site
AhdI  (2484)
PvuI  (2854)
AmpR promoter
SgrDI  (3405)
SnaBI  (3997)
T7 promoter
PaeR7I - PspXI - XhoI  (4735)
BamHI  (4834)
attB1
AarI  (5313)
KflI  (5389)
HpaI  (5723)
AfeI  (6023)
PmlI  (6183)
pcDNA-DEST53 WT
13,749 bp
    
 
80 
 
 
Figure 2.4 Full sequence map for pJFRC19-13XLexAop2-IVS-
myr::GFP. This is the LexAop vector that was utilised in order to insert 
the LRRK2 and LRRK2-G2019S transgenes downstream of the LexAop 
sequence. The vector sized 9011 bp. The map was created using the 
SnapGene software.  
 
 
2.3.8 E. coli Transformation and Amplification of plasmid DNA 
 
For the generation of new transgenic Drosophila lines, XL-1 Blue 
supercompetent E. coli cells (Agilent Technologies, CA, USA) were used in 
order to amplify plasmid DNA, as the desired antibiotic resistant was ampicillin 
(Amp). Transformation was achieved via heat-shock in accordance with the 
manufacturers instructions. The protocol was modified and was scaled to use 20 
μl of cells as opposed to the recommended 100 μl. Luria broth (LB; 10 g/l 
tryptone, 5 g/l yeast extract, 10 g/l NaCl) was also used instead of SOC media. 
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For transformation of plasmid from a ligation mix 1 μl of the ligation reaction 
was used, as recommended. Post-transformation cells were plated on LB agar 
plates (20 g/l agar in LB broth) containing the appropriate antibiotic, in this 
investigation Ampicillin (Amp; 200 μg/ml), in accordance with the 
manufacturers instructions. Plates were then incubated overnight at 37oC.  
 
Individual colonies were harvested from the plates using a sterile pipette tip and 
transferred into a sterile 15 ml falcon tube containing 5 ml sterile LB broth and 
the appropriate antibiotic (Amp). Cultures were incubated at 37oC overnight (12-
16 h) with vigorous shaking. The transformed E. coli stocks can be long-term 
stored at -80oC by adding 50 % v/v sterile glycerol. These glycerol stocks were 
used to streak fresh plates when required.   
 
In order to check for the presence of the insert within transformed colonies, 
following the ligation process during sub-cloning, plasmid DNA should first be 
purified by miniprep (section 2.3.10.1) and then confirm the insert presence by 
restriction enzyme digestion (section 2.3.6). For minipreps 2 ml of each 
overnight culture was pelleted via centrifugation at 13000 g for 2 min at room 
temperature (RT), followed by the removal of the supernatant. That stock was 
stored at -20oC. In order to ascertain those colonies that most likely have taken 
up the insert prior to miniprep, in order to reduce the number of minipreps 
required, colony cracking could be performed using 15 μl of the overnight 
culture.  
 
2.3.9 Colony cracking 
 
Colony cracking is a quick method in order to confirm the presence of the 
desired insert from colonies before carrying on to the purification of the plasmid 
DNA. It relies on cell lysis using alkaline conditions and identification of 
positive clones based on electrophoretic mobility variance between supercoiled 
DNA plasmids with and without the insert. The insert carrying colonies are 
expected to move slower on the electrophoresis gel. By using that method inserts 
as small as 200 bp can be detected.  
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20 μl of bromophenol blue loading dye was added to 1 ml of 5x cracking buffer 
(25 g sucrose, 5 ml 5M NaOH, 2.5 ml 10 % SDS, 40 ml ddH2O). 5 μl of cracking 
buffer and bromophenol blue loading dye was added to 5 μl of resuspension 
buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA, 100 μg/ml RNaseA) and mixed 
with 15 μl of the overnight culture. That mixture was then loaded and run on an 
electrophoresis gel (section 2.3.3) using uncut empty plasmid as the control, with 
no ladder being required. Alternatively, single colonies can be patched and used 
directly for cracking instead of 15 μl of overnight culture. The colonies 
containing the insert will show different electrophoretic mobility compared to the 
control. The colonies that the insert has been successfully inserted can then used 
for purification via miniprep (section 2.3.10.1). 
 
2.3.10 Plasmid Purification 
 
2.3.10.1 MiniPrep Purification 
 
For the purification of the plasmid DNA the QIAprep spin miniprep kit (Qiagen, 
UK) was used providing up to 20 μg of molecular biology grade plasmid DNA 
from E. coli. Frozen pellets produced by centrifugation of 2 ml of overnight 
cultures (section 2.3.8) were processed in accordance with the manufacturers 
instructions. Concentrations of the purified DNA were determined using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific, DE, USA). The purified 
DNA plasmid was stored at -20oC. 
 
The plasmid DNA purified by miniprep was used in order to confirm the 
presence of the insert by restriction digest (section 2.3.6) followed by gel 
electrophoresis.  
 
2.3.10.2 MidiPrep Purification 
 
To provide a greater purity of plasmid DNA (up to 200 μg of transfection-grade 
plasmid DNA) and greater yields for microinjection of Drosophila embryos, 
plasmids were purified using the Qiagen HiSpeed Plasmid Midi kit (Qiagen, 
UK).  
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Following the confirmation of the presence of the desired insert via colony 
cracking, miniprep, restriction digest and gel electrophoresis, 100 μl of the 
appropriate overnight culture (section 2.3.8) was used to inoculate 100 ml of LB 
broth containing Amp (200 μg/ml). 100 ml cultures were incubated at 37oC 
overnight with vigorous shaking. Alternatively, for optimal results a single 
colony could be picked from patched plates or a freshly streaked plate, streaked 
from the appropriate glycerol stock, and used to inoculate a 5 ml starter culture 
of LB broth containing Amp (200 μg/ml). Starter cultures were incubated at 37oC 
for 8h with vigorous shaking before used to inoculate a 100 ml culture (100 μl in 
100 ml) and incubated as above. Following incubation, all 100 ml from the 
culture were centrifuged at 6000 rpm for 15min at 4 oC. After removal of the 
supernatant, the pellets were frozen before being processed for midiprep in 
accordance with the Qiagen HiSpeed Midi kit protocol (Qiagen, 2010).  
 
2.3.11 Ethanol precipitation of DNA 
 
Following midipreps, the concentration of the plasmid DNA was determined 
using a NanoDrop 1000 spectrophotometer (Thermo Scientific, DE, USA). For 
the microinjection of Drosophila embryos, a plasmid concentration of 0.4 μg/μl 
was required. To achieve this concentration the plasmid DNA obtained from 
midiprep was precipitated with a 1/10th volume of sodium acetate (3M, pH 5.2) 
and 3 volumes of cold 100 % ethanol. That mixture was then incubated at -20 oC 
overnight. Following centrifugation at 16000g for 15 min at RT the supernatant 
was carefully removed. 1 ml of 70 % ethanol was then added to the pellet and 
after the mixture was well mixed the supernatant was removed and the pellet was 
resuspended in the appropriate volume of nuclease-free H2O. Concentrations of 
the purified DNA were determined using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific, DE, USA). The purified DNA plasmid was stored at -20 oC. 
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2.3.12 Microinjection of Drosophila embryos 
 
For microinjections, the LRRK2-LexA LRRK2-G2019S-LexA constructs were 
sent to the University of Cambridge, Department of Genetics, Fly Facility. The 
phiC31 integrase system was utilised for microinjections. The phiC31 integrase 
is a sequence-specific recombinase that is encoded within the genome of the 
phiC31 bacteriophage. The phiC31 integrase mediates recombination between 
two 34 bp sequences known as attachment sites (att), one found within the donor 
plasmid (attB) and the other found within the target genome (attP). In the 
presence of phiC31 integrase an attB- containing donor plasmid can be 
unidirectionally integrated into the target genome through recombination with 
the attP site. The phiC31 fly stock used for microinjections during this 
investigation was the stock 13-20, (genotype: y w M (eGFP, vas-int, dmRFP) 
ZH-2A; P{CaryP}attP40) which has an attP site on the 2nd chromosome (25C6), 
marked with RFP and GFP to make it easier to identify those stocks in which 
plasmid integration was successful. Successful lines were balanced over a 2nd 
chromosomal balancer and the integrase was removed before being sent back 
from Cambridge. Moreover, another phiC31 fly stock that was used was the 
stock 13-106:  vas-int; attp-3B, VK00033, (genotype: y w M (eGFP, vas-int, 
dmRFP) ZH-2A;; PBac{y[+]-attP-3B}VK00033) which has an attP site on the 
3rd chromosome (2A3), marked with GFP and RFP to make it easier to identify 
those stocks in which plasmid integration was successful. Successful lines were 
balanced over a 3rd  chromosomal balancer and the integrase was removed before 
being sent back from Cambridge. 
 
2.4 Western Blotting 
 
Western Blotting was performed in order to determine the expression pattern of 
hLRRK2, hLRRK2-G2019S for all the available lines in the lab and control flies. 
The method for western blotting was adapted from Abcam (2016).  
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2.4.1 Protein extraction 
 
Proteins were extracted from 30 whole adult heads per genotype after 3 days 
incubation at 29oC. Flies were collected in 15 ml falcon tubes and were snap 
frozen on dry ice. In order to separate the heads from the rest of the fly body the 
15 ml falcon tubes were placed into a 50 ml falcon tube containing dry ice and 
vortexed 2-3 times for 30sec. The fly heads were then collected under the 
microscope and transferred to 1.5 ml eppendorf tubes keeping them on dry ice. In 
order to extract protein, one complete mini protease inhibitor cocktail tablet  
(cOmplete tablet, Mini EDTA-free, EASYpack; Roche) was dissolved in 7 ml of 
RIPA (Radioimmunoprecipitation assay) buffer (150mM NaCl, 1.0% IGEPAL® 
CA-630, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0; Sigma, 
UK). 30 μl of that mix was added to tubes of 30 fly heads placed on ice. The 
heads were homogenized using a sterile plastic pestle followed by centrifugation 
at 13000g for 15 min at 4oC. The supernatant was removed and placed in a new 
1.5 ml eppendorf tube and the protein concentration was quantified using the 
BCA (bicinchoninic acid) assay (μg/μl).  
 
2.4.2 Quantification of protein concentration: BCA assay 
 
Protein quantification was performed to determine the amount of protein in each 
solution (μg/μl). The BCA assay is highly sensitive colorimetric assay that is not 
affected by chemicals in the sample. It primarily reduces Cu2+ to Cu1+ by 
proteins in an alkaline environment followed by highly sensitive and selective 
colorimetric detection of BCA/copper complex. It is water-soluble and strongly 
absorbs light at 561nm in a linear fashion with increasing protein concentration. 
Protein samples (10 μl) were added to 200 μl BCA reaction solution and the 
absorbance was recorded. A bovine serum albumin (BSA) standard curve was 
also produced by measuring the absorbance of known concentrations of BSA. 
The protein concentrations of the unknown samples were calculated from the 
BSA standard curve. Known amounts of protein sample were mixed in a 3:1 
ratio with sample buffer (100 μl -mercaptoethanol in 900 μl 4x laemmli buffer), 
followed by heating at 95oC for 5min and loaded on the SDS-PAGE gel. The 
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protocol that was followed was in accordance to the manufacturer’s guidelines 
(BCA Protein Assay kit, Cohesion Biosciences, UK).  
 
The concentration determination was estimated by using bicinchoninic acid 
(BCA) reagent with bovine serum albumin (BSA) as a standard. A set of diluted 
BSA standards were added to the reagent in order to produce a coloured reaction 
which is in proportion to the amount of the protein. The absorbance of all the 
BSA standards were measured with the spectrophotometer set to 561 nm within 
10 min as suggested by the manufacturer’s manual.  
 
 
 Figure 2.5 Standard curve for BSA protein. Plot of BSA protein 
standards vs the absorbance at λ=561nm.  
 
 
Table 2.5 summarises the numeric data obtained including the absorbance at 561 
nm and the protein concentration (ug/ul). 
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The intensity of the coloured reaction product is a direct function of the protein 
amount that can be determined by comparing its absorbance value to a standard 
curve. Using Microsoft Office Excel to plot and apply a standard curve (Figure 
2.5) with the absorbance value as the dependent variable (Y-axis) and 
concentration as the independent variable (X-axis), resulted in the equitation y= -
0.0008x2 + 0.0695x - 0.0004, where solving for x determines the protein 
concentration of the sample. After determining the protein concentration for all 
of the tested samples, the concentration that was finally loaded for further 
analysis in the Western blot was 20ug/ul. That applies for all the different 
Western blots performed throughout this course of investigation.  
 
 
2.4.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) 
 
Following heating to 95°C in sample buffer (100 mM Tris, pH 6.7, 15% (v/v) -
mercaptoethanol, 2% (w/v) SDS, 5% (v/v) glycerol, 0.002% (w/v) bromophenol 
blue), protein samples were separated on SDS-PAGE gels. The gels were 
composed of a 7.5 % (v/v) acrylamide resolving gel and a 4% (v/v) acrylamide 
stacking gel. After loading of samples and a protein ladder (7 µl Spectra™ 
Multicolor High Range Protein Ladder, ThermoFisher Scientific, USA), SDS-
PAGE gels were run in running buffer (25 mM Tris, 192 mM Glycine, 0.1 % 
Table 2.5 Numeric report of absorbance generated by 
spectrophotometer  
Concentration of BSA protein (ug/ul) A (λ=561nm) 
0 0 
0.03125 - 0.004 
0.0625 0.007 
0.125 0.009 
0.25 0.016 
0.5 0.04 
1 0.064 
2 0.136 
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SDS) at 75 V for approximately 30 min (to narrow the running front) and then 
increased to 150 V.  
 
2.4.4 Protein transfer to a PVDF membrane 
  
Following SDS-PAGE, a Mini-Trans-Blot® Cell was used in order to transfer 
the proteins from the SDS-PAGE gel to a PVDF membrane (Amersham Hybond 
0.45 μm PVDF; GE Healthcare, UK). Foam pads, 4 pieces of Whatman® gel 
blot paper (0.8 mm thick; Thermo Fisher Scientific Pierce, UK) and the SDS-
PAGE gel were all soaked in transfer buffer (25 mM Tris, 192 mM glycine, 20% 
[v/v] methanol, 0.1% [w/v] SDS). PVDF membrane was cut at the same size as 
the gel and then activated in 100% methanol for 1min, followed by a quick dip 
into the transfer buffer. Each of the soaked foam pads were placed on each side 
of a Mini Gel Holder Cassette, one on the negative (black) side and one on the 
positive (white) side. On top of the foam pads two pieces of soaked Whatman® 
gel blot paper were placed on each side followed by the gel on the negative side 
and the activated PVDF membrane on the positive side. The cassette was then 
closed carefully, making sure no bubbles are trapped, and was placed into the 
tank along with the transfer buffer and a Bio-Ice cooling unit that had been 
stored at -80oC. Proteins were transferred by applying 30V overnight at 4oC, 
increasing to 60V the next morning for another 30 min.    
 
2.4.5 Probing of PVDF membrane 
 
Following the transfer of proteins to the PVDF membrane, then membrane was 
blocked for 1h in 3% (w/v) marvel milk in Tris buffered saline (TBS-T; 10 mM 
Tris, pH 7.6, 150 mM NaCl) supplemented with 0.1% (v/v) Tween® 20 (VWR, 
Pennsylvania, USA). That was followed by staining with the primary antibody in 
3% (w/v) marvel milk in TBS-T after incubation at 4oC overnight. Membranes 
were washed (5 x 3 min) in TBS-T. The appropriate species of secondary 
antibody (conjugated to HRP) was added in 3% (w/v) marvel milk in TBS-T for 
1h at RT. Any excess secondary antibody was removed by washing the 
membranes (5 x 3 min) in TBS-T. All the washes and incubations were 
performed on a rocking platform. Membranes were then incubated in ECL 
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reagent (GE Healthcare, UK) for 1min. CL-XPosureTM x-ray film (Thermo 
Fisher Scientific Pierce, UK) was placed on the blot for 30 sec (α-hLRRK2) or 5 
sec (α-myosin and β-actin). Exposed film was developed in Carestream® 
Kodak® autoradiography GBX Developer/Replenisher (Sigma, UK) for 1min, 
rinsed in dH2O for 1 min and then fixed in Carestream
® Kodak® autoradiography 
GBX Fixer/Replenisher (Sigma, UK) for 1 min. All the antibodies used and their 
concentrations are summarized in Table 2.6. 
 
 
Table 2.6. Antibody dilutions used for western blotting 
Antibody Species Concentration Source 
α -hLRRK2 Mouse monoclonal 1/1000 NeuroMab 
α -hLRRK2 Rabbit polyclonal 1/3000 Novus 
β -actin Mouse 1/180000 Proteintech 
α -myosin Rat monoclonal 1/40000 Abcam 
 
α-rabbit IgG HRP 
linked 
 
Goat 1/1000 New England Biolabs 
α-mouse IgG HRP 
linked 
 
Horse 1/1000 New England Biolabs 
α-rat IgG HRP  
linked 
 
Goat 1/1000 New England Biolabs 
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2.5 Drosophila dissections 
 
2.5.1 Dissection of Drosophila Retina  
 
1 day, 7 days and 14 days post-eclosion adult flies of the correct genotype were 
anesthetised by CO2 (section 2.1.3). Flies were orientated ventral side up and, 
using forceps the thorax was gently grasped causing an extension of legs and 
proboscis. While remaining hold of the body forceps, were used to grasp the 
proboscis in order to gently remove the head. The body was discarded and the 
head submerged in a drop of HL3 (hemolymph-like solution) on a sylgard dish. 
The eye was carefully dissected from the head. That is most easily done by 
teasing apart the connective tissue between the eye and the proboscis and 
working round gently tease the eye from the head. Eyes were transferred into a 
0.5 ml eppendorf tube containing 3.7 % formaldehyde in PBS, for 40 min. Eyes 
were washed 3 times (5 min each time with rocking) in 0.4% PBS-T/PBT (0.4 % 
v/v triton X-100 in PBS). Post-washing eyes were transferred back onto a sylgard 
dish and, in a drop of PBS or PBT, any excess tissue removed from the eyes. 
Eyes were then transferred into a 0.5 % eppenforf containing 0.4 % PBS-T and 
incubated at 4oC, overnight, in the dark under shaking in order to remove any 
auto-fluorescent pigment. Following incubation eyes were washed 3 further 
times in PBT (5 min each time with rocking). The protocol was modified from 
Williamson and Hiesinger (2010), (Williamson and Hiesinger, 2010).    
 
2.5.2 Immunohistochemical Staining of Drosophila Retinas 
 
Following preparation, as was described above, Drosophila retinas were 
incubated in rhodamine conjugated phalloidin (1:100 in 0.4 % PBT) overnight, in 
darkness, with rocking at 4oC. After incubation eyes were washed 3 times in 0.4 
% PBT before being submerged in 70 % glycerol (70 % v/v in PBS) for 1-2 h to 
displace any air from the preparation. Eyes were mounted in Vectashield® 
(Vector Laboratories LTD, UK) on a standard microscope slide. Coverslips were 
elevated, to avoid compressing the eye, on two 22 x 22 mm coverslips fixed 
either side of the preparations. Coverslips were sealed in place using nail varnish.  
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Table 2.7 Antibody dilutions used for staining of the Drosophila retina 
Antibody Concentration Source 
αnti-Rab5 1:100 Abcam (ab31261) 
α-spin 1:1000 
Sweeney lab (Sweeney 
and Davis 2002) 
a-POSH 1:200 Sweeney lab 
 
 
2.5.3 Imaging of Drosophila Retina; Confocal microscopy 
 
Following immunohistochemical staining Drosophila retinas were imaged using 
a Zeiss LSM 710 Axio Observer Z1 confocal microscope, using Zen 2009 
software (Carl Zeiss AG, Germany). Single focal plane images of Drosophila 
retinas were taken using the 40x, 60x and 100x oil objectives during the course 
of this inverstigation. When taking confocal images for quantification of 
fluorescence all settings were kept the same between images.   
 
2.5.4 Dissection of Drosophila brains 
 
The legs and wings were first removed to reduce obstructions to the head. This 
was performed by apposing pairs of forceps against each other to break the 
tissue; this prevented pulling of the peripheral nervous system. Once these 
appendages had been removed, the proboscis was detached from the head by 
lifting the proboscis and severing the connections to the head. The silvery trachea 
and air sacs were excised and the eye and cuticle removed with a peeling action. 
At no point was the brain held within the forceps. The brain was severed from 
the cervical connective and placed in an eppendorf tube containing fresh 0.1% 
perchloric acid (PCA). Once collected they were kept on dry ice and stored at -
80oC until the day of the HPLC analysis.  
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2.6 High Performance Liquid Chromatography (HPLC) analysis 
 
Dopamine and serotonin levels were measured by HPLC–EC on a LC-10AD 
HPLC system (Shimadzu). This set of experiments was performed at Nigel 
Maidment’s and David Krantz’s labs, at UCLA in California. To determine 
intracellular monoamine levels, fly heads were collected and homogenized in 50 
μl perchloric acid (0.1M) and 0.1% EDTA (0.1 % wt/vol) using a sonicator 
(Sonifier cell disruptor, model W185D, Heat systems-Ultasonics). After a 1 min 
centrifugation at 13000g, the samples were filtered using Millipore cartridge and 
centrifuged for 10 min at 5000 rpm. The samples were collected and stored in 
HPLC tubes at -80°C until the day of the experiment where 5 μl of the sample 
were injected into the HPLC.   
 
 
Samples were separated on a C18 reverse phase column (TSKgel Super ODS 3 
μm particle size, 10 Å~ 2.1 mm, maintained at 33 °C, ThermoFisher Scientific) 
using a mobile phase (817.2 mg Sodium dodecane sulfonate, 24.613 mg Sodium 
acetate anhydrous, 500 ml acetonitrile, 500 ml methanol, 0.4 ml EDTA (100mM 
stock), 3000 ml water, pH 5.5) pumped at 0.2 mL/min (LC-10AD pump, 
Shimadzu). Data were collected using EzChrom software (Agilent) (Fitzmaurice 
et al., 2012). 
 
2.7 Statistical analysis 
 
All statistical analyses were carried out in IBM SPSS Statistics v22. Student’s t-
test was performed to test for statistical significance between two groups; 
univariate ANOVA followed by a Bonferroni post-hoc test was performed to test 
for statistical significance between multiple groups; and univariate ANOVA 
followed by a post-hoc Dunnett’s comparison was performed when comparing 
genotypes to a wild-type control. Although the visual neurons are all linked in 
the same neural network, the responses from the photoreceptors, lamina and 
medulla were treated as independent events, with separate univariate ANOVAs 
as previously described in Afsari et al. (2014), rather than a multivariate 
approach. This decision was based on the idea that the visual network would use 
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feedback to regulate signaling in each layer of the network (Zheng et al., 2006, 
Tuthill et al., 2014, Hu et al., 2015). Statistical significance was defined as 
p<0.05 throughout. On graphs with ‘error bars’, these represent the standard 
error, and P values are indicated graphically: * P < 0.05; ** P < 0.01; ***P < 
0.001. 
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Chapter 3 
Understanding the role of Dopamine in 
the pathogenesis of the fly model of 
Parkinson’s disease 
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3.1 Introduction 
 
One of the main aims of this project was to shed new light on our understanding 
of the chain of events that cause nerve cells with the LRRK2-G2019S mutation to 
die. A better understanding of the biological functions of LRRK2 and its 
relationship to dopamine metabolism and signalling may be important for future 
therapeutic developments in PD.  
 
Previous studies have shown that the LRRK2-G2019S mutation severely reduces 
the visual function of the flies after 28 days (Hindle et al., 2013). The fly retina, 
like the human retina, has dopaminergic innervation (Crooks and Kolb, 1992), 
and isolated fly photoreceptors respond to dopamine application (Chyb et al., 
1999). These dopaminergic neurons regulate the visual contrast response (Afsari 
et al., 2014; Jackson et al., 2012). The loss of these dopaminergic neurons in PD 
leads to deficits in neural processing in both the retina (Langheinrich et al., 2000) 
and visual cortex (Price et al., 1992), at least in part due to aberrant contrast 
response functions. The same is true of flies: using an SSVEP (Steady State 
Visual Evoked Potential) assay, modeled on the human scenario, it was found 
that knock-out of PD related genes led to aberrant electroretinograms (Afsari et 
al., 2014). In fact, each gene that was tested shows different deficits, so that it is 
possible to determine the fly genotype from the SSVEP response (West et al., 
2015). The key question is how does dopamine affect the photoreceptors and the 
lamina neurons? This question was addressed by blocking the evoked 
neurotransmitter release from dopaminergic neurons in the CNS of the fly.  
 
Visual assays in the fly provide an alternative approach to the cellular and 
biochemical assays. The fast generation time, fecundity of the fly and fast 
electroretinogram processing facilitates rapid progress, so that we are able to test 
large numbers of flies, and so identify even small changes in neuronal signaling. 
It was demonstrated that of the LRRK2 mutations available, the pathogenic 
G2019S mutation produced the most dramatic loss of vision in old flies, and this 
was most pronounced when it was expressed in the dopaminergic neurons 
(Hindle et al., 2013). Since biochemical assays indicate that the G2019S 
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mutation increases kinase activity, two kinase inhibitors were tested, and found 
that both prevented (or slowed) the loss of vision (Afsari et al., 2014; West et al., 
2015) suggesting the increased kinase activity is indeed the cause of 
neurodegeneration. 
 
Hindle et al (2013) hypothesized that, as G2019S is a gain of function mutation, 
one of the first consequences might be neuronal hyperactivity. On testing this 
hypothesis, it was found that young flies expressing LRRK2-G2019S in their 
dopaminergic neurons (TH > G2019S) had increased visual signaling compared 
with those expressing the wild-type form of LRRK2 (TH > hLRRK2), or controls 
with no LRRK2 expression (Afsari et al., 2014). This transient excitatory 
response may lead to sodium or calcium ion entry, extra demand for ATP from 
the ion exchange pumps, which the mitochondria may not be able to fulfill 
without generating extra oxidative stress. In this scenario, mitochondrial failure 
is followed by autophagy, apoptosis and other forms of cellular damage. A 
transient excitotoxic cascade may be present in mice too, as younger LRRK2-
G2019S animals show hyperactivity, followed by loss of movement and 
cognitive deficits (Volta et al., 2015). The excitotoxic model is also supported by 
cell-culture data, with LRRK2 expression in HEK293 cells leading to increased 
calcium influx as a result of increased calcium channel density (Bedford et al., 
2016). One possible cause of increased calcium channel density is an increase in 
protein production, due to phosphorylation and consequent upregulation of the 
ribosomal s15 activity by pathogenic mutants of LRRK2 (Martin et al., 2014). 
 
In the first part of this chapter, the effect of LRRK2 transgenes on dopamine 
concentration was determined. In addition, it was tested if early hyperactivity 
might be linked to loss of dopamine, finding young TH > G2019S flies have 
reduced dopamine levels, and that the hyperactivity is affected by blocking 
dopamine release with tetanus toxin.  
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3.1.1 Measurement of dopamine in fly heads  
 
As the hallmark of PD is the loss of the dopaminergic neurons in the SNpc, 
which has as a result the loss of dopamine in the striatal projection areas of these 
neurons, the first aim of these sets of experiments was the measure of dopamine 
concentration from fly heads by performing HPLC analysis (as described in 
section 2.6). The discovery of genetic causes of pathogenic PD led to the creation 
of genetic model organisms, with both gain of function (overexpression) and loss 
of function (knock-out) mouse models. Progress with these has been slow, 
whereas rapid progress was made using the fruit fly (Drosophila melanogaster). 
These provided excellent recapitulation of LRRK2 pathology (Hewitt and 
Whitworth, 2017), including locomotion defects and loss of some (but not all) 
clusters of dopaminergic neurons. In particular, old flies show a loss of 
dopaminergic neurons in the PPM and PPL clusters (Liu et al., 2008; Martin et 
al., 2014), and some of the PPL neurons innervate the retina (Hindle et al., 2013). 
 
A very approachable way to measure dopamine levels has been achieved in the 
past, as proposed by Riemensperger et al. (2011). Using fly adult brains, they 
performed HPLC analysis in order to determine the absolute magnitude of 
reduction in adult brain. Tyrosine hydroxylase (TH) is the rate-limiting step in 
dopamine biosynthesis and alternative splicing of the Drosophila TH (DTH) 
produces two isoforms, DTH1 and DTH2.  DTH1 is only expressed in DA 
neurons in the CNS while DTH2 is expressed in peripheral no nervous tissues. 
Moreover, inactivating mutations of the genomic TH, pale (ple) locus results in 
unpigmented cuticle and late embryonic lethality. Taking advantage of this 
alternative splicing, they constructed mutants, the DTHgFS±, which only 
expresses an active TH in noneural tissues and the DTHgFS+ that only expresses 
active TH in neural tissues. Homozygous ple mutants are rescued by this 
transgene to adult stage, generating Drosophila essentially devoid of DA in the 
adult brain. Brain extracts from control flies and DTHg;ple revealed equivalent 
levels of DA per brain, while DTHgFS±  showed ~85% reduction in DA levels.  
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Several other papers were released using HPLC analysis in order to test 
dopamine levels in Drosophila. Faust et al (2009) used 20 fly heads per genotype 
they tested while Kayser et al (2014) used 21 fly brains per sample. On the other 
hand, Gonzalo-Gomez et al. (2012) used 10 fly heads in order to determine the 
DA levels while Calcagno et al (2013) used 5 fly heads per sample providing 
enough statistical power. These findings encouraged us to determine that 10 fly 
heads could provide enough statistical power in order to determine the DA in our 
TH>G2019S and TH>hLRRK2 flies. Even though the amount of fly heads or fly 
brains used in each study varies, the only common parameter within all of them 
was that they used the very sensitive electrochemical detection HPLC analysis.  
 
 
 
3.1.2 Blocking neurotransmission with Tetanus toxin 
 
A number of approaches to block neuronal signalling are available in the fly: use 
of inwardly rectifying potassium channels (Nitabach et al., 2002), tetanus toxin 
(Sweeney et al., 1995) or shibire (Kitamoto, 2001; Potter et al., 2010). In the 
case of dopaminergic neurons, manipulations of VMAT or dopamine synthesis 
would also be possible, or abolition of the dopaminergic cells by expression of 
the pro-apototic gene reaper (Zhou et al., 1997). Many of these systems have 
disadvantages. Expression of inwardly rectifying potassium channels or reaper 
in dopaminergic neurons is lethal. While some have avoided this by using 
temperature sensitive GAL80, it does make the genetics more complex. 
Manipulations of VMAT may have consequences for other aminergic systems 
(octopamine, serotonin), and does not necessarily deliver the specificity required. 
Shibire can be temperature sensitive, making experiments harder to control. Thus 
using tetanus toxin provides the simplest way to manipulate dopaminergic 
neuronal activity.      
 
 
Neurons communicate with their target cells by the Ca2+-regulated exocytotic 
release of neurotransmitters that are stored in synaptic vesicles. Many proteins 
are implicated in the synaptic release machinery, which are located in the 
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synapses (Walch-Solimena et al., 1993). Several proteins are included in this 
machinery, known as N-ethylmaleimide-sensitive fusion proteins (NSF), α-
soluble NSF attachment proteins (α-SNAP), and γ-SNAP.  Specific receptor 
proteins in the vesicle membrane (v-SNAREs) and other proteins in the target 
membranes (t-SNAREs) determine the specificity of that fusion. For the 
neurotransmitter release, synaptobrevin (VAMP) (Trimble et al., 1988; Baumert 
et al., 1989), that is located in the synaptic vesicles, is considered as a v-SNARE 
that targets the vesicle to the plasma membrane using t-SNAREs syntaxin and 
SNAP-25 (Sollner et al. 1993). Several clostridial neurotoxins identify these 
proteins as targets; syntaxin and SNAP-25; which are the targets of 
synaptobrevin in the synaptic vesicle exocytosis process, making these 
neurotoxins potential inhibitors of neurotransmitter release. For the purpose of 
this investigation, Tetanus toxin (TeTx) was used in order to achieve that 
targeted neurotransmitter release.  
 
TeTx belongs to the botulinal neurotoxins family (BoNT/A to G) and consists of 
two polypeptide chains. A heavy chain mediates neuroselective binding, 
internalization, intraneuronal sorting, and translocation of the light chain to the 
cytosol. The light chains catalytically inhibit synaptic transmission when present 
in the cytosol by cleaving either synaptobrevin, syntaxin, or SNAP-25 with 
unique selectivity at single sites (Sweeney et al., 1995). The light chain of 
Tetanus toxin (TeTxLC) targets the membrane protein of the synaptic vesicles, 
synaptobrevin in the synapse. Even though there might be more cellular targets 
for these toxins, for example cellubrevin that is a synaptobrevin homolog, 
synaptobrevin is the only detectable protein to be cleaved (McMahon et al., 
1993). Sweeney et al. in 1995 expressed TeTxLC in synapses in Drosophila, 
showing that it cleaved fly synaptobrevin (n-syb), and abolished synaptic 
transmission at a defined neuromuscular junction (Sweeney et al., 1995).  
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3.1.3 Blockage of neurotransmission in dopaminergic neurons 
 
During the course of this investigation Tetanus toxin was expressed in the 
dopaminergic neurons of the fly in order to block the evoked release of 
dopaminergic vesicles (Figure 3.1). Any potential lethality was avoided as TNT 
permits some spontaneous release (Sweeney et al., 1995). In addition, TNT is 
effective in modulating dopamine-dependent behaviours (Alekseyenko et al., 
2013; Friggi-Grelin et al., 2003; Suster et al., 2003) including arousal, courtship, 
memory and locomotion.  
This was accomplished by the driving expression of the UAS-TNT transgene 
with TH-Gal4 that places the Gal4 under the control of the tyrosine hydroxylase 
locus; where tyrosine hydroxylase is the rate-limiting enzyme for the synthesis of 
dopamine. Moreover, TNT was also expressed in TH>G2019S and TH>hLRRK2 
flies and controls including TH/w- and TH/wapr. Full field SSVEP stimuli was 
used in order to separate the responses of the photoreceptors from the lamina 
neurons.  
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Figure 3.1 Schematic diagram of dopamine pathways in 
neurotransmission. Dopamine is synthesized from tyrosine by L-DOPA, 
and then packaged into vesicles by DVMAT (Drosophila Vesicular 
MonoAmine Transporter). Released dopamine may bind to dopaminergic 
receptors, and/or be taken up the dopamine transporter (DAT). Tetanus 
toxin blocks the release of neurotransmitter vesicles by cleaving the 
intrinsic synaptic membrane protein synaptobrevin. 
 
3.2 Aims 
 
1. Test if the G2019S mutation has any effect in the loss of dopamine that is 
present in PD compared to control flies including the wild type hLRRK2. 
 
2. Test if the blockage of dopamine release by expressing TNT in the 
dopaminergic neurons can reverse the loss of vision present in old flies 
carrying the G2019S mutation. 
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3.3 Results 
 
3.3.1 Measurement of dopamine levels 
 
Manipulations of the fly homolog of hLRRK2 (dLRRK) affect the levels of 
dopamine in fly heads: young dLRRK knockout flies have ~3x elevated 
dopamine, while those with extra kinase activity (expressing dLRRK-I1915T the 
homolog of the human I2020T mutation), have reduced dopamine content (down 
to about 20% of controls) (Imai et al., 2008). We therefore aimed to determine 
the effect of manipulating the human LRRK2 gene in the fly.   
 
Dopamine levels were determined by HPLC analysis of fly heads expressing a 
range of LRRK2 transgenes (Section 2.6). 1 day old, 7 day old and 14 day old 
flies were used in this set of experiments. TH > hLRRK2 flies were used as a 
control, as the wild type version of the gene is being expressed. Two different 
mutations within the kinase domain were also tested, TH>G2019S and TH 
>I2020T and finally another mutation within the GTPase domain of the gene, the 
TH >R1441C. The final volume of fly heads used for this analysis was 90 in total 
(N=90), giving us enough statistical power in order to make our conclusions. 
Figure 3.2 shows the obtained dopamine levels from three different time points 
including the wild type LRRK2, and three additional mutations within this gene.  
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Figure 3.2 Young, but not old flies, expressing LRRK2-G2019S or 
hLRRK2 in dopaminergic neurons show differences in dopamine 
concentration. 1 day, 7 days and 14 days old flies were tested in order 
to measure the dopamine levels. A range of LRRK2 transgenes were 
tested by HPLC analysis in fly heads. Apart from the wild type hLRRK2 
(N= 21), G2019S (N= 22), I2020T (N=21) and R1441C (N=23) mutations 
were also included in the screening. There is a strong interaction term in 
the ANOVA between age and genotype (P= 0.0279), indicating that the 
genotypes behave differently with age. N= 87. 
 
Even though the dopamine levels of the TH > G2019S flies were very consistent 
among all the different ages that were tested, it appears that the ones expressing 
the TH > I2020T mutation are not so consistent. 1 day old flies have similar DA 
levels to the TH > G2019S but after 7 days that levels drop down to wild type 
levels as they exhibit similar levels to the TH >hLRRK2. What is even more 
interesting is that after 14 days the DA levels go back up, similar to wild type 
levels of 1 day old flies. Similar pattern of DA expression is followed by the TH 
>R1441C flies. This strong interaction between genotypes and age is also 
statistical significant for the TH>I2020T and TH>R1441C flies (Two-way 
ANOVA, P=0.0279). 
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Of great interest were the differences of the dopamine levels between the 
genotypes TH>G2019S and TH>hLLRK2 as shown in more detail in Figure 3.3. 
The concentration of dopamine was 65% higher in 1 day old TH > hLRRK2 than 
in TH > G2019S flies. Over two weeks, the levels of dopamine remained 
constant in the TH > G2019S flies, but that in TH > hLRRK2 flies reduced until 
it was about half (53%) of the TH>G2019S flies (Figure 3.3). Wild-type flies 
show a similar decline in dopamine concentration over the first 14 days of life 
(Imai et al., 2008). The conclusion that can be made is that reduced dopamine 
content could contribute to the hyperactivity of young TH > G2019S retina. 
 
 
 
Figure 3.3 The Dopamine levels of TH>G2019S and TH>hLRRK2 flies 
show different effects as they age. Age does not affect dopamine 
concentration in TH>G2019S flies, but TH>hLRRK2 flies show a dramatic 
drop in dopamine, from a mean of 6.7  0.6 to 2.6  0.5. There is a strong 
interaction term in the ANOVA between age and genotype (F2,33df = 6.1, 
P= 0.005), indicating that the genotypes behave differently with age. N= 
39. 
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3.3.2 Blockage of the neurotransmitter release in Drosophila 
 
For the next set of experiments, the aim was to block synaptic transmission in the 
dopaminergic neurons in order to determine how blocking of dopamine release 
affects fly vision. The first result is that flies expressing TNT flies (with or 
without) LRRK2 transgenes were found to be viable. 
 
 
3.3.2.1 Flies co-expressing TH>G2019S, TH>hLRRK2 compared to TH/w- 
and flies co-expressing TH>TNT;G2019S, TH>TNT;hLRRK2 compared to 
TH>TNT 
 
In order to address this question recordings from 1 day old, 7 day old, 14 day old 
and 21 day old flies were conducted, expressing TH>G2019S and TH>hLRRK2 
both in the presence and the absence of TNT. The summarized genotypes of flies 
that were crossed for this experiment are summarized in Table 3.1, with flies 
carrying the balancers CyO or TM6B being rejected.  
 
 
 
 
 
Table 3.1 Summarized  crossing scheme of the experimental flies  
Virgin female 
TH-Gal4 
Male 
  
  
 
w- 
TNT
CyO
;
G2019S
TM 6B
G2019S
TM 6B
TNT
CyO
;
hLRRK2
TM 6B
hLRRK2
TM 6B
TNT
CyO
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3.3.2.2 Measurement of the visual responses using the SSVEP recordings 
 
As previously described in more detail in Chapter 2.2.2, a more sensitive assay 
based on the SSVEP method was developed for recording the visual response of 
flies (Afsari et al., 2014). This is a highly sensitive assay that allows the isolation 
of the responses from the photoreceptors, second-order lamina neurons and third-
order medulla neurons. The fly SSVEP is designed to deliver stimuli that sweep 
through different contrast levels, enabling the measurement and analysis of 
contrast response functions. The SSVEP assay has proved sensitive enough to be 
able to detect abnormal visual phenotypes caused by DA expression of hLRRK2-
G2019S in 1 day old flies (Afsari et al., 2014). Thus this assay provides a robust 
and stable platform to assess the visual response of flies and to determine how 
different genotypes respond (Afsari et al., 2014).  
 
The typical SSVEP analysis from Matlab is shown in Figure 3.4. This 
demonstrates the typical contrast response function (CRF), with the responses 
increasing with contrast. A representative example of two different genotypes are 
shown here; TH>G2019S and TH>TNT;G2019S; at 1 day old and 21 day old 
flies. As expected after 21 days the responses decrease dramatically as part of the 
ageing process.  
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Figure 3.4 Representative example of the MatLab outcome. 
Photoreceptor responses (A) and lamina neuron responses (B) to swept 
contrast flicker with (pink) and without (grey) a 30% mask as the probe 
contrast is increased from 0 to 69%. 1 day old and 21 day old flies are 
shown here, in order to compare the responses between TH>G2019S 
and TH>TNT;G2019S flies (N=50).   
 
 
As well as being more sensitive, the SSVEP assay generates a very large data set, 
with responses at a range of contrasts, with and without the mask and at a range 
of harmonics. Here, a simpler approach is taken, reporting the maximal response 
at 1F1 (photoreceptors) and 2F1 (lamina neurons) of the unmasked signal. 
 
 
 
 
 
B 
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3.3.2.3 Effect of TNT is age dependent 
 
The original hypothesis was that TNT expression in dopaminergic neurons might 
affect the release of dopamine and its expression does affect fly vision. The 
effect of TNT on the fly vision was tested both in the hLRRK2 and the G2019S 
background.  
 
The largest effect of TNT on the fly vision occurs at 7-day-old flies, where TNT 
increases the visual responses both from the photoreceptors and the lamina 
neurons. By 7 days, eye development is complete and all genotypes have their 
largest SSVEP 1F1 and 2F1 responses independently of the expression of TNT. 
Figure 3.5 shows that expressing tetanus toxin increased the maximal response of 
each genotype by about 45% for the photoreceptor and 55% for the lamina 
neurons. That was true for both LRRK2-G2019S and for the wild-type. At older 
time points (14 days and 21 days), TNT also increases the visual responses 
independently of the genetic background.  
 
However, at 1-day-old flies, even though in the TH>hLRRK2 and TH/w- 
background, the effect of TNT was the same as at 7 day old flies, a surprising 
result was established (Figure 3.6). 1-day-old TH>G2019S where TNT is 
expressed, the responses from both the photoreceptors and the lamina neurons 
are at higher levels compared to the responses in the presence of TNT.  
 
After 14 and 21 days gradually the response is decreasing, and this is what is 
expected as a normal aging process. Moreover, the effect of TNT at this later 
time points is the same for all the different genotypes, as its expression leads to 
increased photoreceptor responses compared to the ones we get when it is not 
expressed.  
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Figure 3.5 Expression of TNT in the G2019S background indicates a 
big effect in fly vision. Mean ±95%CI responses from TH>G2019S, 
TH>hLRRK2 and TH/w- flies after incubation at 29oC for 7 days with or 
without expressing TNT. Dopaminergic expression of tetanus toxin (TNT) 
has opposite effects on G2019S or control (hLRRK2, +) 7-day-old flies as 
indicated by the two-way ANOVA (genotype/TNT interaction P<0.0001 
and P<0.0001 for photoreceptors (A) and lamina neurons (B), 
respectively. N = 336 - at least 11 in each sample.  
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Figure 3.6 In Young flies, expression of TNT in the G2019S 
background reduces the SSVEP response, whereas in the other 
(control) genotypes TNT increases the response. Mean ±95%CI 
responses from TH>G2019S, TH>hLRRK2 and TH/w- flies after 
incubation at 29oC for 1 day with or without expressing TNT. 
Dopaminergic expression of tetanus toxin (TNT) has opposite effects on 
G2019S or control (hLRRK2, +) 1-day-old flies as indicated by the 2-way 
ANOVA (genotype/TNT interaction P = 0.027 and 0.012 for 
photoreceptors (A) and lamina neurons (B). N = 107 - at least 11 in each 
sample.  
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A summarized graph presenting the effect of TNT for all the different ages in the 
visual responses from the photoreceptors and the lamina neurons is presented in 
Figure 3.7.    
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Figure 3.7 Flies show largest visual responses at 7 days 
Mean ±95%CI responses from TH>G2019S, TH>hLRRK2 and TH/w- flies 
after incubation at 29oC for 1,7,14 and 21 days with or without expressing 
TNT. Dopaminergic expression of tetanus toxin (TNT) has opposite effects on 
G2019S or control (hLRRK2, +) 1-day-old flies as indicated by the two-way 
ANOVA (genotype/TNT interaction P = 0.027 and 0.012 for photoreceptors 
(A) and lamina neurons (B). N = 107 - at least 11 in each sample. The 
differential effect of tetanus toxin decreases with time:  by 7 days the 
expression of tetanus toxin in the TH > G2019S line has no effect, and this is 
also true at later time points. Over days 7-21, TNT reduced the photoreceptor 
response, independent of genotype (2-way ANOVA, TNT, P = 0.037, 
genotype/TNT interaction P = 0.12), but had no effect on the lamina neurons. 
N = 485 - at least 9 in each sample.  
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3.3.2.4 Effect of TNT depends on the genotype 
 
 
The most interesting finding came from 1-day-old flies, as the expression of TNT in 
the G2019S background didn’t have the same effect as in the w- and hLRRK2 flies at 
the same age (Figure 3.6).  
 
The early onset hyperactivity of TH >G2019S was confirmed (Fig. 3.6): the TH> 
G2019S response in both the photoreceptors and the lamina neurons is larger than that 
of TH >hLRRK2 or TH/+. However, co-expressing tetanus toxin (TNT) with G2019S 
substantially reduced the SSVEP signal on day 1 (photoreceptors by 38 %; lamina 
neurons by 42 %). With increasing age, the difference made by TNT on TH > 
G2019S declined and disappeared by 7 days. In contrast, for the control TH > 
hLRRK2 and TH/+ flies, TNT appeared to have the opposite effect enhancing their 
SSVEP response. Furthermore, for all genotypes, TNT expression increased the visual 
response across all time points – for photoreceptors by 19 %, for lamina neurons by 
10 %.    
 
This finding suggesting the early hyperactivity in young flies expressing the G2019S 
mutation agrees with the data presented by Afsari et al (2013). There is an indication 
that TNT expression is preventing signalling between the dopaminergic neurons and 
the photoreceptors/lamina neurons. The hypothesis was that the flies are failing to 
adapt to the light due to a lack of dopamine. In young flies, there may be dopamine 
circulating from the cuticle, where dopamine is needed too (darken & crosslink) the 
cuticlar proteins.   
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3.3.2.5 Calculated Rmax and C50 for flies expressing TNT 
 
The changes in visual response due to age and TNT expression could be due to an 
effect on the maximum sensitivity of the eye (Rmax) or to a change in contrast 
sensitivity (c50).  
 
 
 
Figure 3.8 Naka-Rushton function presenting two types of gain control 
in the contrast-response function. (Adapted from Soma et al., 2013). 
 
The Rmax represents the max response while C50 represents the semisaturation 
contrast. The Contrast response functions were fitted with the Naka-Rushton function 
(Soma et al., 2013) and the effect of age and TNT were determined.   
 
The Rmax of the responses at the 1F1 (photoreceptors) and 2F1 (lamina neurons) are 
presented in Figure 3.9.  The increased sensitivity of TH>G2019S flies could result 
from a change in either the Rmax or C50 parameter.  
 
The changes in Rmax with age follow the same pattern as the raw data: flies at day 7 
have a bigger Rmax than those aged 1, 14 days and 21 days. At day 7, there is no 
effect of TNT on any of the genotypes in either the photoreceptors or lamina neurons, 
and the same is true for days 14 and 21. However, in young flies, at 1 day old, the 
presence of TNT has the opposite effect for the TH>G2019S and TH>hLRRK2 flies, 
as the absence of TNT increases the responses at significant levels.   
A B 
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Unlike Rmax, the C50 is quite consistent between the different genotypes and ages, as 
the effect of TNT is not statistically significant (Figure 3.9).  
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Figure 3.9 Calculated Rmax from the photoreceptors (A) and the 
Lamina neurons (B). Mean ±95% CI responses from TH>G2019S, 
TH>hLRRK2 and TH/w- flies after incubation at 29oC for 1, 7, 14 and 21 
days with or without expressing TNT. 
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Figure 3.10 Calculated C50 from the photoreceptors. Mean ±95% CI responses from TH>G2019S, TH>hLRRK2 and TH/w- flies 
after incubation at 29oC for 1, 7, 14 and 21 days with or without expressing TNT. 
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3.3.2.6 Eye colour does not affect the maximal SSVEP response 
 
A possible confounding factor is that the flies with TNT have an extra mini-white 
gene. To test if this has an effect in the SSVEP, TH/w¯ with TH/wapr at 1 and 7 
days were compared as the eyes of the wapr flies are similar to the mini-white 
transgenics (Fig. 3.11). No difference was found in either the photoreceptor or 
lamina neuron response (P>0.3, N=25). Thus the differences in visual response 
between TH > G2019S flies and the controls when neurotransmission is blocked 
with tetanus toxin is not likely to be due to eye colour.  
 
 
 
 
 
 
Figure 3.11 Eye pigmentation does not affect the SSVEP response. 
No difference is seen between TH/w- and TH>wapr flies. 1 day and 7 
day old flies were tested but no significant difference was seen in the 
visual responses of that two control flies (P>0.3, N=30). The responses 
from the photoreceptors (A) and the lamina neurons (B) were compared.  
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3.4 Discussion 
 
3.4.1 Measurement of dopamine levels  
 
The hallmark of PD is the loss of the melanised dopaminergic neurons in the 
SNpc leading to loss of dopamine in the areas where these neurons project. That 
has led many research labs using animal models, rodents or Drosophila, to have 
in depth investigate whether that is the case or not. Moreover, the hypothesis that 
was tried to be addressed in this chapter was whether this loss of dopamine is 
LRRK2-G2019S dependent or not.  
 
The data in this chapter show that young TH > G2019S flies have less dopamine 
than the TH>hLRRK2 and that TNT expression in the G2019S background 
reduces the SSVEP response, whereas in the other (control) genotypes TH>TNT 
increases the response. Old flies have similar amounts of dopamine and TNT 
always increases the SSVEP response. 
 
The normal high level of dopamine in young flies is prevented by dopaminergic 
expression of LRRK2-G2019S. Isolated photoreceptors are dopamine sensitive 
(Chyb et al., 1999), so that less dopamine in the retina will make photoreceptor 
responses larger and faster. The axons of some PPL neurons terminate in the 
lamina (Hindle et al., 2013), making this a feasible scenario: LRRK2-G2019S in 
the PPL neurons reduces their dopamine content, leading to decreased release in 
the lamina, faster responses by the photoreceptors and stronger activation of the 
lamina neurons. This fits with the observations described by Afsari et al. (2014) 
of initial hyperactivity in the TH>G2019S flies. In older flies, the levels of 
dopamine are more equal, and the difference in retinal physiology is less. 
Although the focus was on the PPL neurons, because their axons project to the 
lamina, an indirect contribution from the other types of dopaminergic neurons in 
the optic lobes cannot be excluded (Nassel and Elekes, 1992; Nassel et al., 1988). 
Li et al (2010) used transgenic mice as animal models in order to measure the 
dopamine levels from striatum brain lysates. Two BAC transgenic strains were 
created expressing similar levels of wild type LRRK2 and G2019S, providing 
evidence of the physiological function of LRRK2 and unravel the role of the 
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G2019S mutation in the pathogenesis of PD. They established that wild type 
LRRK2 increases striatal dopamine release and enhances motor performance. On 
the contrary, overexpression of the most common familial PD mutation G2019S 
failed to provide these benefits. This decrease in the DA content was age-
dependent. Moreover, the G2019S mice neither enhanced not compromised 
motor function in mice up to 12 months, supporting the hypothesis that LRRK2 
regulates striatal DA transmission facilitating motor activity. The observed loss 
of DA release and content in the mutated G2019S mice surprisingly wasn’t 
accompanied by neuronal death or nigrostriatal degeneration and motor deficits. 
This is surprising because the increased kinase activity of the LRRK2-G2019S 
mutation has been associated with enhanced neurotoxicity (Smith et al., 2006; 
West et al., 2007).  This indicates that maybe the G2019S mutation could impair 
LRRK2 function without activating neuronal cell death pathways at early disease 
stages. And that is further supported from the fact that many G2019S carriers 
never develop PD symptoms.  
 
On the other hand, as has been described in more detail in chapter 1, section 
1.12, Drosophila PD models expressing the G2019S mutation consistently 
produce neurodegeneration (Ng et al., 2009; Liu et al., 2009; Imai et al., 2008). 
Taken together, that supports previous evidence that in mouse models it is very 
unlikely to recapitulate the full spectrum of PD symptoms.  
 
3.4.2 Blocking of neurotransmitter release 
 
Overall, expressing tetanus toxin increases the visual response, as would be 
expected if it blocked transmitter release from dopaminergic neurons. As noted 
earlier, tetanus toxin expression in dopaminergic neurons affects a range of fly 
behaviors (Alekseyenko et al., 2013; Friggi-Grelin et al., 2003; Suster et al., 
2003). However, in young flies, it might be expected that tetanus toxin would 
have minimal effect, because they had less dopamine than the other genotypes. 
In fact, it appears that TNT reduces the photoreceptor and lamina neuron 
response of the young TH > G2019S flies, but increases it in the TH > hLRRK2 
and TH/+ flies which have high dopamine. One explanation for this is that 
G2019S and tetanus toxin may interact to severely affect the development of the 
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dopaminergic projections to the retina. Fly eye development is not generally 
considered to be complete until the 3rd day of adult life, and disruption to 
dopaminergic signaling affects a number of aspects of development, including 
the visual response to flash electroretinograms (Neckameyer, 1996; Neckameyer 
and Bhatt, 2012; Neckameyer et al., 2001). A disruption to sensory startle 
responses in young flies with dopaminergic expression of tetanus toxin (Friggi-
Grelin et al., 2003) might also be indicative of effects of tetanus toxin on 
development.  
 
The evoked neurotransmitter release is abolished by TNT expression in larval 
motoneurons (Sweeney et al., 1995). The neuromuscular junctions are 
structurally normal in the presence of TNT, based on immunohistochemistry and 
electron microscopy. That is an indication that synaptogenesis is not affected by 
the expression of TNT (Broadie et al., 1995). Moreover, targeted TNT induction 
silences adult motor neurons (Thum et al., 2006). On the other hand, 
photoreceptors showed that their mature synapses are resistant to TNT (Rister 
and Heisenberg, 2006). On the other hand, Tabuchi et al (2000) found that 
expression of TNT in the photoreceptors R1-R6 would block synaptic 
transmission eliminating the on/off transient responses when performing ERGs. 
Moreover, Keller et al (2002) expressed TNT in the photoreceptors using the 
GMR-Gal4 driver and concluded that TNT blocks synaptic transmission.   
 
 The only known TNT target in Drosophila is n-synaptobrevin (Sweeney et al., 
1995). Apart from the role n-Syb has on synaptogenesis, this protein could have 
addition functions as it can be detected in the early pupal optic lobe (Hiesinger et 
al., 1999). Expression of TNT in the photoreceptors affects the columnar 
organization and morphology of photoreceptor terminals R7 and R8 which 
project in the medulla neurons (Hiesinger et al., 1999). Temporally restricted 
expression of n-Syb in the early pupa led to a rough eye while the structurally 
similar impotent TNT had no effect (Sweeney et al., 1995). These findings 
indicate that this rough eye genotype that was obtained could be because of the 
absence of n-Syb or it is the result of n-Syb cleavage products.  Rister and 
Heisenberg (2006) showed that TNT-induced effects don’t need to be 
developmental, as expressing the same Gal80ts tool successfully blocked adult 
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motor neurons (Thum et al., 2006). Furthermore, memory phenotypes were 
established after TNT-induction in adult central complex neurons (Liu et al., 
2006). Their findings support the idea that the adult nervous system has two 
types of chemical synapses: TNT sensitive and TNT-resistant.  
 
TNT was originally tested in glutamatergic motor neurons, but perhaps the 
release machinery for biogenic amines, including serotonin, dopamine, 
octopamine, tyramine, and neuropeptides may differ. However, the expression of 
TNT has proven aminergic neurons phenotypes (Friggi-Grelin et al., 2003). As it 
targets a neural-specific protein, it is expected that it should only block vesicle 
release in neurons. Our aim was to block the release of DA in the dopaminergic 
neurons, without being sure that TNT doesn’t affect other co-neurotransmitters 
of DA at the same time.  
 
In addition to that, previous studies have shown that expression of the G2019S 
mutation in mammalian cells, fly motoneurons and sensory cells lead to reduced 
neurite outgrowth (Lin et al., 2010; Lin et al., 2015; MacLeod et al., 2006). 
Failure of the dopaminergic axons to reach the lamina/retina might contribute 
(along with low dopamine production) to the early hyperactivity seen in the 
TH>G2019S visual response.  
 
Lin et al. (2010) expressed the G2019S mutation in DA neurons using 
Drosophila as an animal model. This expression led to several dendritic defects, 
including tau mislocalisation in dendrites and tau hyper-phosphorylation leading 
to the accumulation of tau-positive inclusions with lysosomal characteristics. 
MacLeod et al (2006) first identified that overexpression the most common 
mutation within LRRK2 leads to phospho-tau inclusions that display abnormal 
lysosomal features, undergoing apoptosis.  
 
Tau protein is a microtubule-associated protein (MAP) that has been linked to 
neurodegenerative diseases, including Alzheimer disease (Hanger et al., 2009) 
and PD (Bancher et al., 1993). Tau protein is encoded by the MAPT gene, which 
has also been associated to Frontotemporal dementia (FTD) (Lee et al., 2001). 
The recent findings linking tau to PD pathogenesis and a probable interaction 
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with LRRK2, triggered the interest of my researchers studying this protein in 
more detail. Tau is mostly found in neuronal cells with its main role being 
maintaining the integrity of cytoskeleton by interacting with motor proteins, 
dynein and kinesin.  Tau is also involved in axonal transport along this network 
(De Vos et al., 2008). Hyper-phosphorylation of tau could result in MT 
destabilization and impaired protein transport leading to the creation of toxic 
protein aggregates (Lee et al., 2001) propagating neuronal death, which is 
characteristic of my neurodegenerative disorders. Furthermore, tau co-localizes 
with α-synuclein, the protein aggregates in Lewy bodies (Ishizawa et al., 2003), 
implying a physiological or pathophysiological interaction.  
 
Thus, our results coincide with previously published data, supporting our initial 
hypothesis even further. The early hyperactivity of young flies carrying the 
G2019S mutation was confirmed. Moreover, we can confidently conclude that 
the SSVEP method is more sensitive than the ERGs, as Hindle et al (2013) 
showed that wild type flies, LRRK2 and TH/+, had no ERG changes up to 28 day 
old, while that is not the case with the SSVEP method. This is very encouraging, 
as the SSVEP method could actually have an application in humans and even to 
harder populations to be tested, including children.  
 
3.5 Conclusion 
 
Taken together the results presented in this chapter the overall conclusion that 
could be made is that dopaminergic signaling is defective in the TH>G2019S 
retina of young flies, and this might be a major factor in starting the 
neurodegenerative cascade. This could be the beginning of understanding the 
molecular pathway of PD that leads to the neurodegeneration of the 
dopaminergic neurons.  
 
 
 
 
     
 
121 
 
 
 
 
 
 
Chapter 4 
Genetic interaction of LRRK2 and Rabs 
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4.1 Introduction 
 
One of the main aims of this project was to shed new light on our understanding 
of the chain of events that cause nerve cells with the LRRK2-G2019S mutation to 
die. A better understanding of the biological functions of LRRK2 and its roles in 
signal transduction pathways may be important for future therapeutic 
development for PD, and this is because the kinase pathway is an easy target for 
drug development. Many previous studies have highlighted Rab proteins as 
potential targets that could be phosphorylated by LRRK2, but the exact Rab has 
differed substantially. Since Drosophila has been a highly successful organism 
for genetic screens, we undertook a screen for LRRK2-G2019S⬌Rab genetic 
interactions, using the SSVEP electroretinogram as a readout. 
 
4.1.1 Rab proteins 
 
Rab (Ras related in brain) proteins are small (20-25 kDa), monomeric G-
proteins, constituting the largest subfamily of the Ras GTPase superfamily (Ng 
and Tang, 2008; Pfeffer, 2001; Stenmark, 2009; Zerial and McBride, 2001). Rab 
GTPases were first described in 1987 when Touchot isolated four family 
members from a rat brain cDNA library (Touchot et al., 1987). Later on it was 
established that these proteins are key regulators of membrane organisation and 
intracellular membrane trafficking in all eukaryotic cells (Zerial and McBride 
2001; Pfeffer et al., 2007; Pfeffer et al., 1994; Stenmark et al., 2009). They are 
involved in many steps in membrane trafficking, including vesicle formation, 
vesicle movement and membrane fusion. These processes are responsible for the 
transfer of membrane proteins from the Golgi to the plasma membrane and 
recycled. Specific Rabs are physically associated with each organelle as well as 
their associated transport vesicles (Figure 4.1). Moreover, Table 4.1 summarizes 
all the needed information for each one of the Rabs, including the exact location, 
pathway that they are involved and the human ortholog that each one has been 
associated with. 
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Figure 4.1 The intracellular localization of Rabs.  
Each Rab has been associated to a district cellular compartment and 
vesicle transport pathway(s). Rab1 is located in the intermediate of the 
ER and Golgi regulating the traffic between those two compartments 
while Rab2 is involved in recycling, or retrograde traffic, from Golgi and 
ERGIC back to the ER. Early endocytic steps rely on Rab5, which 
mediates fusion of endocytic vesicles to form the early endosome. Rab7 
is a marker for the lysosomal pathway, which directs traffic towards 
degradation, or to various recycling compartments to return factors to the 
plasma membrane.  More specialised Rab functions include Rab18, 
which is located in the lipid droplets, regulating intracellular lipid storage 
sites. (Adapted from Hutagalung and Novick, 2011).  
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Table 4.1 Summary of the function of the Rab proteins and their similarity to Drosophila (Information taken from Ensembl 
and GeneCards) 
Rab protein Localization Pathway Fly ortholog 
Similarity to the 
human homolog 
% 
Rab1 
Extracellular, Golgi 
apparatus, ER, cytosol 
ER to Golgi, intra-Golgi Rab1 84 
Rab2 
Extracellular, ER, Golgi, ER-
Golgi intermediate 
compartment 
ER to Golgi Rab2 90 
Rab4 Early endosome 
Protein recycling, transport 
to plasma membrane 
Rab4 75 
Rab5 
Early endosome, 
extracellular, cytosol, plasma 
membrane 
Early endosome fusion Rab5 73 
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Rab6 Golgi 
Endosome to Golgi, intra-
Golgi transport, Golgi to 
ER 
Rab6 85 
Rab7 
Late endosomes, lysosomes, 
melanosomes, phagosomes 
Late endosome to lysosome Rab7 76 
Rab8 
Cell membrane, vesicles, 
extracellular 
Exocytosis, TGN/RE to 
plasma membrane 
Rab8 78 
Rab9 Late endosomes, Golgi Endosome to TGN Rab9 50 
Rab10 
ER, Golgi, basolateral sorting 
endosomes, GLUT4 vesicles 
Exocytosis, TGN/RE to 
plasma membrane 
Rab10 80 
Rab11 Golgi, ER, endosomes 
TGN/RE to plasma 
membrane 
Rab11 85 
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Rab14 
Golgi, early endosomes, 
GLUT4 vesicles 
TGN/RE to plasma 
membrane 
Rab14 81 
Rab18 ER, Golgi, lipid droplets Lipid droplet formation Rab18 55 
Rab19 Golgi Unknown Rab-RP3 47 
Rab21 Early endosome Endosomal transport Rab21 65 
Rab23 Plasma membrane, endosome 
Protein recycling/ transport 
to plasma membrane 
Rab23 59.94 
Rab26 Secretory granules Exocytosis Rab26 65 
Rab27 Melanosomes, lysosomes Exocytosis Rab27 60 
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Rab30 ER, Golgi Unknown 
CG9100 
Rab30 
73 
64.22 
Rab32 Mitochondria, melanosomes 
TGN to melanosome, 
mitochondrial fission 
Ltd 69 
Rab34 Golgi 
Intra-Golgi transport, peri-
Golgi positioning of 
lysosome 
RabX5 
CG7980 
38 
52 
Rab35 PM, endosome RE to plasma membrane 
Rab35 
CG9575 
CG2885 
68.52 
66 
44 
Rab36 Golgi Unknown 
RabX5 
CG7980 
55.17 
52 
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Rab37 Secretory granules Exocytosis Rab26 31 
Rab39 Golgi Unknown Rab39 56 
Rab40 Golgi, ER 
Endosome/intracellular 
transport 
Rab40 54 
Rab43 ER, Golgi ER to Golgi Rab19 63 
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There are numerous Rabs associated with the endosomal traffic, and the most 
active site of localization is the early endosome. Most of the early endocytic 
steps rely on Rab5, which is located in the early endosomes, mediating fusion of 
endocytic vesicles to form the early endosome. Traffic can be directed towards 
the lysosome for degradation, which relies on action of Rab7, or to various 
recycling compartments to return factors to the plasma membrane. Rab4, which 
is also located in the early endosomes regulate fast endocytic recycling. Rab9, 
which is located in the late endosomes, regulates membrane traffic between late 
endosomes and the trans-Golgi network (TGN). Rab21 regulates transport of 
integrins to control cell adhesion and cytokinesis while Rab23 acts downstream 
to negatively regulate Sonic hedgehog (Shh) signaling during dorsoventral 
development of the mouse spinal cord. It potentially interacts with the 
transcription factors activated by the Shh pathway. Rab27 is well-studied in the 
melanosome transport system, which also relies on Rabs 32 and 38. Rab35 is one 
of the less characterised Rabs, controlling plasma membrane recycling of an 
essential factor in cytokinesis (Reviewed from Shi et al., 2017; Hutagalung and 
Novick, 2011).  
 
Several Rab GTPases have been associated with the ER-Golgi trafficking 
pathway. Rab1 is located in the intermediate of the ER and Golgi, regulating this 
traffic pathway while Rab2 is involved in recycling, or retrograde traffic, from 
Golgi and the ERGIC back to the ER. Rab6 is involved in the intra-Golgi 
trafficking. Several other Rabs including Rab8 and Rab10 are responsible for the 
biosynthetic pathway from the trans-Golgi network (TGN) to the plasma 
membrane. Rab18 has a more specific role as it mediates the regulation of the 
lipid droplets, which are intracellular lipid storage sites. Rab40 acts in a 
signalling pathway where it recruits components of the ubiquitination machinery 
to regulate Wnt pathway (Reviewed from Shi et al., 2017; Hutagalung and 
Novick, 2011).  
 
Many Rabs have been implicated in the vesicle recycling pathway being located 
in the synaptic vesicles or the glucose transporters (GLUT4). GLUT4 is found in 
vesicles that can use different Rabs to reach the plasma membrane. One of these 
Rabs is Rab8. Apart from that Rab8 also regulates the biosynthetic traffic from 
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the trans-Golgi network (TGN) to the plasma membrane. Several secretory 
vesicles and granules use Rab3, Rab26, Rab27 and Rab37 in order to exocytose 
their cargo. Rab35 that belongs to this pathway is very poor characterized. Rab26 
and Rab27 localise in the synaptic vesicles regulating exocytosis to the plasma 
membrane (Reviewed from Shi et al., 2017; Hutagalung and Novick, 2011).  
 
4.1.2 Rab proteins structure 
 
Overall, Rab proteins show a typically conserved core structure that is mainly 
conserved among the entire Ras superfamily. That includes the presence of a 20 
kDa catalytic GTPase fold composed of a six-stranded β-sheet, with five parallel 
strands and one anti-parallel stand, flanked by five α-helices (Figure 4.2). The 
structural basis of the Rab molecular switch can be defined as the portions of the 
Rab protein that are unique to and therefore specify the GDP and GTP-bound 
conformations. These elements are known as “Switch regions” (Hutagalung and 
Novick 2011; Pfeffer 2005). As with Ras, there are two Switch elements, termed 
Switch I and Switch II. These regions appear to be the only elements of the 
protein that change conformation upon nucleotide binding.   
 
 
 
 
Figure 4.2 Structure of three different Rabs. In yellow are shown the 
Switch regions and in red are domains that correspond to the 
complementarity-determining regions identified in Rab3a. Green positions 
are the hydrophobic triad residues in which side chains have different 
orientation in Rab structures despite their identical sequences. (Adapted 
from Pfeffer 2005).  
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Apart from the N-terminal catalytic core Rab proteins also contain a 
hypervariable C-terminal domain, which was originally implicated in the 
localization of Rab’s to specific target membranes (Chavrier et al., 1991). 
However, assessment of a wider range of Rabs suggests that multiple regions 
contribute towards the localization of the Rabs (Ali et al., 2004). For most of the 
Rab proteins the C-terminal domain terminates with a distinctive cysteine rich 
motif (CC, CCX, CCXX or CCXXX) (Leung et al., 2007; Calero et al., 2003). 
This motif is then recognised by RabGGT (Rab geranylgeranyl transferase) 
catalysing the addition of prenyl groups that is essential for membrane associate 
and anchoring of Rabs (Leung et al., 2007; Calero et al., 2003). 
 
4.1.3 The function of Rab GTPases; Molecular Switches 
 
The Rab proteins, as GTPases, function as molecular switches that alternate 
between two conformational states: the GTP-bound ‘on’ form and the GDP-
bound ‘off’ form. Exchange of GDP with GTP is catalysed by Guanine 
nucleotide exchange factors (GEFs), which recognise specific residues in the 
switch regions and facilitate GDP release (Delprato et al., 2004). Conversion 
from GTP- to GDP-bound form occurs through GTP hydrolysis, which is 
catalysed by GTPase-activating proteins (GAPs). That cycling between GTP- 
and GDP-bound form is associated with significant conformational alternations 
in two distinct variable regions, the Switch I and Switch II (Zhu et al., 2010).  
 
Rab proteins cycle between the cytosol and the membrane of its respective 
transport compartment (Figure 4.3). The nucleotide-bound state of the Rab 
influences its localization and activity. The newly synthesised Rabs are 
associated with Rab escort proteins (REP), which present the Rab to Rab 
geranylgeranyl transferase (RabGGT) that catalyses the addition of one or two 
geranylgeranyl lipid groups to the COOH terminus of the Rab (Alexandrov et al., 
1994; Andres et al., 1993; Desnoyers et al., 1996). In its inactive, GDP-bound 
form, the Rab is inserted into its respective membrane. A GDP dissociation 
inhibitor (GDI) and dissociation factor (GDF) may also assist to insert the Rab in 
the appropriate membrane (Collins, 2003); Sivars et al., 2003). A guanine 
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nucleotide exchange factor (GEF) acts on the membrane where the Rab has been 
inserted to convert it to a GTP-bound or to its active state. Now the activated Rab 
interacts with effector proteins that facilitate trafficking in its respective pathway. 
A GTPase accelerating protein (GAP) then binds to the activated Rab inducing 
hydrolysis of the GTP-bound to GDP-bound converting in that way the Rab back 
to its inactive state (Pfeffer, 2001; Segev, 2001). The GDP-bound form of the 
Rab is now a substrate for GDI, which is now able to extract the Rab in its GDP-
bound conformation from the membrane. The Rab is now ready to be reinserted 
into a membrane and begin the cycle again (Hutagalung and Novick 2011).  
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Figure 4.3 The Rab GTPase cycle.  
Newly synthesized Rab proteins associate with Rab escort proteins 
(REP) which direct them to Rab geranylgeranyl trasnferase (RabGGT) in 
order to receive their prenyl tails (shown in red wavy lines). REP proteins 
deliver Rabs to their target membranes. Throughout that process, the 
Rabs are GDP-bound. A guanine nucleotide exchange factor (GEF) then 
catalyses exchange of GDP for GTP to activate the Rab. The GTP-bound 
Rab then interacts with effector proteins that mediate membrane traffic in 
the pathway regulated by its associated Rab. This process is followed by 
Rab interacting with its associated GTPase activating protein (GAP) 
which catalyses hydrolysis of GTP to GDP by the Rab. The Rab is then 
removed from the membrane by guanine nucleotide dissociation inhibitor 
(GDI) in preparation for the next cycle. Insertion of the Rab into its 
associated membrane is mediated by a GDI dissociation factor (GDF) 
that releases the Rab from GDI. (Adapted from Hutagalung and Novick, 
2011).  
 
 
Through this conformational cycling, and the specific localization of different 
Rabs, and the effector proteins they activate and/or recruit, Rab proteins act as 
multifaceted organisers (Ng and Tang, 2008; Stenmark, 2009).  For that reason 
they convey strict regulation to both rate and specificity for almost all trafficking 
event occurring in the eukaryotic cells (Ng and Tang, 2008; Stenmark, 2009).  
These events include vesicle transport, tethering and docking to target 
membranes and exocytosis by interaction with cytoskeletal motor proteins, N-
ethylmaleimide-sensitive factor (NSF) and soluble NSF attachment receptor 
(SNARE) proteins, respectively (Ng and Tang, 2008; Pfeffer, 2001; Stenmark, 
2009).  When in GTP-bound active state Rab proteins have been shown to 
activate and recruit several effector proteins including motor proteins, tethering 
factors, adaptor proteins, kinases and phosphatases. They also recruit and 
activate GEF’s that proceed to activate other, downstream, Rab proteins 
(Knodler et al., 2010).  
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4.1.4 The role of Rab proteins in Disease 
 
The physiological importance of Rab GTPases, which is expected from their 
central role in membrane trafficking, is reflected by the association of these 
proteins and their regulators or effectors with many diseases. In general, 
infectious, neurological and endocrinological diseases can be the result of 
pathogen-induced or inherited dysfunctions of Rab pathways (Stenmark 2009).  
 
Neurons have specialized demands on membrane trafficking both during 
development and function indicating the importance of Rab function in the 
nervous system. That is highlighted by observations that mutations within Rab 
genes and their effectors and interactors cause several hereditary and 
neurological diseases (Chan et al., 2011). A summary of their function and their 
association with specific neurological and neurodegenerative diseases is listed on 
Table 4.2.  
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Table 4.2 The role of Rab proteins and their functions in Neurodegenerative Diseases (Adapted and modified from Hutagalung and 
Novick, 2011; Seixas et al., 2013). 
Rab protein Localization/ Function 
Membrane Traffic 
Pathway 
Association with  
a Disease 
Reference 
Rab1 ER, Golgi 
ER to Golgi complex 
trafficking 
Parkinson’s disease Cooper et al., 2006 
Rab3a Secretory vesicles, plasma membrane 
Exocytosis, 
neurotransmitter release 
Warburg Micro/Martsoft 
syndromes 
Aligianis et al., 2005; 
Dalfo et al., 2004; 
Gitler et al., 2008 
Rab4a Early endosome 
Protein recycling, 
transport to plasma 
membrane 
Alzheimer’s disease 
Ginsberg et al., 2011 
 
Ginsberg et al., 2010 
Rab5a 
Early endosome, clathrin-coated vesicles, 
plasma membrane 
Early endosome fusion 
Alzheimer’s disease Ginsrberg et al., 2011 
Parkinson’s disease Dalfo et al., 2004 
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Rab7 Late endosomes 
Late endosome to 
lysosome 
Alzheimer’s disease 
Ginsberg et al., 2011; 
Ginsberg et al., 2010 
Charcot-Marie-Tooth 
Disease Type 2B 
De Luca et al., 2008; 
McCray et al., 2010; 
Verhoeven et al., 2003 
Batten disease 
Agola et al., 2011; 
Luiro et al., 2004 
Rab8 Cell membrane, vesicles 
Exocytosis, TGN/RE to 
plasma membrane 
Huntington’s Disease 
Del Toro et al., 2009; 
Hattula and Peranen, 2000 
Parkinson’s Disease 
Dalfo et al., 2004; 
Gitler et al., 2008 
 
Alzheimer’s Disease Kametani et al., 2004  
Rab9 Late endosomes, Golgi Endosome to TGN 
Niemann Pick C Ganley and Pfeffer, 2006 
Batten Disease Agola et al., 2011; 
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Luiro et al., 2004 
 
Rab10 
Golgi, basolateral sorting endosomes, 
GLUT4 vesicles 
Exocytosis, TGN/RE to 
plasma membrane 
Parkinson’s disease Steger et al., 2016 
Rab11 Golgi, ER, early endosomes 
TGN/RE to plasma 
membrane 
Huntington’s Disease 
Li et al., 2009b; Li et al., 
2009c 
Batten disease 
Agola et al., 2011; Luiro et 
al., 2004 
Charcot-Marie-Tooth 
Disease Type 4C 
Roberts et al., 2010 
Rab23 PM, endosome 
Protein recycling/ 
transport to plasma 
membrane 
Carpenter Syndrome 
Eggenschwiler et al., 2001; 
Jenkins et al., 2007 
Rab27 Melanosomes Exocytosis Griscelli syndrome 
 
Meschede et al., 2008 
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4.1.5 Interaction between LRRK2 and Rabs 
 
As LRRK2 is a multi-domain protein with the presence of many protein-protein 
binding domains, it has been proposed that this protein acts as a scaffold for 
several other proteins. Many different LRRK2 substrates have been identified 
including FADD [Fas-associated protein with death domain, (Ho et al., 2009)], 
heat shock protein 90 [Hsp90, (Wang et al., 2008)], the dishevelled family 
members [DVL1-3, (Sancho et al., 2009)] and others (Dachsel et al., 2007). 
 
 More recent studies identified several Rab GTPases as LRRK2 substrates, 
initiating a whole new era of investigation in PD genetics. Most of these 
approaches focused on in vitro experiments or to cellular systems using 
overexpressed kinase (Jaleel et al., 2007; Kumar et al., 2010; Ohta et al., 2011; 
Kawakami et al., 2012; Bailey et al., 2013; Martin et al., 2014; Qing et al., 2009; 
Chen et al., 2012; Gloeckner et al., 2009; Imai et al., 2008; Gillardon, 2009; 
Kanao et al., 2010; Matta et al., 2012; Xiong et al., 2012; Yun et al., 2013; Yun 
et al.,2015; Krumova et al., 2015). The first Rab identified as LRRK2 substrate 
was Rab7L1 (MacLeod et al., 2013). Since then Rab8a, Rab1 and Rab3a have 
been also linked contributing to the pathogenesis of PD, by functionally 
interplaying with known PD factors (Cooper, 2006; Gitler et al., 2008). The 
different Rabs that have been identified interacting with LRRK2 are listed on 
Table 4.3. Additionally, Rabs have been linked to other genetic forms of PD (e.g. 
α-synuclein) (Gitler et al., 2008; Stefanis, 2012; Shi et al., 2017). Even though 
the interaction between LRRK2 and several Rab GTPases has been confirmed, it 
is not clear yet if LRRK2 directly or indirectly modulates Rabs at the molecular 
level and by which mechanism. In vitro experiments indicated that LRRK2 
directly phosphorylates Thr but not Ser sites in Rab isoforms (Jaleel et al., 2007; 
Martin et al., 2014; Nichols et al., 2009), although the major characterised in vivo 
LRRK2 autophosphorylation site is a Ser residue (Ser1291) (Sheng et al., 2012). 
Investigating the functional role of LRRK2-mediated Rab phosphorylation, it 
was established that LRRK2 is an important regulator of Rab homeostasis which 
is very likely contributing to PD development (Steger et al., 2016). PD-
associated LRRK2 mutations could shift the membrane-cytosol balance of Rabs 
towards the membrane compartment, leading to the accumulation of inactive 
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Rabs in the membranes. The T73 residue, that is located in the Switch II domain, 
is characteristic of the Rab GTPase proteins. This domain changes conformation 
upon nucleotide binding and regulates the interaction with multiple regulatory 
proteins (Pfeffer, 2005). Sequence alignment of that residue revealed its high 
evolutionary conservation among more than 40 human Rabs, which is an 
indication of a strong functional relevance.  
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Table 4.3 Summary of that Rab proteins that have been identified interacting with LRRK2 
Rab interacting with hLRRK2 Function of Rab Reference 
Rab3 Exocytosis through synaptic vesicles              Islam et al., 2016 
Rab5b 
Key regulator of endocytic vesicular transport from PM to 
endosomes 
Shin et al., 2008 
Rab7 Late endosomal/lysosomal pathway Dodson et al., 2012 
Rab8 Exocytosis, TGN/RE to plasma membrane 
Steger et al., 2016 
Kim et al., 2017 
Rab10 Exocytosis, TGN/RE to plasma membrane 
Steger et al., 2016 
Ito et al., 2016 
Rab29 (Rab7L1) Trans-Golgi network 
Beilina et al., 2014 
MacLeod et al., 2013 
Rab32 TGN network/ transport of key enzymes in melanogenesis Waschbusch et al., 2014 
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4.1.6 Drosophila as an animal model for Rabs 
 
Drosophila is considered an ideal model for the investigation of Rab GTPases in 
the nervous system. There are ~33 Rab or Rab-related genes in the fly genome of 
which at least six do not have a clear vertebrate ortholog (Chan et al., 2011). 
Twenty-three rab genes have direct orthologs in human that are at least 50% 
identical at the protein level. Therefore, Rab proteins in Drosophila exhibit high 
evolution conservation and low redundancy compared to over 70 Rab genes in 
humans (Colicelli, 2004). Clear orthologs exist that serve as gold standard 
markers for many intracellular compartments across species, as different Rab 
proteins are found to be associated with distinct subcellular membrane 
compartments. For instance, Rab1 acts as a marker for the endoplasmic 
reticulum, Rab5 for the early endosomes, Rab6 for Golgi, Rab7 for late 
endosomes and Rab11 for recycling endosome. Apart from the fact that there are 
fewer Rab proteins in Drosophila compared to vertebrates, Drosophila genetics 
will be useful in identifying interacting genes and proteins. Moreover, most 
developmental signalling pathways are also evolutionally conserved from 
Drosophila to humans and are easily studied in the fly. Studying and 
characterization of Rab functions in flies will improve our understanding of the 
normal cellular functions of Rab proteins and the molecular nature of Rab-
induced diseases.  
 
Zhang et al (2007), taking into account all the benefits obtained by using 
Drosophila as an animal model, isolated cDNA clones representing 31 out of the 
33 Rab genes. They generated transgenic flies that can be stimulated, under 
UAS-control, to produce yellow fluorescent protein (YFP)-tagged wild-type, 
dominant negative and constitutively active forms of each of the 31 Drosophila 
Rab proteins. A few years later, a ‘Rab-Gal4 kit’ was created making Gal4 lines 
for each Rab gene, which provided further details on the comparative analysis of 
the cellular and subcellular expression of all Rab GTPases (Jin et al., 2012; Chan 
et al., 2011). Most recently, a ‘Rab-knockout kit’ was provided, showing that 
removal of any Rab was not lethal (Dunst et al., 2015). 
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4.2 Aims 
 
1. Test for genetic interaction between LRRK2 and Rabs in vivo, by 
dopaminergic expression of different Rab transgenes in Drosophila both 
in isolation and in combination with the G2019S mutation. 
 
2. Take advantage of the evolutionary conservation using Drosophila as an 
animal model in order to test in which subcellular compartment LRRK2-
G2019S mutation could be involved. 
 
 
4.3 Results 
 
4.3.1 Expression of different UAS-Rab constructs in the dopaminergic 
neurons 
 
More than 1000 flies were recorded in this genetic screen, including 21 different 
Rabs and 3 different controls. One of the aims of this study was to test if it is a 
specific cellular pathway that can be implicated in the interaction between 
LRRK2 and Rabs. As every Rab is associated with a different cellular 
compartment, Rabs were grouped according to their subcellular localization. As 
described in more details in section 2.1.1, TH-Gal4;G2019S or TH-Gal4 flies 
were crossed to UAS-Rab flies and the SSVEP (Steady State Visual Evoked 
Potential) of the F1 generation was tested at 1 and 7 days old. 
 
In this course of investigation three controls were deployed including 
TH>G2019S, TH>hLRRK2 and TH/w-. For all the recorded Rabs that were 
tested here, the visual response is represented as a percentage (%) of that 
recorded from TH/w- and TH::G2019S/w- flies at 1 and 7 days old. Figure 4.4 
shows the raw data from the controls that utilised during this set of experiment.  
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Figure 4.4 Presentation of the deployed controls in this genetic 
screen. The mean responses ±SE from the photoreceptors (A) and the 
lamina neurons (B) are presented. TH>G2019S, TH>hLRRK2 and TH/w- 
flies were tested both in the presence and the absence of the G2019S 
mutation. Each fly line was tested at 1 day and 7 days, after being 
crossed to TH-Gal4 or TH::G2019S-Gal4. N=123. For all the different 
groups two-way ANOVA was performed, when * P<0.05, ** P<0.01 and 
when *** P<0.001. 
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The criteria by which the Rab⬌G2019S interaction was determined was 
increased (P<0.05) 1F1 and 2F1 responses in the presence of the G2019S 
mutation at 1 or 7 days compared with the expression of the Rab alone. In 
addition, responses to expression of a Rab that increased the photoreceptors 
responses above control levels in the absence of the G2019S mutation are 
reported.  
 
4.3.1.1 Rabs involved in the endo-lysosomal pathway 
 
The available Rab fly stocks that were associated with the endo-lysosomal 
pathway including Rab4, Rab5, Rab7, Rab9, Rab21, Rab23, Rab27 and Rab35 
were tested. All the UAS-Rabs were expressed in the dopaminergic neurons 
using the TH-Gal4 driver and the visual responses were obtained using the 
SSVEP assay as described in section 2.2.2. 
 
The eight different UAS-Rabs were recorded in both the presence and the 
absence of the G2019S mutation. From the SSVEP recording, the visual 
responses from the photoreceptors and the lamina neurons were obtained as 
shown in Figure 4.5 (A and B, respectively).  
 
From this genetic screen, it was established that there is an interaction between 
LRRK2-G2019S and Rab5 and LRRK2-G2019S and Rab9, as the presence of the 
G2019S mutation has a big effect on the vision of flies expressing these Rabs. 
The photoreceptor responses are massively increased compared to the absence of 
the Rab transgene and compared to the control levels as well. At 1 day and 7 
days there is 100% increase in the photoreceptor response in the 
TH::G2019S>Rab5 compared with TH>Rab5 (P=0.04 and 0.025, respectively), 
establishing a strong interaction. Additionally, the lamina neurons show a similar 
effect: TH::G2019S>Rab5 is 35% bigger on day 1 and 50% on day 7 compared 
with TH>Rab5 (P=0.03, P=0.0091, respectively); (Figure 4.5; B).  
 
Rab5 is not the only Rab in the endo-lysosomal pathway to show an interaction 
with G2019S: Rab9 also shows some interaction. At 7 days, there is a 250% 
increase in the responses from the photoreceptors in the TH::G2019S>Rab9 
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compared with TH>Rab9 (P=0.001) (Figure 5.5; A). This interaction is also 
confirmed from the responses from the lamina neurons as there is a 50% increase 
at 7 days (P=0.03) (Figure 4.5; B).  
 
The rest of the tested Rabs show responses similar to the control levels 
irrespectively of the presence of the G2019S mutation.  
 
 In a cluster analysis, the percentage change in visual response due to expression 
of an endo-lysosomal Rab was plotted against the combined effect (expression of 
Rab and G2019S (Figure 4.5: C- 1 day; D- 7 days). Most of the Rabs are in a 
cluster, and Rab5 is a clear outlier on day 1, but both Rab5 and Rab9 are outliers 
on day 7.  
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Figure 4.5 Rab5 and Rab9 interact with hLRRK2.   
From the endosomal/lysosomal Rabs, Rab5 has a much bigger response 
than any other Rab, or control flies. Additionally, it shows a strong 
interaction with G2019S. Rab9 also indicates a strong interaction with the 
G2019S, as at 7-day-old flies the presence of the G2019S mutation 
increases the visual responses.  The percentage (%) visual responses 
from the photoreceptors (A) and the lamina neurons (B) are shown, with 
the 100% being the baseline as represents the mean responses from the 
control flies TH/w-. (C) This graph confirms a strong interaction between 
G2019S and Rab5 at 1 day, as its presence dramatically increases the 
visual response compared to the other Rabs. (D) This graph confirms a 
strong interaction between G2019S and Rab9 at 7 days, as its presence 
dramatically increases the visual response compared to the other Rabs.  
Each fly line was tested at 1 day and 7 days, after being crossed to TH-
Gal4 or TH-Gal4;G2019S. (N=416). For all the different groups two-way 
ANOVA was performed, when * P<0.05, ** P<0.01 and when *** 
P<0.001. 
 
 
4.3.1.2 Rabs involved in Golgi and the Endoplasmic reticulum  
 
The available Rab fly stocks that were associated with the Golgi/Endoplasmic 
reticulum pathway include Rab1, Rab2, Rab6, Rab8, Rab10, Rab18, Rab19, 
Rab30 and Rab40, were tested.  
 
The visual responses from the photoreceptors and the lamina neurons are shown 
in Figure 4.6 (A and B, respectively).  
 
From the genetic screening, the most marked interactions are between LRRK2-
G2019S and Rab10 and Rab18. In both cases, the visual responses are massively 
increased compared to the absence of the G2019S transgene and compared to the 
control levels as well, on both 1 day and 7 days. 
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For Rab10, there is a 70% increase in the photoreceptor responses at 1 day in the 
TH::G2019S>Rab10 compared to TH>Rab10 (P=0.03), establishing a strong 
interaction. Moreover, at 7 days, there is a 170% increase in the responses from 
the photoreceptors in the TH::G2019S>Rab10 background (P=0.01) (Figure 4.6; 
A). This interaction is also confirmed from the responses from the lamina 
neurons, as there is a 40% and 70% increase in the lamina neuron responses at 1 
day and 7 days respectively (P=0.05, P=0.021) (Figure 5.6; B).  
 
The second Golgi/Endoplasmic reticulum Rab that shows a strong interaction 
with G2019S is Rab18. For Rab18 there is an 80% increase in the photoreceptor 
responses in the TH::G2019S>Rab18 compared to TH>Rab18 at 1 day 
(P=0.018) while there is a 100% increase at 7 days (P=0.03). In addition, there is 
a 40% increase in the responses from the lamina neurons at 7 days (P=0.01). 
That increase in the photoreceptor and lamina neuron responses establishes a 
strong interaction to LRRK2-G2019S according to our criteria, even though there 
was no increase in the lamina neurons at day 1.  
 
While Rab10 and Rab18 gave the most consistent interaction over the timepoints 
tested, one more Rab, Rab40, indicate an interaction to the G2019S at some 
timepoints. At 1 day, photoreceptor responses in the TH::G2019S>Rab40 
compared to TH>Rab40 increased by 150% (P=0.05), while the responses are in 
general increased, independently of the presence of the mutation. In addition, the 
responses from the lamina neurons show a 30% increase at 1 day (P=0.05), 
confirming the interaction.  
 
Rab1 and Rab19 on the other hand, do not show an interaction to the G2019S 
mutation but to the dopaminergic expression, as their expression increased the 
photoreceptor responses compared to the control TH/w- and TH;G2019S/w- 
averages.  For Rab1 the photoreceptor responses increase by 200% compared to 
the baseline of the control TH/w- flies, irrespectively of the presence of the 
G2019S mutation (P=0.02). For Rab19 there was a 180% increase in the 
photoreceptor responses compared to the baseline of the control TH/w- flies, 
irrespectively of the presence of the G2019S mutation (P=0.04). 
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The rest of the tested Rabs show responses similar to the control levels 
irrespectively of the presence of the presence of the G2019S mutation.  
 
Using a similar cluster analysis, the percentage change in visual responses due to 
expression of Golgi-Endoplasmic reticulum Rabs was plotted against the 
combined effect (expression of Rab and G2019S) (Figure 4.6, C-1 day and D- 7 
days). Most of the Rabs cluster while Rab10 and Rab18 are clear outliers at 7 
days. 
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Figure 4.6 Rab1, Rab10, Rab18, Rab19 and Rab40 interact with 
hLRRK2.  From the ER-Golgi Rabs, Rab1, Rab10, Rab18, Rab19 and 
Rab40 have much bigger responses than any other Rab, or control flies. 
Additionally they show a strong interaction with G2019S. The percentage 
(%) visual responses from the photoreceptors (A) and the lamina neurons 
(B) are shown, with the 100% being the baseline as represents the mean 
responses from the control flies TH/w-. (C) This graph confirms the strong 
interaction between G2019S-Rab1, G2019S-Rab19 and G2019S-Rab40, 
at day 1, as its presence dramatically increases the visual response 
compared to the other Rabs. (D) This graph confirms a strong interaction 
between G2019S-Rab10 and G2019S-Rab18 at 7 days, as its presence 
dramatically increases the visual response compared to the other Rabs.  
Each fly line was tested at 1 day and 7 days, after being crossed to TH-
Gal4 or TH::G2019S-Gal4. N=465.  
 
 
4.3.1.3 Rabs involved in vesicle recycling 
 
The available Rab fly stocks that were associated with the secretory pathway 
including Rab3, Rab8, Rab27 and Rab35, were tested. All the UAS-Rabs were 
expressed in the dopaminergic neurons using the TH-Gal4 driver and the visual 
responses were obtained using the SSVEP assay giving responses from the 
photoreceptors and the lamina neurons were obtained as shown in Figure 4.7 (A 
and B, respectively).  
 
From the genetic screening, it was established that in this group there is an 
interaction between LRRK2-G2019S and Rab3, as the presence of the G2019S 
mutation has a big effect in the fly vision. The visual responses are massively 
increased compared to the absence of the mutation and compared to the control 
levels as well. At 7 days there is a 300% increase in the photoreceptor responses 
in the TH::G2019S>Rab3 compared to TH>Rab3 (P=0.027), and a 150% 
increase in the lamina neuron responses (P=0.05) establishing a strong 
interaction (Figure 4.7; A). Moreover, compared to the baseline, which 
 
 
153 
represents the mean responses from the TH/w- control flies, there was a 400% 
increase in the photoreceptor responses.  
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Figure 5.7 Rab3 interacts with hLRRK2.   
From the vesicle recycling Rabs, Rab3 seems to have an effect on fly 
vision in the presence of the G2019S mutation, indicating an interaction. 
The percentage (%) visual responses from the photoreceptors (A) and 
the lamina neurons (B) are shown, with the 100% being the baseline as 
represents the mean responses from the control flies TH/w-.  Each fly line 
was tested at 1 day and 7 days, after being crossed to TH-Gal4 or 
TH::G2019S-Gal4. N=253.  
 
 
4.3.1.4 Rabs involved in mitochondria  
 
The available Rab fly stocks that were associated with the mitochondria, 
including Rab27 and Rab32, were tested. All the UAS-Rabs were expressed in 
the dopaminergic neurons using the TH-Gal4 driver and the visual responses 
were obtained using the SSVEP assay as described in section 2.2.2. 
 
The two different UAS-Rabs were recorded in both the presence and the absence 
of the G2019S mutation. From the SSVEP recording, the visual responses from 
the photoreceptors and the lamina neurons were obtained as shown in Figure 4.8 
(A and B, respectively).  
 
From the genetic screening, it was established that there is no interaction 
between LRRK2-G2019S and any of these two Rabs, as the presence of the 
G2019S transgene did not have any effect in the fly vision. Moreover, compared 
to the baseline, which represents the mean responses from the TH/w- control 
flies, there was not much of increase in the photoreceptor or the lamina neurons 
responses (Figure 4.8; A and B). 
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Figure 4.8 None of the Rabs involved in the mitochondria indicate a 
possible interaction to LRRK2. Two Rabs involved in the mitochondria 
were tested, Rab27 and Rab32. The percentage (%) visual responses 
from the photoreceptors (A) and the lamina neurons (B) are shown, with 
the 100% being the baseline as represents the mean responses from the 
control flies TH/w-. Each fly line was tested at 1 day and 7 days, after 
being crossed to TH-Gal4 or TH::G2019S-Gal4. N=194 (N>10 per 
genotype and age).  
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Table 4.4 summarizes the identified Rab proteins that regulate the phenotype of 
LRRK2 mutants based on the set criteria. In addition, two Rabs show no genetic 
interaction with LRRK2 but a strong association with the dopaminergic neurons. 
 
Table 4.4  Summary of Rab effects on the visual system  
  
Effect of dopaminergic Rab 
expression at 
Interaction with G2019S at 
Rab Pathway 
ph – 
day 1 
Ln – 
day 1 
ph – 
day 7 
Ln – 
day 7 
ph – 
day 1 
Ln – 
day 1 
ph – 
day 
7 
Ln – 
day 
7 
1 ER-Golgi x x x x     
3 
Synaptic 
vesicles 
      X X 
5 Endo-lysosomal     X X X X 
9 Endo-lysosomal       X X 
10 ER-Golgi     X X X X 
18 ER-Golgi     X X X X 
19 ER-Golgi x x x x     
40 ER-Golgi x x x x x x   
 ph: photoreceptors, Ln: Lamina neurons 
 
Thus, in summary, even though the Rabs identified as LRRK2 interactors belong 
to all of the subcellular pathways, five out of eight (62.5%) are associated with 
the ER-Golgi trafficking pathway, suggesting a stronger interaction with 
LRRK2.  
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4.4 Does the kinase domain cause these increased visual 
responses? 
 
The screen of Rab lines shows that dopaminergic expression of some lines had a 
big impact on the fly visual system. In particular, Rab3, Rab5, Rab9, Rab10, 
Rab18 and Rab40 showed a strong positive interaction with LRRK2-G2019S, 
based on the criteria set on this study. As noted in section 1.3, LRRK2 is a 
multidomain protein with both kinase and GTPase functions. In order to test the 
initial hypothesis that it really is the kinase domain of the LRRK2 protein that 
interacts with several Rab proteins, it was decided to express a LRRK2 transgene 
containing a substitution in the GTPase domain of the protein: R1441C (Figure 
1.1). As both TH-Gal4 and the UAS-R1441C are on the 3rd chromosome, they 
were recombined. This permitted co-expression in the dopaminergic neurons and 
subsequent visual assays. If it really is the kinase domain that plays a vital role in 
the interaction between LRRK2 and Rabs then the expected visual responses 
would be similar to the levels obtained from expressing just a Rab in the 
dopaminergic neurons.  
 
From the eight identified Rabs interacting with LRRK2-G2019S or the 
dopaminergic neurons in this genetic screening, three were chosen in order to test 
this hypothesis. Rab1 was chosen because of the increased visual responses 
independently of the presence of the G2019S mutation, while Rab10 and Rab18 
were chosen because of the big effect that G2019S had in the responses 
compared to the ones that it was absent from. Flies expressing TH::R1441C with 
and without Rab1 or Rab5 or Rab18 were tested and the mean photoreceptor and 
lamina neuron responses are shown in Figure 4.9.  
 
As presented in Figure 4.9 for all of the three different Rabs, the expression of 
the R1441C mutation decreases the visual responses to wild type levels, when the 
Rabs are expressing in the dopaminergic neurons without the presence of any 
other factor. Taken together, the increased visual responses obtained from the 
expression of the G2019S mutation and the reduced responses in the R1441C 
background establishes that it really is the kinase domain playing a vital role in 
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the LRRK2-G2019S-Rabs interaction. That applies both for the photoreceptor 
and the lamina neuron responses.  
 
 
Figure 4.9 Co-expression of the R1441C mutation with Rabs reduces 
the visual responses to wild type levels.  The mean responses ±SE 
from the photoreceptors (A) and the lamina neurons (B) are shown. Three 
Rabs were tested in this set of experiments, Rab1 (N=71), Rab5 (N=70) 
and Rab18 (N=65). The presence of the R1441C mutation decreases the 
visual responses down to wild type levels, when only the Rabs are 
expressed in the dopaminergic neurons. That’s an indication that it really 
is the kinase domain that plays a vital role in the LRRK2-Rabs interaction. 
Each fly line was tested at 1 day and 7 days, after being crossed to TH-
Gal4 or TH::G2019S-Gal4. N=206.  
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For all the different Rabs that were expressed, two-way ANOVA was performed 
followed a Bonferroni post-hoc test, and from that analysis it was determined 
than none of the tested TH>Rab were statistically significant to the 
TH;R1441C>Rab. That is an indication that the expression of the R1441C 
mutation in the dopaminergic neurons does not have an effect on the fly vision. 
On the other hand, the expression of the G2019S mutation does affect the visual 
responses, as in the Rab18 background at 1 day old and 7 day old flies its 
expression leads to increased visual responses (P=0.014, P=0.013, respectively). 
In the Rab5 background, the expression of the R1441C mutation has a similar 
effect, as there in no statistically significant difference to the TH>Rab5 flies 
(P=0.3 at 1 day and P=0.9 at 7 days), while there is a significant difference in the 
G2019S background (P=0.001 at 1 day and P=0.03). On the other hand, there is 
statistically significant difference between the TH>Rab5 and TH;G2019S>Rab5 
(P=0.032). The same pattern is followed in the responses from the lamina 
neurons as well, confirming the hypothesis that the interaction between LRRK2 
and different Rabs depends on the kinase domain of the gene. 
 
4.5 Does LRRK2 prefer Threonine to Serine? 
 
The first hypothesis that was addressed in this study was whether or not all of the 
identified Rabs interacting with LRRK2-G2019S were part of the same 
subcellular pathway or not. Apart from that, in vitro it is suggested that LRRK2 
protein shows a preference of phosphorylating Thr over Ser in the Rab 
sequence,at the position corresponding to T73 in Rab10 (Steger et al., 2016). 
This hypothesis can now be tested in vivo. Table 4.5 summarizes the identified 
Rabs linked to LRRK2-G2019S according to that criteria. 
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Table 4.5 In vivo analysis of LRRK2 phosphorylation  preference  
T73-Rab10 residue 
Rabs showing an 
interaction 
Rabs not showing an 
interaction 
Serine 
Rab5 
Rab9 
Rab2 
Rab4 
Rab6 
Rab7 
Rab21 
Rab23 
Rab26 
Rab27 
Threonine 
Rab3 
Rab10 
Rab18 
Rab40 
Rab1 
Rab19 
Rab30 
Rab35 
 
Taken together these results, there is an indication that LRRK2 protein indeed 
prefers Thr over Ser, as four out the six identified Rabs contain a Thr residue at 
this position. That means that 67% of the identified Rabs interacting with the 
G2019S have a Thr in this vital residue for the function of Rab proteins, 
confirming the hypothesis that LRRK2 protein has a preference for Thr residues. 
On the other hand, most of the Rabs that were not identified as LRRK2 
interactors have a Ser at this conserved residue, indicating that Thr plays a vital 
role in the LRRK2-Rab interaction. 
 
4.6 Are eye deformities induced by the G2019S/Rab5 
combination?  
 
The co-expression of the G2019S and Rab5 in the dopaminergic neurons leads to 
increased visual responses, indicating an interaction between the two proteins. 
The mechanism under which the two proteins could interact was not clear and for 
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that reason eye screening was performed in order to test if the presence of the 
G2019S mutation could lead to any eye phenotype.  
 
4.6.1 External Morphology: Eye screening 
 
For eye screening 1 day and 7 day old flies co-expressing hLRRK2 or G2019S in 
the Rab5 background in the fly eye using the GMR-Gal4 driver were examined. 
The GMR-Gal4 driver was chosen as it is regularly used in screens for eye 
deformities (Freeman, 1996). For each genotype 100 flies were tested (Figure 
4.10).  
 
Co-expression of LRRK2 or LRRK2-G2019S in the Rab5 background did not 
induce any eye phenotype, as in both cases the external surface of the eye was 
similar to control LRRK2 and G2019S flies.  
 
 
Figure 4.10 The presence of the G2019S does not induce an eye 
phenotype. Expression of hLRRK2 and G2019S in the fly eye, under the 
control of the eye specific driver GMR-Gal4, does not induce any district 
phenotype, as the wild type hLRRK2 and the G2019S flies present 
normal eye phenotypes (n=100 per genotype). Flies at 1 and 7 days old 
were tested after incubation in the dark at 29 0C.  
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4.6.2 Internal morphology: Staining of Drosophila retinas 
 
 
Since the visual responses increased in the G2019S/Rab5 background, but the 
external morphology was not affected, the next step was to examine the internal 
anatomy of the eye, using endosomal markers.  1 day and 7 day old flies were 
tested after incubation in the dark at 29 oC, and dissection of the Drosophila 
retinas followed (section 2.5.1).  
 
From that analysis it can be determined that there is no difference between the 
TH>G2019S and TH>hLRRK2 flies, indicating that the enlarged endosomes seen 
are not dependent on the genotype but probably on the genetic background of the 
flies that have an extra mini-white gene. That theory is also supported from the 
fact that the TH/w- flies do not show these enlarged endosomes.  
 
 
 
 
 
 
A 
B 
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Figure 4.11 Enlarged endosomes present in the hLRRK2 and 
G2019S retinas. Confocal images show enlarged endosomes (as 
pointed by the white arrows) for the hLRRK2 and G2019S flies in contrast 
to the w- background flies. The fly retinas were stained with an anti-Rab5 
antibody (green) as an early endosome marker and an anti-actin antibody 
(magenta) that stains the photoreceptors. The data shown 1 day old (A) 
and 7 day old (B) retinas after incubation at 29oC in the dark. N=60 (10 
retinas per genotype). 
  
 
4.7 Rab7 and its interaction with LRRK2 
 
 
Based on the findings from MacLeod et al. (2013) and Beilina et al. (2014), 
proposing that LRRK2 protein interacts with Rab7L1, the fly homolog Lightoid 
(ltd) (Hermann et al., 2005) and as Rab7L1 is risk factor for PD , independently 
of any other factor, triggered the interest for further investigation. Furthermore, 
ltd is a known Rab32 homolog (Ma et al., 2004). Dodson et al (2012; 2014) on 
the other hand, proposed that LRRK2 interacted with Rab7, rather than 
Rab32/ltd. Even though neither Rab7 nor Rab32 were identified interactors from 
my overexpression genetic screen, it was decided to test the effect of RNAi 
mediated knockdown of these genes. The RNAi lines aimed to silence Rab7 or 
ltd in order to test if these proteins contribute to the visual responses. If Rab7 and 
ltd really interact with the G2019S mutation, the expression of the RNAi lines 
would bring the visual responses down to control levels, as this interaction 
wouldn’t be functional anymore.  
 
As described previously, flies were tested at 1 day and 7 days both in the 
presence and the absence of the G2019S mutation. UAS-Rab7, UAS-Rab7RNAi, 
UAS-ltd and UAS-ltdRNAi were expressed in the dopaminergic neurons under the 
control of the TH-Gal4 driver and the TH::G2019S-Gal4 recombinant. The 
visual responses that were obtained both from the photoreceptors and the lamina 
neurons are presented in Figure 4.12. 
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Expression of the RNAi lines both in the Rab7 and ltd background increased the 
photoreceptor and the lamina neuron responses, compared to the TH>Rab7 and 
TH>ltd responses. Although, the presence of the G2019S mutation didn’t have a 
big effect on the visual responses.  
 
 
Figure 4.12 Expression of RNAi increased the visual responses. 
The mean responses ±SE from the photoreceptors (A) and the lamina 
neurons (B) are being presented. Each fly line was tested at 1 day and 7 
days, after being crossed to TH-Gal4 or TH::G2019S-Gal4. Total number 
of flies tested N=286.  
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4.8 Discussion 
 
 
In this course of investigation, where a genetic screening was performed in order 
to identify LRRK2 substrates in vivo, Rab3, Rab5, Rab9, Rab10, Rab18 and 
Rab40 were identified as LRRK2 interactors in the dopaminergic neurons. 
Whenever G2019S was added in the genetic background, the responses for theses 
Rabs increased both from the photoreceptors and the lamina neurons. Rab1 and 
Rab19 showed increased visual responses that were obtained independently of 
the presence of the G2019S mutation, compared to the control TH/w- flies.  
 
Furthermore, the preference of LRRK2 to threonine residues was confirmed, as 
six out of the eight identified Rabs interacting to LRRK2-G2019S had a Thr 
residue in their conserved T73-Rab10 equivalent site. In addition, five out of the 
eight identified Rabs are associated with the ER-Golgi trafficking pathway, 
shedding new light on the function of the LRRK2 protein. 
 
In addition, expression of RNAi lines for Rab7 and ltd showed increased visual 
responses both from the photoreceptors and the lamina neuros independently of 
the presence of the G2019S mutation, indicating that there is no interaction 
between LRRK2 and those two tested Rabs. 
 
The insertion site for all the UAS-Rab stocks that were used in this study were 
not the same, as for most of them the landing site of the transgenes was random. 
That could cause questions on whether or not the eye colour of the different 
stocks could contribute differently in the obtained visual responses. Although, as 
it was described in Chapter 3, section 3.3.3.5, the eye colour is not a confounding 
factor, indicating that this increase in the visual responses is real and not because 
of the eye colour.  
 
Figure 4.13 summarizes the expression pattern of the Rabs in the visual system 
of Drosophila as was described by Jin et al. (2012) and whether they have been 
linked to LRRK2 protein from previous studies or not. In addition, the findings 
from this course of investigation are summarised.  
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Figure 4.13 Expression pattern of Rabs in the Drosophila visual 
system related to the visual physiology shown by the SSVEP assay. 
 
 
4.8.1 Rabs involved in the endo-lysosomal pathway 
 
The findings from this course of investigation confirm the LRRK2-G2019S-Rab5 
and LRRK2-G2019S-Rab9 interaction, as in the genetic screening that was 
performed Rab5 and Rab9 are two of the Rabs that support this interaction. In the 
presence of the G2019S the visual responses both from the photoreceptors and 
the lamina neurons are higher compared to ones in the absence of the mutation. 
In addition, as far as the X73 residue is concerned, both Rab5 and Rab9 contain a 
Ser in this catalytic region of the switch II domain, which is surprising taking 
into account LRRK2 preference on Thr residues.  
 
This is the first time that Rab5 and Rab9 are confirmed as LRRK2 interactors in 
vivo. This builds on similar data from previous studies on in vitro models, 
making more powerful the findings from this study.  
 
Rab5 is by far the best-characterised endosomal Rab protein, which localises 
mainly to the sorting endosome (as shown in Figure 5.1), but it is also present on 
the plasma membrane and on endocytic vesicles. It has been proposed that the 
active form of Rab5 promotes endosome fusion by recruiting cytosolic 
components of the fusion apparatus (Woodman, 2000). Rab5, co-operating with 
LRRK2, contributes to the pathogenesis of PD by regulating the endocytosis of 
synaptic vesicles, proving for the first time that LRRK2 has a functional role in 
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the regulation of synaptic vesicles endocytosis. The reduced rate of endocytosis 
may cause defects in synaptic transmission in the long run, especially during 
intense neuronal activity, where the vesicle replenishment from the endosomal 
compartments is crucial for effective neurotransmitter secretion (Shin et al., 
2008).  
 
Heo et al. (2010) showed two years later that LRRK2, and more specifically 
LRRK2-G2019S, is a more critical factor than Rab5 in regulating neurite 
outgrowth even though they both functionally coordinate regulation of neurite 
outgrowth (Hen et al., 2010). Several studies proposed that increased kinase 
activity in mutant forms appears to induce decrease of neurite length and 
branching, formation of inclusion bodies, and/or neuronal toxicity (Gloeckner et 
al., 2006; Greggio et al., 2006; Smith et al., 2005; MacLeod et al., 2006; Smith et 
al., 2006; West et al., 2007). The active form of Rab5 negatively regulates 
neurite outgrowth (Liu et al., 2007). However, the conclusion that was made was 
that the regulation of the neurite outgrowth via LRRK2 and Rab5 is not effected 
independently, but through a shared mechanism (Heo et al., 2010).   
 
On the other hand, Rab9 is less well characterised. Using Drosophila as an 
animal model, and more specifically dLRRK, was proved that it co-localises with 
Rab7 in the late endosomes and lysosomes. dLRRK loss of function mutants 
display abnormalities in the endosomes and dLRRK can negatively regulate Rab-
7 dependent perinuclear localisation of lysosome (Dodson et al., 2012). In 
contrast, a gain of function mutation within dLRRK that is equivalent to G2019S 
in LRRK2, promotes Rab7-dependent perinuclear positioning of lysosomes. 
Accumulation of autophagosomes and the presence of enlarged lysosomes and 
endosomes were also observed in dLRRK loss of function mutants (Dodson et al., 
2014). This phenotype was rescued by the over-expression of Rab9, which 
promotes recycling of the endosomes to the TGN via the retromer, possibly due 
to a direct interaction (Dodson et al., 2014). 
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4.8.2 Rabs involved in Golgi and the Endoplasmic reticulum  
  
The findings from this course of investigation establish an interaction between 
LRRK2-G2019S and Rab10, Rab18 and Rab40. In the presence of the G2019S 
the visual responses both from the photoreceptors and the lamina neurons are 
higher compared to ones in the absence of the mutation. In addition, as far as the 
X73 (where X is Thr or Ser) residue is concerned, all the identified Rabs contain 
a Thr in this catalytic region of the switch II domain, confirming the preference 
of LRRK2 to Thr. Furthermore, Rab1 and Rab19, even though they do not show 
an interaction with G2019S, an association with the dopaminergic neurons is 
shown, as the visual responses were increased compared to the control levels 
independently of the G2019S presence.  
 
This is the first time that these Rabs are confirmed as LRRK2 interactors in vivo. 
Although, previous studies based on in vitro models, have identified Rab10 as 
LRRK2 interactor, emphasising the findings from this study.  
 
Rab10 is a well characterised GTPase protein that regulates the intracellular 
vesicular transport. It is located in the TGN regulating its traffic to the synaptic 
vesicles. The T73 residue of Rab10 is located in the Switch II domain, which is 
characteristic of the Rab GTPase proteins. This domain changes conformation 
upon nucleotide binding and regulates the interaction with multiple regulatory 
proteins (Pfeffer, 2005). Steger et al (2016) showed that the interaction between 
LRRK2 and Rab10 is direct, as both the wild type and the G2019S, but neither 
kinase inactive D1994A mutant nor small molecule-inhibited LRRK2, effectively 
phosphorylated Rab10 (Steger et al., 2016). In this study was also confirmed the 
preference of LRRK2 for Thr compared to Ser residues (Nichols et al., 2009), as 
all the Rabs family members containing Thr sites in the switch II region (Rab1b, 
Rab8a and Rab10) were effectively phosphorylated compared to the Rabs 
containing a Ser in the equivalent position (Rab5b, Rab7a, Rab7L1, Rab12 and 
Rab39b), which were phosphorylated to a drastically lower extent.  
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Rab18 has been linked to lipid droplet formation (Martin et al., 2005; Ozeki et 
al., 2005), ER–Golgi trafficking (Dejgaard et al., 2008), and the regulation of 
secretory granules (Vazquez-Martinez et al., 2007) and peroxisomes 
(Gronemeyer et al., 2013), and may be exploited during hepatitis C infection 
(Salloum et al., 2013). However, no clear molecular function or site of action has 
been defined for Rab18 (Gerondopoulos et al., 2014). Not many effectors of 
Rab18 have been identified, the only human disease that it has been associated to 
is Warburg Micro syndrome, a developmental disorder with brain abnormalities 
(Bem et al. 2011). However, an affinity chromatography screen reported that 
dLRRK, the Drosophila ortholog of human LRRK2, is a GTP-specific interactor 
to Rab18 (Gillingham et al., 2014). This is the only previous link between Rab18 
and PD. 
 
Rab1 is located at the endoplasmic reticulum (ER) exit sites and the pre-Golgi 
intermediate compartment (IC) mediating ER–Golgi trafficking (Stenmark 
2009). Rab1 has been linked to PD by interacting with α-synuclein, rescuing the 
toxicity induced by aberrant α-synuclein. α-synuclein accumulation could lead to 
the collapse of the ER-Golgi trafficking during the process of tethering or 
docking (Shi et al., 2017). Winslow et al. (2010) determined that overexpression 
of α-synuclein impairs macro-autophagy, with the proposed interaction between 
Rab1 and SNCA being in the early steps in autophagy during the synthesis of 
auto-phagosomes.  Even though no interaction has been identified between 
LRRK2 and Rab1, impairment of Rab1 contributes to the pathogenesis of PD 
through the SNCA gene, which has been identified contributing to sporadic PD. 
However, Steger et al. (2016) based on a phospho-proteomics analysis, proved 
that LRRK2 protein phosphorylates Rab1a, but it is not determined if this 
interaction is direct or indirect. This could shed new light in our understanding of 
the molecular pathways causing the neuron cells to die in PD.  
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4.8.3 Rabs involved in vesicle recycling 
 
The findings from this course of investigation determined the interaction 
between LRRK2-G2019S and Rab3. In the presence of the G2019S the visual 
responses both from the photoreceptors and the lamina neurons are higher 
compared to ones in the absence of the mutation. Moreover, the preference of 
LRRK2 protein in Thr was confirmed, as Rab3 contains a Thr at the T73-Rab10 
equivalent site (T86).  
 
This is the first time that Rab3 is confirmed as interacting with LRRK2 in vivo. 
However, previous in vitro work has identified Rab3 as a LRRK2 interactor, 
increasing the interest of this study. 
 
Rab3 localises in the synaptic vesicles regulating the traffic to the plasma 
membrane playing an important role in exocytosis and neurotransmitter release. 
Rab3 has been confirmed interacting with both SNCA and LRRK2 contributing to 
PD (Chen et al., 2013; Steger et al., 2016). Rab3 co-localizes with α-synuclein 
and regulates its distribution. On the other hand, it has been determined that 
Rab3 is a substrate of LRRK2-mediated phosphorylation (Steger et al., 2016). 
Overexpression of Rab3a protein induces α-synuclein cytotoxicity in cellular and 
animal models of PD (Cooper et al., 2006; Gitler et al., 2008).  
 
 
4.8.4 Rabs involved in mitochondria  
 
From this course of investigation, none of the tested Rabs (Rab27 and Rab32) 
were confirmed as LRRK2 interactors.  
 
However, Rab32 has been identified as a LRRK2 interactor from in vitro studies. 
It is a well characterised Rab that is located in the mitochondria (Bui et al., 2010) 
and the melanosomes (Wasmeier et al., 2006; Park et al., 2007) mediating the 
fission of mitochondria and the trafficking from TGN to the melanosomes 
playing a key role in melanogenesis. Waschbusch et al. (2014) confirmed that 
Rab32 binds to the amino-terminal region of LRRK2.  Moreover, they found co-
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localisation of LRRK2 and Rab32 wild type at transport vesicles and recycling 
endosomes, suggesting a role of Rab32 in the late endosomal trafficking of 
LRRK2. Besides that, the exact role of Rab32 in PD pathogenesis is still unclear. 
However, it is a promising target for further functional analyses.  In flies, Rab32 
is mainly localised in the pigment cells surrounding the photoreceptors, so may 
be too far away from the dopaminergic neurons to influence the SSVEP assay. 
Possibly, utilising another pigment cell Gal4 line would show an interaction 
between Rab32 and LRRK2.   
 
4.8.5 Examination of the Drosophila compound eye 
 
During this study, examination of the external and internal of the Drosophila 
compound eye was performed. External examination of the fly eye in the Rab5 
background did not induce any district phenotype. On the other hand, staining of 
Drosophila retinas with endosomal markers established enlarged endosomes 
both in the LRRK2 and G2019S background. In w- control flies these enlarged 
endosomes were not present independently of the age that the retinas were 
examined. That indicates an interaction between LRRK2 and Rab5 in the endo-
lysosomal trafficking pathway, paving the way for a more clear understanding on 
the molecular pathway that these two proteins interact contributing to the 
pathogenesis of PD.  
 
Previous studies have tried to address the role of LRRK2 in the compound 
Drosophila eye. Chuang et al. (2014) established that LRRK2 could rescue 
neuronal apoptosis that was induced by expression of death genes, grim, hid and 
reaper in the fly visual system. On the other hand, expression of the PD-linked 
mutations R1441C and G2019S did not suppress the grim-induced apoptosis, 
resulting in reduced eye size phenotype. These findings highlight a pro-survival 
role of LRRK2 that is mediated through activation of the Akt signalling pathway. 
A role that is compromised in the presence of the R1441C or the G2019S 
mutations (Chuang et al., 2014).  
 
Hindle et al. (2013) established a decline in vision after 28 days in the 
TH>G2019S background. Their follow up on that discovery was whether this 
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loss of vision is accompanied by anatomical phenotypes and neurodegeneration 
or not. TH>G2019S flies at the age of 28 days in contrast to TH>LRRK2 and 
TH/w- flies, showed strong neurodegeneration in the internal structure of the 
retina, which was disorganised while the visual lobes (lamina and medulla) had 
frequent vacuoles. Furthermore, TH>G2019S flies showed increased autophagy 
and apoptosis in the photoreceptors in 21 day old flies. In addition, the 
mitochondria in the photoreceptors became swollen and broken. Even though 
there was an established neurodegeneration in the internal structure of the 
TH>G2019S flies, the exterior surface was normal. This discovery coincides 
with the findings observed in this study, as there was no district eye phenotype in 
the TH::G2019S>Rab5 flies, while enlarged endosomes were shown in the 
Drosophila retina. 
 
Venderova et al. (2009) also examined the role of LRRK2 in contributing to eye 
defects. Their first examination after incubation of the flies at RT did not induce 
any eye phenotype independently of genotype. The next step was to examine 
flies at 29OC, as it is known that GMR can induce defects at 29oC. Examination 
of LRRK2 and LRRK2 mutants under the optic microscope showed significantly 
more black lesions compared to controls. They next analysed the eyes using 
scanning electron microscopy (SEM), which only confirmed that LRRK2 and 
LRRK2 mutants caused large defects, including glossy, rough and sometimes 
collapsing surface of the eye, disorganised interommatidial bristles and irregular 
lens shape. Finally, examination of the ommatidial structure on sections showed 
that the regular trapezoidal arrangement of the photoreceptor cells was disrupted, 
accompanied by the presence of large holes that altered the architecture of the 
ommatidial array (Venderona et al., 2009). The presence of large holes is 
characteristic in many fly models of neurodegenerative diseases (Marsh et al., 
2000).  
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4.9 Conclusion 
 
Taken together, this chapter provides new insights into LRRK2 function, which is 
still very unclear even though it is under thorough investigating for the last few 
years. Six new interactors of LRRK2 have been identified in this in vivo analysis, 
indicating a role in dopaminergic neurons. These are Rab3, Rab5, Rab9, Rab10, 
Rab18 and Rab40. In addition, two Rabs, Rab1 and Rab19, were identified 
interacting with the dopaminergic neurons. From these, Rab18 has not been 
reported previously.  
 
The increase in the visual responses in the G2019S background, might indicate 
failure of the photoreceptors to adapt in light, with dopamine playing a very 
important role, as it has been proposed that in the G2019S flies the levels of 
dopamine are reduced compared to the wild type (Harnois et al., 1990). That is 
based on the fact that dopamine is a very important neurotransmitter playing a 
significant role in the light adaptation. The question that now remains, is how the 
interaction of hLRRK2 and Rabs, might affect this role of dopamine on the light 
adaptation.  
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Chapter 5 
Generation of novel LRRK2 transgenic 
flies in a second binary system and their 
protein expression 
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5.1 Introduction 
 
In order to have a better understanding of the function of hLRRK2 and how the 
G2019S mutation contributes to the pathogenesis of PD, it would be beneficial to 
be able to manipulate LRRK2 and a second protein simultaneously.   In other 
words, the creation of new transgenic flies carrying an alternative binary 
expression system would give us the opportunity to express different transgenes 
under different drivers simultaneously. This chapter describes the generation of 
novel LRRK2 transgenics for one such system, the LexA-LexAop. Their success 
was validated by Western blotting, comparing the protein production with 
existing Gal4-UAS transgenics. 
 
5.1.1 Creation of new transgenic flies 
 
5.1.1.1 LexA-LexAop binary system 
 
The Gal4-UAS system is considered the workhorse of Drosophila genetics, and 
only few papers have been published that are not using it as their primary system. 
As described in more detail in section 1.10.2 the Gal4-UAS system consists of 
two components. The yeast GAL4 transcriptional activator, which determines the 
expression pattern under which the gene downstream of the UAS promoter is 
going to be expressed (Brand et al., 1993). The Gal4-UAS binary system is the 
most extensively used binary system in Drosophila, with thousands of Gal4 
drivers being available which determine various expression patterns during 
development (Brand and Perrimon, 1993). Because of this extensive use of this 
binary system, several tools have been established that control the expression or 
the activity of the Gal4 driver (Duffy, 2002). These tools include the yeast 
repressor Gal80 that efficiently represses Gal4 (Lee and Luo, 1999; Del Valle 
Rodriguez et al., 2013); a temperature sensitive Gal80 mutant (Gal80ts) which 
allows temporal control (McGuire et al., 2003) and also the yeast Flp/FRT 
recombinase system to render the Gal4 system inducible in an irreversible 
manner (Nellen et al., 1996; Pignoni and Zipursky, 1997). Despite the fact that 
this system is so powerful, there are a number of sophisticated experiments that 
can’t be performed by using this system alone. Two independent binary 
transcriptional systems could permit the targeted expression of distinct 
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transgenes in different patterns in the same organism, facilitating various studies 
in the Drosophila nervous system (Lai and Lee, 2006). 
 
These conditions spawned the generation of a second independent binary system 
for Drosophila, the LexA-LexAop, which is extensively used in yeast two-hybrid 
assays. LexA binds to and activates the LexA operator (LexAop) (Lai et al., 
2006). LexA is a 202 amino acid protein consisting of a DNA-binding domain 
from a bacterial transcription factor and a dimerization domain that binds as a 
dimer with varying affinities to single or multiple copies of gene-specific LexA 
(Figure 5.1). DNA-binding motifs (LexAop) found upstream of its target genes 
(Little and Mount 1982; Butala et al., 2008).  
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Figure 5.1 The LexA-LexAop binary system.  
In order to achieve this cell or tissue specific expression of a gene of 
interest a fly line that expresses LexA under the control of a tissue 
specific promoter is crossed to a second line that the gene of interest has 
been inserted downstream of the LexAop, which is the binding site of 
LexA. Once these two components are together in a mating scheme, 
progeny will be generated in which that gene of interest is only expressed 
in that cell or tissue specific pattern. Fly images generated using the 
Genotype Builder from Roote and Prokop (2013).  
 
 
The TH-LexA stock was already available in the lab (Chris Elliott’s lab stock) 
and the LRRK2 plasmids (Invitrogen, California, USA) were a kind gift from 
Gareth Evans, University of York. The LexAop plasmids were bought from 
Addgene (Addgene, Cambridge, Massachusetts, USA). Therefore, sub-cloning 
was performed in order to create a vector containing LexAop-hLRRK2 or 
LexAop-hLRRK2-G2019S. 
 
5.2 Aims 
 
1. To generate new transgenic flies in order to be able to have an 
alternative binary system apart from the Gal4-UAS.  
 
2. To determine protein expression of all the available UAS and 
LexAop stocks available in the lab in order to compare protein 
expression levels between hLRRK2 and G2019S.        
 
5.3 Results 
 
5.3.1 Pathway for the generation of new transgenic flies 
 
The first step was to confirm that the donor vector with the insert was the one of 
our interest, containing the genes that we were expecting. Restriction digestion 
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was performed followed by agarose electrophoresis. The restriction enzymes 
used were BamHI and ApaI in order to confirm that it was the expected size 
(Figure 5.2). BamHI was chosen as it only cuts at one site the backbone vector 
and ApaI was chosen as it only cuts within the hLRRK2 sequence at one site. In 
that way it was confirmed that hLRRK2 and hLRRK2-G2019S were really present 
in the backbone vector.  
 
As before, for the LexAop vector restriction digestion was performed in order to 
confirm that it really was the expected vector. For that reason NheI and Pmel 
enzymes were used (Figure 5.2). For each one of these restriction enzymes there 
was one recognition site within the plasmid sequence.  
 
 
 
 
Figure 5.2 Restriction digest of hLRRK2 and LexAop vectors show 
the expected bands. For the hLRRK2 and hLRRK2-G2019S vectors 
BamHI and ApaI restriction enzymes were used and the expected size 
bands were obtained; 11Kb and 3Kb (3 and 4). For the LexAop vector 
NheI and PmeI restriction enzymes were used and the expected size 
bands were obtained; 7Kb and 2.2Kb (2). In that way it was confirmed 
that both vectors were the ones of our interest. 1Kb DNA ladder (NEB) 
was used in order to confirm the size of all the DNA bands (1 and 5). 
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After DNA gel extraction, DNA samples were also sent for sequencing and the 
presence of the hLRRK2 sequence was confirmed using primers within exon 1 of 
hLRRK2 (Figure 5.3).  
  
 
 
 
Figure 5.3. Sequencing confirmed the presence of the hLRRK2 
transgene within our donor vector. Sanger sequencing of the hLRRK2 
vector using primers within the exon 1 of our gene of interest in order to 
confirm its presence. The highlighted ATG codon is the starting codon of 
the LRRK2 transgene.  
 
 
5.3.2 Ligation of the hLRRK2 transgene into the LexAop vector 
 
The next step was the ligation of the cut insert and the cut host vector in order to 
insert hLRRK2 and hLRRK2-G2019S downstream of the LexAop sequence. To 
achieve that the hLRRK2 vector was digested with BamHI and EagI as these 
enzymes cut around the hLRRK2 gene but not within the hLRRK2 sequence. 
From that digestion two bands were expected, one was 9 Kb, which contained 
hLRRK2 and one 4.7 Kb which contained the rest of the plasmid (Figure 5.4). 
Moreover, restriction digestion of the LexAop vector was performed with NotI 
and BglII (Figure 5.4) so compatible ends in the same orientation to the insert 
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were being created in order the cut insert to be able to be ligated between these 
endings.  The expected size DNA bands from this digestion were 9 Kb and 79 
bp. The recognition sites of the enzymes used in the process of ligation are 
summarized in table 5.1. 
 
 
    Table 5.1 Recognition sites of the enzymes used 
Enzyme (For the hLRRK2 vector) Ligated to (For the LexAop vector) 
BamHI 
5’ G/GATCC 3’ 
BglII 
5’ A/GATCT 3’ 
EagI 
5’ C/GGCCG 3’ 
NotI 
5’ G/CGGCCGC 3’ 
 
 
 
 
 
Figure 5.4 Steps for the ligation of hLRRK2 downstream the LexAop 
sequence. Restriction digest of both the host vector and the donor vector 
in order to get compatible ends to proceed with the ligation. The hLRRK2 
vector was cut with BamHI and EagI (3) and the hLRRK2-G2019S vector 
was also cut with BamHI and Eagl (4). The LexAop vector was cut with 
NotI and BglII (2). 1Kb DNA ladder (NEB) was used in order to confirm 
the size of all the DNA bands (1). 
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Ligation was followed by transformation and colony cracking to test if there 
were any successfully ligated samples. In colony cracking single colonies run 
next to the uncut host vector and any colonies that are heavier than the uncut, so 
they run slower, was an indication that the insert had been ligated successfully. A 
summary diagram of the procedure that was followed is shown in Figure 5.5. 
 
 
 
 
 
Figure 5.5 Summary diagram of the restriction digest protocol.  
This protocol was followed in order to successfully ligate the insert that 
was containing the hLRRK2 or the hLRRK2-G2019S downstream the 
LexAop sequence.  
 
 
In order to confirm that the ligation was really successful restriction digest was 
performed using enzymes that recognise either hLRRK2 or the LexAop vector. 
Xbal was used from which two DNA bands were expected sized 11.8 Kb and 6 
Kb and SacI from which three DNA bands were expected sized 9.7 Kb, 4.38 Kb 
and 3.3 Kb (Figure 5.6).  
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Figure 5.6 Restriction digestion of the successfully ligated 
candidates.  
A) Restriction digestion of the LexAop-hLRRK2 plasmid in order to 
confirm that the ligation was being successful. That was confirmed by 
digesting with SacI, which has three recognition sites within the newly 
created plasmid. As expected three DNA bands were obtained (1) sized 
9.7 Kb, 4.38 Kb and 3.3 Kb. From the digestion with Xbal, which has two 
recognition sites within the newly created plasmid, also revealed the 
expected DNA bands (3) sized 11.8 Kb and 6 Kb confirming that the 
hLRRK2 transgene has been successfully inserted downstream of the 
LexAop sequence. 1Kb DNA ladder (NEB) was used in order to confirm 
the size of all the DNA bands (2). B) Restriction digestion of the LexAop-
G2019S plasmid in order to confirm that the ligation was being 
successful. That was confirmed by digesting with SacI, which has three 
recognition sites within the newly created plasmid. As expected three 
DNA bands were obtained (2) sized 9.7 Kb, 4.38 Kb and 3.3 Kb. As a 
comparison, an unsuccessfully ligated DNA was also digested with SacI 
(3), which revealed four DNA bands that were not of the expected size. 
From the digestion with Xbal, which has two recognition sites within the 
newly created plasmid, revealed the expected DNA bands (4) sized 11.8 
Kb and 6 Kb confirming that the hLRRK2 transgene has been 
successfully inserted downstream of the LexAop sequence. The 
unsuccessfully ligated LexAop-G2019S was also digested with Xbal 
confirming that the hLRRK2 transgene wasn’t inserted, as 4 DNA were 
obtained which were not of the expected size (5). 1Kb DNA ladder (NEB) 
was used in order to confirm the size of all the DNA bands (1). 
 
 
The plasmid DNA of all the successfully ligated samples that were obtained were 
sent for microinjection of fly embryos (as described in section 2.3.12) in order to 
create flies of the desired genotype (Fly facility, Department of Genetics, 
University of Cambridge).  
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Figure 5.7 Full sequence map for the LexAop-hLRRK2 created 
vector. This is the final LexAop-hLRRK2 vector that was created in order 
to insert the LRRK2 transgene downstream the LexAop sequence, sized 
17929 bp. The map was created using the SnapGene software. 
 
 
5.3.3 DNA Sequencing of the new transgenic flies 
 
In order to confirm the presence of the hLRRK2 and hLRRK2-G2019S genes 
downstream from the LexAop sequence, DNA was extracted from single flies 
followed by PCR using primers within the kinase domain of the gene (Figure 5.8 
and Figure 5.9). 
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Figure 5.8 Confirmation of the presence of the hLRRK2-G2019S 
gene in the new transgenic flies. PCR was performed using primers 
within the kinase domain of the hLRRK2 gene, after DNA extraction from 
the LexAop-G2019S flies. The expected sized band was obtained at ~ 
1Kb (2). As a positive control the plasmid DNA from the LexAop-G2019S 
vector was also tested (3) while a negative control was included 
containing DNA extracted from TH flies where no bands were seen (4). 
1Kb DNA ladder (NEB) was used in order to confirm the size of all the 
DNA bands (1). 
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Figure 5.9 Confirmation of the presence of the hLRRK2 gene in the 
new transgenic flies. PCR was performed using primers within the 
kinase domain of the hLRRK2 gene, after DNA extraction from the 
LexAop-hLRRK2 flies. The expected sized band was obtained at ~ 1Kb. 
Each lane represents a single hLRRK2 fly. 1Kb DNA ladder (NEB) was 
used in order to confirm the size of all the DNA bands. 
 
 
The PCR confirmed the presence of the hLRRK2 gene in both stocks, LexAop-
hLRRK2 and LexAop-hLRRK2-G2019S. The next step was to confirm that the 
G2019S mutation was present in the LexAop-G2019S stock, but not in LexAop-
hLRRK2. DNA samples were sent for sequencing at GATC Company, which 
indeed confirmed the presence of the G>A mutation (Figure 5.10). 
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Figure 5.10 Confirmation of the presence of the G>A mutation. DNA 
sequencing of the LexAop-hLRRK2 and LexAop-G2019S stocks. Within 
the kinase domain where the mutation lies, in the LexAop-hLRRK2 flies 
the codon is GGC (Glysine, G), while in the LexAop-G2019S the AGC 
codon (Serine,S).  
 
 
5.4 Protein expression of hLRRK2 and hLRRK2-G2019S  
 
In order to be able to compare the protein expression of the newly created 
LexAop-hLRRK2 and LexAop-G2019S flies that were created to the UAS lines, 
Western blots were performed to all the different hLRRK2 and G2019S lines 
available in the lab. Three independently generated TH-Gal4>hLRRK2 and TH-
Gal4>G2019S lines (Lin et al., 2010, Liu et al., 2008, Lundbeck, unpublished) 
were examined. The Liu et al. (2008) fly stocks were also FLAG tagged. In 
summary, 30 female fly heads were collected after 3 days of incubation at 29oC, 
and after homogenisation with RIPA (Radioimmunoprecipitation assay) buffer, 
in order to extract the protein from the fly heads, BCA (bicinchoninic acid assay) 
protein assay was performed, in order to determine the total concentration of 
protein in the solution (ug/ul) (Full details on section 2.4).   
LexAop-G2019S LexAop-hLRRK2 
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5.4.1 Protein expression levels after expression of LRRK2 and G2019S 
in the fly eye 
 
 
To begin with, the protein expression levels of hLRRK2 in comparison to 
G2019S were tested by expressing the UAS-hLRRK2, UAS-G2019S or UAS-
I2020T in the eye under the GMR-Gal4 control. The GMR-Gal4 driver was 
chosen as it is the most widely used driver for targeting expression in the 
developing eye. A CS/w- cross (such flies will contain dLRRK protein) and 
dLLRKe03680 flies (knock-out of the dLRRK gene, expressing no dLRRK protein), 
were used as controls in order to confirm if the dLRRK protein is recognised by 
the human hLRRK2 antibody.  
 
Figure 5.11 shows the staining achieved with the Novus anti-hLRRK2 rabbit 
polyclonal antibody, while Figure 5.12 shows staining from the same protein 
samples with the NeuroMab anti-hLRRK2 mouse monoclonal antibody. Two 
different gels were run at the same time.  
 
Both antibodies suggest that hLRRK2 is expressed in higher levels compared to 
the G2019S, when the hLRRK2 transgene is expressed in the eye. Moreover, it is 
worth mentioning that G2019S and I2020T proteins, which are both mutations 
within the kinase domain of the hLRRK2 gene, are expressed at similar levels in 
the eye. 
 
Even though both antibodies recognise the C-terminus of the LRRK2 protein, the 
anti-LRRK2 rabbit polyclonal (Novus), also gave some non-specific bands, at 
around ~250 KDa, as well as the expected band at 286 KDa. On the other hand, 
the mouse monoclonal antibody (NeuroMab), was more specific giving only the 
expected band at ~286 KDa. For that reason, it was determined that for the 
following up experiments, only the NeuroMab antibody would be used. 
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Figure 5.11 hLRRK2 is expressed at higher level than G2019S.  
Western blot showing protein levels in head lysates from flies with eye 
expression of CS/w- (1), dLRRKe03680 (2), UAS-hLRRK2 (3), UAS-
G2019S (4), UAS-hLRRK2 II (sample 2) (5), UAS-G2019S II (sample 2) 
(6) and UAS-I2020T (7). Probing with anti-hLRRK2 rabbit polyclonal 
antibody (Novus) reveals the expected bands at 286 KDa. β-actin was 
used as the loading control. For both of the different UAS stocks of 
hLRRK2 and G2019S that were tested, expression levels of hLRRK2 are 
much higher compared to the G2019S. The hLRRK2 and G2019S flies 
were the Liu (2008) lines, with the two samples derived from stocks 
maintained by different members of the lab.  
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Figure 5.12 A second antibody confirms that hLRRK2 is expressed 
much more than the G2019S. Western blot showing protein levels in 
head lysates from flies with eye expression of CS/w- (1), dLRRK;e03680 
(2), UAS-hLRRK2 (3), UAS-G2019S (4), UAS-hLRRK2 II (sample 2) (5), 
UAS-G2019S II (sample 2) (6) and UAS-I2020T (7). Probing with anti-
hLRRK2 mouse monclonal antibody (NeuroMab) reveals the expected 
bands at 286 KDa. β-actin was used as the loading control. For both of 
the different UAS stocks of hLRRK2 and G2019S that were tested, 
expression levels of hLRRK2 are much higher compared to the G2019S. 
The hLRRK2 and G2019S flies were the Liu et al. (2008) lines, with the 
two samples derived from stocks maintained by different members of the 
lab. 
 
 
5.4.2 Protein expression levels of LRRK2 and G2019S in the 
dopaminergic neurons 
 
In the next round of assays, it was decided to perform a BCA assay before 
Western blotting, in order to determine the protein concentration of each sample 
and to ensure equal loading between samples (Section 2.4.2). This time all the 
different UAS stocks were expressed in the dopaminergic neurons under the 
control of the TH-Gal4 driver.  
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5.4.2.1 Protein expression levels of LRRK2 and G2019S after the BCA 
analysis 
 
For this set of experiments, four different pairs of UAS-hLRRK2 and UAS-
G2019S were tested while TH/dLRRKe03680 was used as a control, which is a 
cross between the TH-Gal4 and the knock-out of the Drosophila LRRK2 (Figure 
5.13;A). The fly stocks that were tested included the UAS- hLRRK2 2008 and 
UAS-G2019S 2008 (Liu et al., 2008), three stocks of each were analysed like 
previously, which are labelled as TH> hLRRK2 2008, TH> hLRRK2 II 2008, 
TH> hLRRK2 III 2008, TH>G2019S 2008, TH>G2019S II 2008 and 
TH>G2019S III 2008. Moreover, the FLAG tagged stocks were also used (Lin et 
al., 2010), labelled as TH> hLRRK2 2010 and TH>G2019S 2010. In addition, the 
newly created UAS fly stocks for hLRRK2 and G2019S were tested (Lundbeck) 
which are inserted at the same site, unlike the Liu et al. (2008) and Lin et al. 
(2010) where the insertion site is unknown (Figure 4.13; B & C). In the last set 
of these experiments, two additional mutations within the LRRK2 gene were also 
tested, R1441C (which lies within the GTP domain of the LRRK2 protein) and 
G2019S-K1906M (a kinase-dead LRRK2). The controls that were used included 
CS/w- flies and a cross between TH-Gal4 and the Drosophila knock-out 
(TH/e03680).  In order to establish that there is no undriven expression of the 
UAS- hLRRK2 and UAS-G2019S stocks, hLRRK2/w- and G2019S/w- genotypes 
were also included (Figure 5.13;D). As before, 3-day-old fly heads were 
collected and the protein was extracted (Section 2.4.1). 
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    Figure 5.13 hLRRK2 higher expression levels are confirmed.  
Western blot showing protein levels in head lysates from flies. Probing with 
anti-hLRRK2 mouse monclonal antibody (NeuroMab) reveals the expected 
bands at 286 KDa. β-actin was used as the loading control. (A) 
TH/dLRRKe03680 (1), UAS-G2019S II 2008 (2), UAS-hLRRK2 II (3), UAS-
G2019S 2010 (4), UAS-hLRRK2 2010 (5), UAS-G2019S 2008 (6), UAS- 
hLRRK2 2008 (7), UAS-G2019S III 2008 (8) and UAS-hLRRK2 III 2008 
(9). (B and C) TH/dLRRKe03680 (1), UAS-G2019S Lundbeck (2), UAS-
hLRRK2 Lundbeck (3), UAS-G2019S II 2008 (4), UAS-hLRRK2 II (5), 
UAS-G2019S 2010 (6), UAS-hLRRK2 2010 (7), UAS-G2019S III 2008 (8) 
and UAS-hLRRK2 III 2008 (9). (D) TH/dLRRKe03680 (1), CS/w- (2), UAS- 
hLRRK2 III 2008 (3) and UAS- G2019S III 2008 (4), UAS-G2019S-
K1906M (5), UAS-R1441C (6), hLRRK2/w- (7) and G2019S/w- (8). For all 
the different lines that were tested (Lin, 2010; Liu, 2008 and Lundbeck, 
unpublished) hLRRK2 is expressed in higher levels compared to G2019S.  
hLRRK2 is also expressed in higher levels compared to the additional 
mutations within the LRRK2 gene that were tested. Moreover, hLRRK2/w- 
and G2019S/w- do not show any bands, proving that there is no undriven 
expression.  
 
 
As before, expression of hLRRK2 and G2019S in the dopaminergic neurons 
indicated that LRRK2 protein is expressed in higher levels compared to the 
G2019S (Figure 5.13; A, B, C). That applies for all the different UAS stocks that 
were used (Lin et al., 2010; Liu et al., 2008; Lundbeck, unpublished). The 
Lundbeck likes, which were created expressing the hLRRK2 and G2019S 
transgenes at specific landing sites, are expressed in lower levels compared to the 
other UAS stocks, in which the landing site of the transgenes is unknown (Figure 
5.13; B and C). In the last panel of Figure 4.16, different mutations within the 
hLRRK2 gene were expressed, and it is indicated that the kinase-dead form of 
LRRK2 protein is expressed at similar levels to the G2019S, while the R1441C 
form of the hLRRK2 protein, which is a mutation within the GTPase domain, is 
expressed in lower levels. The undriven expression of hLRRK2 and G2019S 
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shows that the hLRRK2 and the G2019S transgenes are not expressed in the 
absence of the TH-Gal4 driver.  
 
5.5 Expression levels of hLRRK2 and hLRRK2-G2019S in the 
newly created LexAop transgenic flies 
 
The next step was to perform a Western blot in order to compare the Lundbeck 
lines to the newly made LexAop-hLRRK2 and LexAop-G2019S lines, in which 
the insertion site of the transgenes is like the Lundbeck oneson the 2nd 
chromosome or else on the 3rd chromosome (Section  2.3.12). For the expression 
of the transgenes in the dopaminergic neurons the TH-Gal4 and TH-LexA drivers 
were utilised.  
 
 
 
Figure 5.14 The LexAop lines are expressed in lower levels 
compared to the UAS ones. Western blot showing protein levels in head 
lysates from flies with DA expression of UAS-hLRRK2 (1), UAS-G2019S 
(2), LexAop-hLRRK2 inserted on the thrid chromosome (3), LexAop-
G2019S inserted on the third chromosome (4), LexAop-hLRRK2 inserted 
on the second chromosome (5) and LexAop-G2019S inserted on the 
second chromosome (6). β-actin was used as the loading control. 
Probing with anti-hLRRK2 reveals the expected bands at 286 KDa. 
Expression of the UAS lines are at higher levels compared to the LexAop 
ones, while the protein expression between the hLRRK2 and G2019S 
seems to be at similar levels for the LexA lines. 
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From this protein analysis, it can be concluded that the newly created LexA-
LexAop lines are expressed in lower levels compared to the UAS. The Lundbeck 
lines were chosen because among all the available UAS lines available, they are 
expressed in the lower levels, so they could be comparable to the newly created 
lines. For the LexAop lines, hLRRK2 and G2019S proteins are expressing in 
similar levels, irrespective of the landing site. On the other hand, the UAS-
hLRRK2 is expressed at higher levels compared to the UAS-G2019S.  
 
5.6 Discussion 
 
Having created new transgenic flies including LexAop-hLRRK2 and LexAop-
G2019S will be a big advantage, allowing us to express at the same time two 
different transgenes under different expression pattern in the same animal. 
Validation by Western blotting shows that the LRRK2 protein is expressed at 
higher levels than the G2019S for all the available UAS lines. Protein analysis of 
the newly created LexAop lines didn’t dispose any differences between LRRK2 
and G2019S, although these lines are expressed at much lower levels than the 
UAS ones.  
 
Hindle et al. (2013) performed Western blots in order to compare the expression 
pattern of hLRRK2 and hLRRK2-G2019S. Their interpretation was that the 
expression of hLRRK2 was at a comparable level to G2019S (Hindle et al., 
2013). Re-examination of their blot suggests that in fact hLRRK2 is expressed in 
greater levels than the G2019S. This finding is similar to the results obtained 
from this investigation as it is suggested that for all the available lines tested 
hLRRK2 is expressed in greater levels compared to G2019S. This was shown 
both with expression in the eye (GMR-Gal4) and in the dopaminergic neurons 
(TH-Gal4). The independent insertions by Liu et al. (2008) and Lin et al. (2010) 
also both show this effect. In addition, comparing LRRK2 to I2020T, proposes 
that LRRK2 is again expressed at higher levels compared to I2020T, which is 
expressed at similar levels to G2019S. The fact that both of these mutations lie 
within the kinase domain of the gene is an indication that this decrease in the 
protein expression could be a common kinase effect.  
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Venderova et al. (2009) generated new LRRK2 and LRRK2 mutant lines and in 
order to confirm the expression of these transgenes they performed Western 
blotting by driving the expression in the eye using the GMR-Gal4 driver. From 
the data they presented, it can be concluded that LRRK2 is expressed in higher 
levels compared to the I2020T mutated protein. Even though they didn’t include 
the G2019S mutation in their analysis, their data our consistent with the results 
presented in this thesis, as I2020T mutant protein is also expressed in lower 
levels compared to the wild type.  As both mutations, I2020T and G2019S, lie 
within the kinase domain of the protein is an indication that the kinase activity of 
the protein should play a role in this difference in the expression pattern 
observed.  
 
In previous stocks that were tested, the transgenes were inserted in unknown 
sites, while the Lundbeck lines were all inserted on the 2nd chromosome, where 
they have the attP site,  which is the same landing site as the newly created 
LexAop lines. In the Lundbeck lines the TH>G2019S was expressed in lower 
levels than TH> hLRRK2, just like the other UAS lines. Even though it was 
expected that the LexAop lines would show similar protein production, 
TH>G2019S and TH> hLRRK2 were expressed in similar levels in these lines.  
 
That poses the question, why is the level of protein consistently lower in the 
G2019S background? West et al. (2005) suggested that LRRK2 may be broken 
down by the proteasome, so it is possible that differences exist in the rate at 
which LRRK2 is degraded. One possibility is that the rate of breakdown of 
LRRK2 is determined by its phosphorylation level, with G2019S and I2020T 
being more phosphorylated than the wild type LRRK2.  Ding et al. (2017) 
showed that manipulating the F-box protein Fbx118 affected the rate of 
breakdown of LRRK2, with increases in Fbx118 ubiquinating LRRK2 and 
targeting it for proteasomal degradation. Phosphorylated LRRK2 wild-type was 
degraded faster than unphosphorylated protein in these HEK293 cells. On the 
other hand, Lobbestael et al. (2016) concluded that de-phosphorylation of 
LRRK2 induced degradation of the LRRK2 protein in SH-SY5Y cells. These 
differences that were established from different research groups could reflect the 
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cell types that were utilised during their investigation. The present data shown in 
this thesis on the other hand, are based on an in vivo studying of the 
dopaminergic neurons of the fly, which probably is a better representation of 
what is actually happening at the molecular level.  
 
Sharma et al. (2011) used post-mortem frozen tissue from controls and idiopathic 
PD (IPD) patients and G2019S positive PD cases and performed protein 
expression analysis. They determined that LRRK2 protein was ubiquitously 
present in the cytoplasm of neurons for all the studied groups. This cytoplasmic 
expression of LRRK2 was often accompanied by extension to the apical 
dendrites. No significant differences were obtained in the LRRK2 
immunoreactivity between controls, IPD and G2019S positive PD cases. On the 
other hand, prominent differences in the intensity of LRRK2 staining were 
observed in different regions. The CNS of the fly would also be like this, where 
different transgenes are present in different regions or degradation of the 
accumulated proteins is taking place in different regions. Moreover, regions that 
are known to be vulnerable to α-synuclein pathology in IPD presented extensive 
variability in LRRK2 immunoreactivity. It was established that in the 
nigrostriatal dopamine system neurons the weakest LRRK2 immunoreactivity 
was recorded, irrespective of the disease status. Moreover, they discovered that 
LRRK2 is present in the halo of a small proportion of LBs. The inconsistence of 
LRRK2 presence in brainstem LBs and its absence in cortical LBs, indicates that 
LRRK2 in not an obligate component of LBs. Other studies have confirmed that 
LRRK2 phosphorylates α-synuclein in vitro (Qing et al., 2009), even though a 
physical interaction between them hasn’t been confirmed. The key question that 
arises is if LRRK2 functions upstream of α-synuclein in the PD pathway as a 
signalling molecule triggering α-synuclein aggregation.  
 
Taken together, this study establishes that LRRK2 protein is expressed in higher 
levels than the G2019S mutated one in all the available UAS lines tested. On the 
other hand, the newly created LexAop lines do not follow this pattern, as no 
difference was observed between LRRK2 and G2019S. Taking into account the 
much lower expression levels of the LexAop lines in comparison to the UAS 
ones, one explanation could be that the protein expression levels are so much 
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lower that Western blotting is not a sensitive enough assay to detect any 
differences between these lines. In addition, if the breaking down of LRRK2 by 
the proteasome plays any role in the observed expression differences, one 
reasonable explanation could be that this degradation process is only activated 
after higher levels of proteins are expressed in the cells. The low levels of 
LRRK2 and G2019S proteins in the LexAop lines could prevent this process to 
start, explaining the similar levels of protein expression obtained from these 
lines.  
 
5.7 Conclusion 
 
Taken together the results presented in this chapter the overall conclusion that 
could be made is that hLRRK2 is massively expressed compared to the G2019S 
mutated version of the gene. This could be the beginning of understanding the 
molecular pathway of PD that leads to the neurodegeneration of the 
dopaminergic neurons. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
199 
6. Discussion and Future Research 
 
6.1 Introduction 
 
The overall aim of this course of investigation was to advance our knowledge on 
how LRRK2 contributes to the pathogenesis of PD using Drosophila as an animal 
model. The purpose was to shew new light on the molecular pathway and the 
physiological progression, leading to neurodegeneration and more specifically 
what role the G2019S mutation has on this process. The key role of LRRK2 as a 
kinase could pave the way for new drug discoveries in the future, as the kinase 
pathway has always been an easy target for drug development. In order to 
achieve that, the following primary questions were investigated: 
 
1. Determine if manipulating dopamine release from the synaptic vesicles leads 
to visual defects in adult flies. 
 
2. Establish if the dopamine levels are affected in the LRRK2-G2019S mutated 
flies causing neuronal death. 
 
3. Test the hypothesis that Rab proteins are in vivo substrates of LRRK2. 
 
This final chapter reviews the outcome of these questions, providing a 
comprehensive, succinct overview of the key data generated from this 
investigation. It also looks to pose further questions and areas for further 
investigation.  
 
6.2 LRRK2 and dopamine relation 
 
DA is a very important neurotransmitter in the brain and retina of both insects 
and mammals. Even though the pathophysiology of the DAergic loss in PD 
remains unclear, it seems that DA may play a role in this process. Cytosolic DA 
and its metabolites conjugate to PD-related proteins and generally increase 
oxidative stress. One of the proposed protein candidates interacting with 
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dopamine is LRRK2. As has been described in more detail in Chapter 1, section 
1.3, LRRK2 is the most common cause of PD, being responsible for ~10% of all 
the familial PD cases. More specifically the G2019S mutation, which lies within 
the kinase domain of the protein, is the most common genetic cause of PD being 
responsible for 2-40% of all the PD cases depending on the population under 
study (Houlden and Singleton, 2012).  The key hypothesis in this thesis was that 
it is the interaction between dopamine and LRRK2-G2019S leading to the 
neurodegeneration observed in PD.   
 
Taking advantage of the Drosophila visual system, which has been a great and 
approachable in vivo model to study neurodegeneration, the relation between 
dopamine and LRRK2 was tested. The photoreceptors project into the lamina 
where they ramify, possibly contacting the terminals of the photoreceptors. The 
medulla also contains many dopaminergic neurons that could interact with the 
terminals of the lamina neurons.  
 
The findings from this thesis, both HPLC assay and TNT manipulation, confirm 
the interaction between LRRK2-G2019S and dopamine. Measurement of 
dopamine levels from flies with the G2019S mutation determined that young 
flies carrying the mutation have reduced levels of dopamine compared to the 
normal high levels observed in the wild type LRRK2 flies. This supports the idea 
of the early onset excitotoxicity pathway, as having less dopamine in the retina 
would make the photoreceptor responses faster and larger. As described by Chyb 
et al. (1999) dopamine slows the response of individual photoreceptors forcing 
the visual system to respond faster. The less dopamine observed in the G2019S 
flies could lead to decreased release in the lamina leading to faster responses by 
the photoreceptors and stronger activation of the lamina neurons. This discovery 
could explain how the excitotoxic pathway starts. Older flies, 7 day and 14 day 
old, that have similar dopamine levels, do not exhibit any significant differences 
in their visual responses when TNT is expressed, and the retinal physiology is 
also similar. This implies a hyperactivity in the G2019S retina confirming the 
initial hypothesis of an early onset hyperactivity in these flies. As a follow up 
analysis, blockage of dopamine release and synaptic signalling was performed by 
expressing tetanus toxin in the dopaminergic neurons.  It appears that expression 
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of TNT reduces the photoreceptor and lamina neuron responses in young 
TH>G2019S flies, but increases in the TH>LRRK2 and TH/w- flies. It would be 
expected that expression of TNT would increase the visual responses if it 
blocked transmitter release from dopaminergic neurons. The effect TNT has on 
the G2019S flies is not surprising as they have less dopamine at this stage 
compared to LRRK2 and w- flies.  
 
My findings also support the data of Afsari et al. (2014) that young flies 
expressing the G2019S mutation had increased visual signalling compared to the 
wild types. This excitotoxicity response could lead to extra ATP demand from 
the ion exchange pumps, contributing to mitochondrial failure that might not be 
able to fulfil without the generation of extra oxidative stress. That would only 
lead to mitochondrial defects followed by increased apoptosis and autophagy. 
That coincides with the enlarged endosomes that were observed in TH>G2019S 
and TH>hLRRK2 young flies in this thesis. Another independent study by Imai 
et al. (2008) showed that manipulations of the Drosophila homolog of LRRK2 
(dLRRK) also affect the levels of dopamine in fly heads. They determined that 
young dLRRK knock-out flies have elevated DA levels, while those that were 
expressing a mutation leading to increased kinase activity, I1915T, which is the 
homolog of the human I2020T, had reduced dopamine levels compared to the 
controls.  
 
This early onset hyperactivity observed in young TH>G2019S could be only the 
first step towards the neurodegeneration, which is the hallmark of PD. The 
findings from this study support the theory that young TH>G2019S flies have 
defective dopaminergic signalling in their retina, and that could be a vital factor 
in starting the neurodegeneration cascade.  
 
Taking into account the strong clinical association between LRRK2-G2019S and 
PD, the research interest focused on how the G2019S mutation affects the 
survival of the SNpc DA neurons in vivo. The initial hypothesis was that cells 
carrying the G2019S mutation have no robust transgene overexpression. Liu et 
al. (2015) overexpressed the wild type LRRK2 and the LRRK2-G2019S 
selectively in mouse mid brain DA neurons utilising the tetracycline-dependent 
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binary expression system. In the LRRK2-G2019S model, a 6-fold increase in the 
LRRK2 protein expression was detected compared to the non-transgenic 
controls. Moreover, the dopamine levels were measured, and the G2019S mice 
were characterised by a significant reduction in dopamine content and release. 
That finding triggered the interest of researchers to proteins that are responsible 
for dopamine synthesis, transport and degradation, including dopamine vesicular 
monoamine transporters (VMAT), dopamine transporters (DAT) and aldehyde 
dehydrogenase 1 (ALDH1A1). Their findings support the hypothesis that the 
LRRK2-G2019S mutation supresses DA transmission by down-regulating key 
DA genes (Liu et al., 2015).  
 
As described in Chapter 3, section 3.3.1, my findings agree with the ones 
previously published (Li et al., 2010; Lin et al., 2010; Lin et al., 2015). Using 
Drosophila heads, the flies carrying the LRRK2-G2019S mutation exhibit 
reduced dopamine levels in young age compared to the controls. That only 
confirms the interaction between LRRK2 and dopamine, triggering our interest 
for further investigation.  
 
6.3 LRRK2 and dopamine vesicular monoamine transporters 
(DVMATs) 
 
While tetanus toxin has provided a good way to manipulate transmitter release 
from dopaminergic neurons, it would be good to support this with a second 
experimental manipulation. One way to achieve this might be to exploit the tools 
available with the transporters responsible for the DA take up from the 
extracellular space (DAT) and the package of DA into the synaptic vesicles-the 
vesicular monoamine transporters (DVMAT) (Krantz, 2006).  
 
Since DA is synthesized in the cytoplasm, VMATs are responsible in all the 
aminergic neurons to transport the neurotransmitter out of the cytoplasm and into 
the lumen of synaptic vesicles. Inside these vesicles, the oxidation-prone 
dopamine is stable because of the acidic pH inside there. That prevents oxidative 
stress in the cytosol and the accumulation of the toxic by-products of the 
dopamine metabolism (Lawal et al., 2010; Meiser et al., 2013). The VMAT 
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transportation of DA from the cytoplasm into the synaptic vesicles is considered 
as neuroprotective. Invertebrates like Drosophila melanogaster contain a single 
VMAT gene providing a genetically tractable model to study the effects of VMAT 
on neurodegenerative processes (Lawal et al., 2010; Romero-Calderón et al., 
2008).   
 
The effects of increasing and blocking the vesicular transport could be examined 
in both the G2019S and hLRRK2 background, in order to test for improvement or 
suppression of the visual function. The transport of DA into the synaptic vesicles 
could be blocked by manipulating two dVMAT loss of function alleles: DVMATP 
and DVMATΔ14 (Lawal et al., 2010; Romero-Calderón et al., 2008). More 
recently (2014), two more loss of function mutations were created, the DVMATΔ3 
and DVMATY600A. The DVMATΔ3 is a deletion of the terminal 23 amino-acids of 
the Drosophila VMAT. This deletion disrupts known and predicted endocytosis 
signals proposed to be required for both de novo trafficking and recycling to 
synaptic vesicles following exocytosis at the synapse. The DVMATY600A is an 
alanine substitution mutant that disrupts a tyrosine-based sorting motif (Y600A) 
(Grygoruk et al., 2014). Moreover, overexpression of the wild type DVMATA 
transgene could be used as a control, testing what effect the manipulation of DA 
packaging would have in visual function. 
 
6.4 Utilising new binary expression systems in Drosophila 
 
One of the greatest challenges in Drosophila genetics is the fact that using one 
binary expression system makes it very challenging to perform multiple tasks 
independently at the same time. For example, the use of the Gal4-UAS system 
alone, does not allow the expression of different transgenes in different cell types 
in the same animal. Having another binary transcriptional system would provide 
solutions to that limitation. Using two independent binary systems could allow 
the targeted expression of distinct transgenes under different expression patterns 
in the same animal. In addition, a complementary binary system in conjunction 
with Gal4-UAS has been very useful for mosaic analysis (Lai and Lee, 2006), 
GFP reconstruction across synaptic partners (Feinberg et al., 2008; Gordon and 
     
 
204 
Scott, 2009), and intersectional strategies for refining gene expression patterns 
(Shang et al., 2008). 
 
Lai and Lee (2006) for the first time used two independent binary expression 
systems, providing insights in the Drosophila nervous system, by introducing the 
LexA-LexAop system. The transgenes of interest were put under the control of a 
basal promoter containing eight LexA binding sights (LexAop). Fusing LexA 
with VP16 or GAD, they obtained both GAL80-insensitive and GAL80-
suppressible transcriptional factors that can efficiently drive the expression of 
LexAop-controlled transgenes in vivo. Different LexA drivers were used 
demonstrating how combining Gal4 and LexA systems facilitate the dissection of 
the cellular and molecular networks in the Drosophila CNS.  Since then many fly 
geneticists have started using dual binary expression systems (Yagi et al., 2010; 
Pfeiffer et al., 2010). 
 
The creation of the new transgenic lines in this study will give us the opportunity 
to express at the same animal under different expression patterns the wild type 
LRRK2 and the G2019S. That could shed new light on our understanding on how 
LRRK2 functions and how the G2019S mutation could affect different cell types 
and regions of the Drosophila CNS. In addition, an interesting question that 
could be addressed would be how the simultaneous expression of LRRK2 and 
G2019S affects the fly visual system. Moreover, the confirmed interaction 
between dopamine and G2019S can be further investigated by manipulating the 
DA receptors postsynaptically using the Gal4-UAS system while at the same 
time LRRK2 or G2019S is expressed in the dopaminergic neurons of the fly using 
the LexA-LexAop system. There are many different ways that the newly created 
transgenic flies could be utilised in order to investigate the role of G2019S 
mutation in the pathogenesis of PD.  
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6.5 LRRK2 and Rab proteins interaction 
 
Even though it has been more than 15 years that the role of LRRK2 in the 
pathogenesis of PD was confirmed, it’s actual function and localisation in the 
cell hasn’t been established yet. The presence of all that different protein-protein 
interactions domains within the gene is an indication that this protein acts as a 
scaffold for several other proteins. Moreover, having two enzymatic domains 
within the gene contributes to its importance as a therapeutic target, as kinases 
has always been at the front for new drug discoveries. For that reasons LRRK2 
seems as very promising target that is targeted for new therapeutic interventions.   
 
The other proteins that LRRK2 could phosphorylate and interact with has been 
of great interest for the last few years. This course of investigation focused on a 
genetic screening aiming to identify new LRRK2 substrates, and more 
specifically which of the Rab GTPase proteins interact with LRRK2 in vivo. 
Many Rab proteins have been identified interacting with LRRK2, with the first 
one being Rab7L1, which is itself a risk factor for PD (Dodson et al., 2002; 
MacLeod et al., 2013; Beilina et al., 2014). Rab5b has also been identified to 
physically interact with LRRK2, based on in vitro studies, which has a vital role 
in the early endosomal pathway (Shin et al., 2008; Yun et al., 2015). This 
interaction indicates that LRRK2 is present in the early endosomes, broadening 
our knowledge on the LRRK2 localisation, which has been so blurred so far. 
Moreover, Steger et al. (2016) identified Rab10, Rab1b and Rab8a as LRRK2 
interactors, placing LRRK2 in the endoplasmic reticulum and Golgi trafficking 
to the synaptic vesicles. Within this sub-cellular trafficking pathway, Rab32 has 
also been identified as a LRRK2-mediated phosphorylation. In addition, Rab7, 
which is regulating the endo-lysosomal pathway has been identified, linking 
LRRK2 to the lysosomes.  
 
Most of these Rabs have a confirmed role in the pathogenesis of PD; Rab1 
(Cooper et al., 2006), Rab5a (Dalfo et al., 2004), Rab8a (Dalfo et al., 2004; 
Gitler et al., 2008), Rab3a (Dalfo et al., 2004; Gitler et al., 2008) and Rab10 
(Steger et al., 2016). Among the other Rabs, several have been identified to 
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contribute to other neurodegeneration diseases. The identification of all these 
different Rab proteins pave the way for a new era of investigation, as LRRK2 
focus now has shifted to vesicle trafficking and its role on that among with the 
other theories on its role in mitochondrial dysfunction, protein misfolding and 
aggregation and impaired autophagy-lysosome system.  
 
From this thesis, six different Rabs were identified as LRRK2 interactors based 
on the in vivo analysis that was performed. Among the 21 Rabs that were 
screened, Rab3, Rab5, Rab9, Rab10, Rab18 and Rab40 were confirmed as 
LRRK2 substrates. In addition, two Rabs were identified interacting with the 
dopaminergic neurons in the fly visual system including Rab1 and Rab19. These 
Rabs regulate both the endo-lysosomal pathway and the Endoplasmic Reticulum-
Golgi trafficking to the synaptic vesicles. That means that LRRK2 plays a key 
role in both of the sub-cellular signaling pathways, confirming the original 
theory that LRRK2 is really implicated in many different pathways.  
Rab1 is located in the intermediate of ER-Golgi, regulating their traffic. Even 
though Rab1 has been identified as a LRRK2 interactor, its actual role in the 
pathogenesis of PD has not been very clear. On the other hand, Cooper et al. 
(2006) confirmed that the interaction of Rab1 and α-synuclein leads to PD, as 
Rab1 rescues the toxicity that is caused by the accumulation of α-synuclein. That 
aggregation of α-synuclein is cytotoxic, disrupting the ER-Golgi trafficking and 
they proved that overexpression of Rab1 protected the dopaminergic neuron loss 
induced by α-synuclein.  
 
Rab3 is located in the synaptic vesicles, regulating their traffic to the plasma 
membrane and having a vital role in the exocytosis. Same as Rab1, it has been 
confirmed that LRRK2 phosphorylates this Rab protein, but its actual connection 
to the pathogenesis of PD has not been established. On the other hand, it was 
proved that α-synuclein co-localizes with Rab3a in the presynaptic membranes 
forming a complex with the actual role of Rab3 being regulating the α-synuclein 
distribution. Their results suggest that the membrane bound GTP-Rab3a 
stabilizes α-synuclein on the synaptic vesicles preventing the accumulation of 
this protein, indicating a protective role over the pathogenesis of PD (Chen et al., 
2013). 
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As previously described, Rab5 is a key regulator of the early endosomal pathway 
and previous studies have linked it to both SNCA and LRRK2. Shin et al. (2008) 
determined the role of LRRK2 in the regulation of synaptic vesicles endocytosis 
by interacting with Rab5a. That sheds new insight on LRRK2 function, and helps 
us have a better understanding on the molecular pathway leading to the 
generation of PD. 
 
Rab10 was only recently identified as a substrate of LRRK2-mediated 
phosphorylation (Steger et al., 2016; Ito et al., 2016) implicating this small Rab 
GTPase in the pathogenesis of PD. That places LRRK2 is the exocytosis 
pathway and its localization in the TNG-ER and synaptic vesicles, confirming 
previous studies that had already linked LRRK2 to these pathways.  
 
The extensive genetic toolbox of Drosophila provides us with the appropriate 
tools to further investigate gene functions by performing knockout experiments. 
That tools give us the opportunity to test the role of Rab proteins by following 
loss of function strategies. One approach generating mutations and deletions 
within the Drosophila genome is the transposon-mediated mutagenesis. Utilising 
P-elements has many advantages, as more than two-thirds of all P-element 
insertions occur within 400 bp of transcription start-sites (Bellen et al., 2004; 
Spradling et al., 1999). Moreover, it is predicted that more than 80% of the 
Drosophila genes can be tagged and mutated with P-elements (Bellen et al., 
2004). On the other hand, one disadvantage of P-elements is their insertional 
preference. One-third of all P-element insertions are not found in hot or medium-
hotspots (which are defined as genes that ‘attract’ numerous P-element 
insertions).  
 
Another approach for the inhibition of gene function that is widely used 
nowadays is by RNAi lines, enabling systematic surveys of gene function by 
reverse genetics. In that way, the function of almost every predicted gene can be 
disrupted and the obtained phenotype is assessed (Dietzl et al., 2007). This 
method is successfully used in Drosophila (Boutros et al., 2004) and mammalian 
cells (Berns et al., 2004; Paddison et al., 2004) in culture, enlightening our 
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knowledge on many basic cellular processes. In Drosophila the expression of 
RNAi is cell autonomous and it can be triggered by the expression of a long 
double stranded ‘hairpin’ RNA from a transgene that contains a gene fragment 
cloned as an inverted repeat. By utilizing the Gal4-UAS binary expression 
system, RNAi transgenes can trigger the inactivation of the gene of interest in 
any desired cell type and during any stage of the animal’s lifespan.  
 
In overall, these results indicate that Rabs could be regarded as novel biomarkers 
or therapeutic targets in order to halt or at least slow down the progression of PD. 
In addition, discovery of other interactors for LRRK2 could be crucial for a 
better understanding of physiological functions of LRRK2 and pathogenic 
mechanisms of PD as well as for development of novel therapeutic treatments. 
For further investigation, RNAi, dominant-negative and constantly active Rab 
lines of the identified Rab interactors could be used in order to determine the 
resulting phenotypic consequences occurring through their manipulation.  
 
6.6 LRRK2 and its effect on the neuronal outgrowth 
 
Expressing the LRRK2-G2019S in hiPSCs cell lines from PD patients determined 
that the differentiation of DA neurons is happening but it displays morphological 
defects compared to the controls. After 1, 3 and 5 days of neuronal 
differentiation, the G2019S mutated cells have a more complex neuritic 
arborisation and also shorter total neurite length at day 5 in contrast to the 
controls (Borgs et al., 2016). Those results are similar to previous cell culture 
experiments at older time points, which also showed reduced neuritic length that 
is the hallmark of PD (Gillardon et al., 2009; MacLeod et al., 2006).  
 
MacLeod et al. (2006) established the role of LRRK2 in neuronal outgrowth. 
Overexpression of the LRRK2-G2019S mutation led to a reduction in neuron 
process length and complexity and the accumulation of tau-positive inclusions 
with lysosomal characteristics ultimately leading to increased apoptosis and 
autophagy. On the other hand, suppression of LRRK2  by using shRNAs led 
to the opposite phenotype showing increased neurite process length and 
complexity.  
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Zou et al. (2015) using C. elegans and Drosophila as animal models showed that 
Rab10 is also required for the growth and branching of higher-order dendrites in 
PVD neurons. Loss of function mutations of Rab10 led to severe dendrite 
arborisation defects in the proximal region of PVD neurons.  Those findings 
were consistent with Taylor et al (2015) who established that Rab10 mutants led 
to dramatic dendritic morphogenesis defects in the PVD neurons. These 
discoveries suggest a role of Rab10 in branch outgrowth and in the regulation of 
the distribution of branching activity along the dendrite. The confirmed 
interaction between Rab10 and LRRK2-G2019S while both genes play vital role 
in neuronal outgrowth could shed new light on our understanding of the 
molecular pathway leading to the loss of the dopaminergic neurons in PD.  
 
The implication of autophagy in the maintenance of neurite length has been 
associated with the neuropathology of PD (Sanchez-Danes et al., 2012; Menzies 
et al., 2011; Yang and Mao, 2010). Borgs et al. (2006) detected the induction of 
autophagy at 7 days of differentiation in cells expressing the G2019S mutation 
contributing to neurite length defects with increased branching complexity at 
early developmental stages. At later developmental stages, DA neurons 
differentiated from PD hiPSCs display decreased branching complexity 
indicating a cellular pathotoxicity that could result from increased oxidative 
stress and impaired autophagy that contributes to the vulnerability of the 
DAergic neurons.  
 
That agrees with my hypothesis of early hyperactivity of the G2019S flies 
proposing elevated ATP demand and ROS production, which contributes at later 
stages to the degeneration of DA neurons. Hindle et al. (2013) provided evidence 
that expressing the G2019S mutation in flies increased autophagy and apoptosis 
in the outer part of the photoreceptors in old flies (22 day old flies) while 28 day 
old flies exhibited dilated mitochondria in the photoreceptors. These data suggest 
an increase in the energy demand contributing to neurodegeneration. All these 
studies contribute to the in depth understanding of the pathophysiology 
underlying the LRRK2 mutations contributing to neurodegeneration.  
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6.7 Conclusion 
 
Throughout this thesis, biochemical assays and SSVEPs have been utilised to 
record the visual responses of flies carrying the G2019S mutation. Together, 
these approaches have provided us with a rapid assay of the role that the G2019S 
mutation has in the pathogenesis of PD. Using Drosophila visual system as an 
animal model gave us the opportunity to investigate the role of LRRK2 and in 
that way we could begin to understand the role that LRRK2 plays within the 
human visual system. Applying the same SSVEP approach in humans carrying 
this common mutation will enable us to confirm if the findings that we have seen 
in flies directly relates to LRRK2-linked PD in humans. In this thesis the 
findings from Afsari et al. (2014) were confirmed, where young TH>G2019S 
flies have abnormal SSVEPs, providing us the opportunity to apply SSVEP in 
humans in order to identify people who might be at risk of developing PD before 
even they manifest any symptoms.   
 
 
The key results and conclusions of this study are summarised as follows: 
 
1. The TH>G2019S young flies exhibit an early hyperactivity that could be 
the first step towards neurodegeneration. 1 day old G2019S flies display 
elevated visual responses compared to LRRK2 and other controls. 
 
2. Expression of TNT in conjunction with G2019S, only confirmed the early 
excitotoxicity pathway, as in young flies co-expression of G2019S and 
TNT reduced the visual responses in contrast to LRRK2 and w- flies. 
 
3. Detection of dopamine levels from fly heads revealed reduced DA levels 
in young G2019S flies compared to the normal higher DA levels in 
controls. 
 
4. The generation of the new transgenic flies expressing LRRK2 and 
G2019S under the control of LexA, will pave the way for the design of a 
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whole new era of experiments, where two different transgenes will be 
expressed in the same animal by combining the Gal4-UAS and LexA-
LexAop binary systems.  
 
5. The LRRK2 and Rab GTPases genetic screening that was performed, 
provided for the first time an in vivo analysis, identifying new LRRK2 
substrates. From that screening six Rab proteins were linked to the 
G2019S mutation, including Rab3, Rab5, Rab9, Rab10, Rab18, and 
Rab40, while Rab1 and Rab19 were linked to dopaminergic 
neurotransmission. That discovery provides new insights into the LRRK2 
function, broadening our knowledge on the underlying molecular 
pathway contributing to the pathogenesis of PD.  
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Abbreviations: 
 
α-Syn Alpha-Synuclein 
AADC Aromatic amino acid decarboxylase  
AC Adenylyl cyclase 
AD Autosomal dominant 
ADHD Attention deficit hyperactivity disorder 
ALS Amyotrophic Lateral Sclerosis 
ANK Ankyrin-like repeat 
ANOVA Analysis of Variance 
AR Autosomal recessive 
BH4 Tetrahydrobiopterin 
cAMP Cyclic 3,5 adenine-monophosphate  
COMT Catechol-o-methyl-transferase 
COR C-terminal of ROC 
CNS Central nervous system 
CyO Curly of Oster 
DA Dopamine 
DBS Deep brain stimulation 
ddH20 Double distilled water 
dH2O Distilled water 
DVMAT Dopamine vesicular monoamine transporter 
E Epinephrine 
EDTA Ethylenediaminetetraacetic acid 
EMS Ethyl methanesulphonate 
EOPD Early onset Parkinson’s disease 
EtOH Ethanol 
ER Endoplasmic reticulum 
FTD Frontotemporal dementia 
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GAP GTPase activating protein 
GDP Guanosine-5’-diphosphate 
GEF Guanine exchange factor 
GPCRs G-protien coupled receptors 
GMR Glass Multimer Reporter 
GST Glutathione-S transferase 
GTP Guanosine-5’-triphosphate 
GTPCH GTP cyclohydrolase 
GWAS Genome wide association studies 
HD Huntington disease 
IPD Idiopathic Parkinson’s disease 
KD Kinase dead 
LB Luria Broth 
L-DOPA Levodopa 
LexAop LexA operator 
LOPD Late onset Parkinon’s disease 
LRR Leucine-rich repeats 
LRRK2 Leucine-rich repeat Kinase 2 
MAO Monoamine oxidase 
MAPK Mitogen-Activated Protein Kinase 
MAPT Microtubule Associated Protein Tau 
mRNA  messenger RNA 
Mi Medulla intrinsic  
MS Multiple Sclerosis 
NE Norephinephrine 
NMJ Neuromuscular Junction 
nSyb neuronal Synaptobrevin 
PBS Phosphate Buffered Saline 
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PBS-T Phosphate Buffered Saline with detergent Tween 20 
PCR Polymerase Chain Reaction 
PD Parkinson’s disease 
PIGD Postural imbalance and gait disorder 
PKA Protein Kinase dependent of cAMP 
Rab Ras related in Brain 
RabGGT Rab Geranyl Geranyl Transferase 
REM Rapid-eye movement 
REP Rab Escort Protein 
Rh1 Rhodopsin 1 
RNAi RNA interference 
ROC Ras of complex proteins 
ROS Reactive Oxygen Species 
RT Room Temperature 
SDS Sodium Dodecyl Sulphate 
SEM Standard Error of Mean 
siRNA small interferring RNA 
SNARE Soluble N-ethylmaleimide-sensitive factor attachment protein Receptor 
SNCA α-synuclein 
SNpc Substantia nigra pars compacta 
TH Tyrosine hydroxylase 
TGN Trans-Golgi network 
Tm melting Temperature 
Tris-HCl Tris (hydroxymethyl) aminomethane hydrochloride 
TNT Tetanus Toxin 
TS Tourette Syndrome 
UAS Upstream Activator Sequence 
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VMAT Vesicular monoamine transporter 
WD40 Beta-transducin repeat  
WT Wildtype 
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